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8Introduction and outline
1 From GWAS to SNP function
 In the last few years, a large number of genome-wide 
association studies (GWASs) have been performed in attempts to 
uncover the genetic basis of many different complex diseases and 
traits. GWAS typically ascertain at least 300,000 common single 
nucleotide polymorphisms (SNPs) throughout the genome, and for 
each of these variants association with the disease is tested. 
For many traits, this approach has turned out to be highly 
successful; disease and trait associations for over 12,000 SNPs 
from over 1700 publications have now been reported (NHGRI 
Catalog of Published Genome-Wide Association studies)1. 
However, it soon became clear that the identified genetic variants 
typically explain only a very modest proportion of the total 
heritability of these traits. 
 One plausible explanation was that these GWAS had only 
investigated common SNPs (those with a minor allele frequency 
(MAF) above 5%). As such, many rare variants had not been 
ascertained, and it was therefore assumed that the common  
SNPs identified for a disease were actually tagging rarer variants  
(MAF < 5%) with a larger effect size. To test this hypothesis, 
fine-mapping studies were conducted, made possible with the 
availability of the next generation sequencing (NGS) methods:  
by sequencing candidate genes, whole exomes or genomes it is 
possible to identify rare variants2 and their association with  
disease became testable through the development of dedicated 
oligonucleotide arrays that specifically target these rare variants 
(e.g. the ImmunoChip and MetaboChip). Although this helped to 
fine-map loci for various diseases, few rare variants have so far 
been identified that have a large effect size.
 These results, along with the observation that many smaller-
effect loci became genome-wide significant upon increasing the 
sample sizes used in many GWASs, suggested that the genetic 
architecture for many traits could well be highly polygenic.  
This was further supported by the availability of polygenic models 
in 20093,4: these methods estimate the total proportion of variation 
that can be explained by all genotyped common SNPs, without 
requiring that any of the SNPs individually shows significant 
association (after correction for multiple testing). Initial results on 
adult height (which has an estimated heritability of 80% and is a 
phenotype that can be highly accurately quantified4) revealed that 
common genetic variants captured approximately 45% of the total 
variation in height, whereas the 180 genome-wide significant loci 
that had been found (when studying 180,000 samples) explained 
less than 10% of the variation in height. These results suggested 
that hundreds, or maybe even thousands, of genetic variants  
could well play a causal role in many traits.
 These observations have proven highly problematic in trying  
to move from the discovery of these variants through GWAS to 
their biological interpretation for various reasons: given that many 
of the disease-causing variants are likely to be common, have small 
effect-sizes, and are often in near-perfect linkage disequilibrium 
(LD) with nearby SNPs. It is difficult to unequivocally identify  
the causal variant for each locus through traditional fine-mapping 
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(Bethesda). 2, 597–605 (2012).
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methods. This also strongly impairs the ability to accurately 
pinpoint the causal gene(s) in each locus. Additionally, the mechanisms 
and function of each of these trait-associated variants are largely 
unknown, since many of the trait-associated SNPs are not actually 
changing the protein structure (i.e. are non-synonymous or nonsense 
mutations), but are often located in non-coding regions 
of the genome. This suggests that these variants have a regulatory 
function. A compounding problem is that often tens of disease-
associated variants have now been identified for many diseases, 
making it infeasible to knock-down, knock-out or over-express 
each of the genes within these loci. 
 In order to identify which genes are regulated by genetic variation, 
Jansen and Nap introduced the concept of ‘genetical genomics’5 
in 2001: by correlating the genetic variants with intermediate 
molecular quantitative traits (such as gene expression levels, 
protein levels or methylation levels), it is possible to identify 
quantitative trait loci (QTLs). The first product of the genome, 
mRNA levels, can be quantified easily for thousands of genes at 
once, by either using microarrays or by conducting 
RNA-sequencing. It soon became clear that gene expression levels 
are strongly heritable: for all human genes the average heritability 
was estimated to be around 0.256–8. Soon, expression QTL (eQTL) 
mapping was conducted in humans9–11 (and model organisms such 
as Arabidopsis Thaliana12, Caenorhabditis Elegans13, mice and rats14), 
resulting in the identification of many genetic variants that affect 
gene expression levels.
Cis-eQTL
SNP X has an effect on local Gene A
Trans-eQTL
SNP X has an effect on distant Gene B through an
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 Figure 1.
 eQTLs can be either local effects (cis-eQTLs), or distant, indirect effects (trans-eQTLs)
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2 eQTLs as a means to functionally annotate trait
 associated SNPs
 eQTLs can be divided into those that have local effects
(cis-eQTLs), where the genetic variant is located near the affected 
gene (e.g. within 1 megabase), and those with distant effects 
(trans-eQTLs), where the genetic variant is located further away 
from the affected gene (e.g. more than 5 megabases away, or on a 
completely different chromosome; Figure 1).
2.1 Cis-eQTLs
 Since cis-eQTLs often have a large effect size15, relatively 
modest sample sizes permit the detection of cis-eQTLs for 
thousands of genes6,16–20. Cis-eQTL effects appear to be mostly 
additive effects21, and cis-eQTL SNPs are often located close to the 
transcription start site (TSS) of genes or within gene bodies22–24. 
As the distance between the eQTL SNP and the TSS decreases, 
the eQTL effect size generally increases. Cis-eQTL SNPs that are 
located close to the TSS may alter transcription factor binding sites 
or other cis-regulatory elements (CREs), which in turn may affect 
transcription. The observation that cis-eQTL SNPs tend to be 
overlapping with activating CREs, such as DNAse-I hypersensitive 
sites (DHSs) and transcription factor binding sites, and tend to be 
depleted for repressive CREs (such as CTCF binding sites) 
strengthened this hypothesis25. Finally, trait-associated SNPs have 
been shown to be enriched for cis-eQTL effects20,26–28 (Chapter 7 
of this thesis), which further indicates that trait-associated SNPs 
 16
Myers, A. J. et al. A survey of genetic human 
cortical gene expression. Nat. Genet. 39, 1494–9 
(2007).
 17
Innocenti, F. et al. Identifi cation, replication, and 
functional fi ne-mapping of expression quantitative 
trait loci in primary human liver tissue. PLoS 
Genet. 7, e1002078 (2011).
 18
Stranger, B. E. et al. Relative impact of nucleotide 
and copy number variation on gene expression 
phenotypes. Science 315, 848–53 (2007).
 19
Fehrmann, R. S. N. et al. Trans-eQTLs reveal that 
independent genetic variants associated with a 
complex phenotype converge on intermediate 
genes, with a major role for the HLA. PLoS Genet. 
7, e1002197 (2011).
 20
Westra, H.-J. et al. Systematic identifi cation of 
trans-eQTLs as putative drivers of known disease 
associations. Nat. Genet. 45, 1238–43 (2013).
 21
Powell, J. E. et al. Congruence of additive and 
non-additive effects on gene expression estimated 
from pedigree and SNP data. PLoS Genet. 9, 
e1003502 (2013).
 22
Stranger, B. E. & De Jager, P. L. Coordinating 
GWAS results with gene expression in a systems 
immunologic paradigm in autoimmunity. Curr. Opin. 
Immunol. 24, 544–551 (2012).
 23
Veyrieras, J.-B. et al. High-resolution mapping of 
expression-QTLs yields insight into human gene 
regulation. PLoS Genet. 4, e1000214 (2008).
 Figure 2.
  Functional genomic studies translate GWAS fi ndings into clear biological insight. A) A recent 
GWAS conducted on red blood cell traits identifi ed a locus on chromosome 1 associated with mean 
hemoglobin concentration. Through subsequent cis-eQTL mapping and gene function prediction 
(using a compendium of 80,000 microarrays), SMIM1 was identifi ed as the possibly causal gene in the 
locus on chromosome 1 that was predicted to be involved in hemoglobin metabolism. Subsequent 
exome-sequencing revealed this gene underlies the rare Vel blood group, and knock-down of Vel1 in 
zebrafi sh resulted in a reduced number of red blood cells. B) Through trans-eQTL mapping in healthy 
individuals the downstream effects for the systemic lupus erythematosis (SLE) SNP rs4917014 were 
identifi ed. These effects are identical to the key hallmarks of SLE: decreased complement 1q levels 
and an increased type 1 interferon response. C) SNPs that increase risk for the same disease 
‘converge’ on the same downstream genes: two unlinked type 1 diabetes SNPs affect exactly the 
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are often regulatory. Cis-eQTLs can aid in pinpointing the causal 
variant within a locus: after a GWAS on red blood cell traits29, 
cis-eQTL mapping was performed in whole blood samples, 
which identified a cis-eQTL in the SMIM1 locus on chromosome 1. 
Subsequent functional annotation using a gene expression 
co-regulation network suggested SMIM1 was the causal gene 
within the locus. A follow-up exome sequencing study and knock 
down experiment in zebrafish revealed that SMIM1 underlies the 
Vel blood group (Figure 2A) .
 Although cis-eQTLs, such as the SMIM1 example, can provide 
valuable information about the likely causal gene for trait-
associated SNPs, finding the causal gene underneath GWAS peaks 
is not always straightforward: LD might be so extensive that many 
candidate genes remain, or the regulatory regions that are 
influenced by the genetic variants may actually be located 
megabases away from the transcription start site of the causal 
gene. This has recently been observed for intronic variants within 
the FTO gene that have been found to be associated with Type 2 
diabetes and obesity31,32. Surprisingly, these variants do not show a 
cis-eQTL effect on FTO, but they do affect the gene expression 
levels of IRX3, which is located megabases away from the FTO 
locus33. Knocking-out IRX3 in mice results in a 30% weight 
decrease in mice, confirming the importance of IRX3 in regulating 
weight. These results illustrate that the genes that are located in 
very close proximity to the associated variant are not always the 
causal gene and also that variants associated with GWAS may have 
functional consequences on genes located megabases away, 
which raises the question whether such effects should be 
considered trans-eQTLs.
2.2 Trans-eQTLs
 In contrast to cis-eQTL effects, the effect sizes of trans-eQTLs 
are generally small9,34. As a consequence, the sample sizes required 
to detect such effects are large, and as a result, the number of 
reported trans-eQTLs has remained small9,17,19,35–37 in comparison to 
the number of reported cis-eQTLs. However, initial trans-eQTL 
studies have shown that trans-eQTL analysis provides valuable 
insight into disease pathogenesis. For example, multiple trans-eQTL 
genes were previously identified that are affected by a single SNP 
that is associated with type 2 diabetes and high-density lipoprotein 
levels. SNPs associated with these trans-genes also showed genetic 
association with various metabolic phenotypes37, indicating that 
trans-eQTL mapping is able to identify coherent networks of genes 
that are likely to be causally involved in disease pathogenesis. 
Similarly, trans-eQTL genes were identified that are affected by a 
SNP in the IRF7 locus, associated with the auto-immune disease 
type 1 diabetes. These downstream trans-genes showed an 
association with viral response36. To detect more trans-eQTL 
effects, sample-sizes were increased by performing meta-
analyses19,20: a meta-analysis of 1469 whole blood samples showed 
that HLA SNPs were 10-fold enriched for showing trans-eQTL 
effects. For a few different complex traits it was also shown that 
SNPs independently associated with these traits affected the 
expression of exactly the same downstream genes in trans, 
creating functional converging pathways that are relevant for the 
traits associated with these SNPs19 (Chapter 3 of this thesis). 
A larger meta-analysis involving 5311 whole blood samples further 
 24
Dimas, A. S. et al. Common regulatory variation 
impacts gene expression in a cell type-dependent 
manner. Science 325, 1246–50 (2009).
 25
Brown, C. D., Mangravite, L. M. & Engelhardt, B. E. 
Integrative Modeling of eQTLs and Cis-Regulatory 
Elements Suggests Mechanisms Underlying Cell 
Type Specificity of eQTLs. PLoS Genet. 9, 
e1003649 (2013).
 26
Nicolae, D. L. et al. Trait-associated SNPs are 
more likely to be eQTLs: annotation to enhance 
discovery from GWAS. PLoS Genet. 6, e1000888 
(2010).
 27
Nica, A. C. et al. Candidate causal regulatory 
effects by integration of expression QTLs with 
complex trait genetic associations. PLoS Genet. 6, 
e1000895 (2010).
 28
Dubois, P. C. A. et al. Multiple common variants 
for celiac disease influencing immune gene 
expression. Nat. Genet. 42, 295–302 (2010).
 29
Van der Harst, P. et al. Seventy-five genetic loci 
influencing the human red blood cell. Nature 492, 
369–75 (2012).
 30
Cvejic, A. et al. SMIM1 underlies the Vel blood 
group and influences red blood cell traits. Nat. 
Genet. 45, 542–5 (2013).
 31
Frayling, T. M. et al. A common variant in the FTO 
gene is associated with body mass index and 
predisposes to childhood and adult obesity. 
Science 316, 889–94 (2007).
 32
Dina, C. et al. Variation in FTO contributes to 
childhood obesity and severe adult obesity. Nat. 
Genet. 39, 724–6 (2007).
 33
Smemo, S. et al. Obesity-associated variants 
within FTO form long-range functional 
connections with IRX3. Nature 507, 371–375 
(2014).
 34
Cookson, W., Liang, L., Abecasis, G., Moffatt, M. & 
Lathrop, M. Mapping complex disease traits with 
global gene expression. Nat. Rev. Genet. 10, 184–94 
(2009).
 35
Fairfax, B. P. et al. Genetics of gene expression in 
primary immune cells identifies cell type-specific 
master regulators and roles of HLA alleles. Nat. 
Genet. 44, 502–10 (2012).
 36
Heinig, M. et al. A trans-acting locus regulates an 
anti-viral expression network and type 1 diabetes 



















increased the number of reported trans-eQTL genes to 430 and 
showed that trans-eQTLs can be informative of disease 
pathogenesis: in two previous cross-sectional studies, several 
interferon response genes had been identified that show strongly 
dysregulated expression in the blood of systemic lupus 
erythematosus (SLE) patients (Figure 2B). The trans-eQTL study 
identified a single SNP, associated with SLE, that affected exactly 
these genes, indicating that dysregulation of these interferon 
response genes is already detectable when a healthy individual is 
carrying SLE susceptibility alleles20 (Chapter 7 of this thesis). 
Similar to the meta-analysis in 1469 individuals, this larger meta-
analysis provided information on the convergence of functional 
pathways, including converging effects originating from two type 1 
diabetes associated variants, affecting the well-known type 1 
diabetes gene STAT1 (Figure 2C).
2.3 Cell type and tissue specificity
 Gene expression levels often vary considerably between 
different tissues and cell types38. As such, eQTL mapping studies 
have now been performed in various cell-types and tissues, such as 
fibroblasts, liver17,39–41, lung42, brain16, muscle41, adipose tissue41, 
skin43, various purified blood cell types (e.g. lymphoblastoid 
cell-lines (LCLs)10,40,43–45, B-cells35, monocytes35, and T-cells24), and 
whole blood19,20,46. Early comparisons between cell types showed 
that the number of shared eQTL effects varies widely with the cell 
types or tissues under study. A comparison of skin and LCL eQTLs 
showed that 70% of cis-eQTLs found in LCLs could also be 
detected in skin43, while a comparison of fibroblasts, T-cells and 
B-cells showed an overlap of up to 12% of the detected cis-eQTLs 
in any combination of two of these three cell types24. 
However, these studies had overestimated the cell-type specificity 
because of their small sample size and the statistical methods 
employed to make these comparisons. A more recent comparison 
of B-cells and monocytes in over 280 individuals showed a higher 
overlap: 21.8% of the detected cis-eQTLs and 7% of the detected 
trans-eQTLs were shared between both cell types35, which suggests 
that genetic regulation in trans is more cell-type-specific than cis 
regulation. Only a small proportion of the identified eQTL effects 
in this study could be replicated in whole blood (even though blood 
is partly comprised of monocytes and B-cells), indicating that eQTL 
mapping in a tissue that is composed of many cell types may reduce 
the power to find cell-type-specific eQTL effects.
 
 Another recent study, comparing five tissues (subcutaneous and 
visceral adipose tissue, muscle, liver, and whole blood), described 
how 28.7% of the cis-eQTLs show differences across tissues41. 
Of these, 33% had eQTL effects unique to one of the tissues, 
47.9% showed eQTLs originating from different SNPs in different 
tissues, and 4.4% unexpectedly showed a different direction of 
effect in one or more tissues, something that has recently been 
observed in other studies as well35,47. This study also showed 
cis-eQTL effects for 46.4% of the tested trait-associated SNPs, 
and indicated that these SNPs are enriched for tissue-dependent 
effects, compared to frequency matched SNPs. Another study on 
the same tissue samples showed that this tissue specificity is not 
limited to protein coding genes, but is also present for long 
intergenic non-coding RNAs48 (Chapter 5 of this thesis). 
eQTLs that are shared across tissues and cell types have larger 
 37
Small, K. S. et al. Identification of an imprinted 
master trans regulator at the KLF14 locus related 
to multiple metabolic phenotypes. Nat. Genet. 43, 
561–4 (2011).
 38
Su, A. I. et al. Large-scale analysis of the human 
and mouse transcriptomes. Proc. Natl. Acad. Sci. U. 
S. A. 99, 4465–70 (2002).
 39
Schadt, E. E. et al. Mapping the genetic 
architecture of gene expression in human liver. 
PLoS Biol. 6, e107 (2008).
 40
Zhong, H. et al. Liver and adipose expression 
associated SNPs are enriched for association to 
type 2 diabetes. PLoS Genet. 6, e1000932 (2010).
 41
Fu, J. et al. Unraveling the regulatory mechanisms 
underlying tissue-dependent genetic variation of 
gene expression. PLoS Genet. 8, e1002431 (2012).
 42
Hao, K. et al. Lung eQTLs to help reveal the 
molecular underpinnings of asthma. PLoS Genet. 8, 
e1003029 (2012).
 43
Ding, J. et al. Gene expression in skin and 
lymphoblastoid cells: Refined statistical method 
reveals extensive overlap in cis-eQTL signals. Am. J. 
Hum. Genet. 87, 779–89 (2010).
 44
Stranger, B. E. et al. Patterns of cis regulatory 
variation in diverse human populations. PLoS 
Genet. 8, e1002639 (2012).
 45
Choy, E. et al. Genetic analysis of human traits in 
vitro: drug response and gene expression in 
lymphoblastoid cell lines. PLoS Genet. 4, e1000287 
(2008).
 46
Mehta, D. et al. Impact of common regulatory 
single-nucleotide variants on gene expression 
profiles in whole blood. Eur. J. Hum. Genet. 21, 
48–54 (2013).
 47
Francesconi, M. & Lehner, B. The effects of genetic 
variation on gene expression dynamics during 
development. Nature 505, 208–11 (2014).
 48
Kumar, V. et al. Human Disease-Associated 
Genetic Variation Impacts Large Intergenic 
Non-Coding RNA Expression. PLoS Genet. 9, 
e1003201 (2013).
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effect sizes, and their associated SNPs are located closer to the 
TSS25,41 than tissue- and cell-type specific eQTLs. On average, 
29% of the cis-eQTL loci also appear to have multiple independent 
SNPs affecting the same transcript25. Overall, these studies show 
that the genetic regulation of gene expression is complex and 
differs across cell-types and tissues, especially for disease-
associated genetic variants.
2.4 Context specificity
 Apart from differences in cell types, a large fraction of gene 
expression variation is due to the effect of environmental factors, 
begging the question whether some of these environmental factors 
might induce eQTLs. Several environmental factors have now been 
assessed in the context of eQTLs, which include response to 
radiation49, geography50, different treatments for disease51,52, 
response to influenza vaccination53, and infections with 
tuberculosis54 and malaria55. However, the sample sizes for these 
studies have generally been rather small (up to 194 individuals), 
due to the difficulties and costs involved in acquiring samples that 
are relevant for the specific environmental factor. More powerful 
studies have been published as well: a study in monocytes from 
1490 independent individuals showed 651 cis-eQTLs that have 
interactions with either age, smoking status, gender, 
blood pressure and lipid traits56. However, the early stage of the 
studies of context-specific eQTLs has sometimes led to discrepant 
results being observed: for example, a gender-stratified analysis in 
379 LCLs suggested that between 12% and 15% of the autosomal 
eQTLs function in a sex-biased manner57, and a larger study in 
peripheral blood samples from 1240 individuals showed 
interactions for 623 eQTLs with age58. Although the large fraction 
of gender mediated effects in the LCLs may be caused by 
(epi-)genomic alterations caused by the Eppstein Barr virus 
immortalization of these cell-lines59, a subsequent, but much larger 
study of 5254 peripheral blood samples showed only 14 and 10 
eQTLs interacting with gender and age, respectively60. 
One potential explanation for these discrepancies could be the 
statistical challenges, associated with performing large-scale gene 
environment interaction analysis. In order to get robust 
significance estimates of interaction effects, heteroscedasticity-
consistent standard errors should be used61 (e.g. available through 
the R package ‘Sandwhich’).
 Still, context-specific eQTL studies hold great promise. 
For instance, it should be possible to use whole blood eQTL data 
to make inferences about the specific cell-types in which these 
eQTLs manifest themselves, by using the abundance of such cell 
types as an interaction term (Chapter 3 of this thesis). 
Additionally, a recent study in monocytes, comparing the effect 
sizes of eQTLs before and after stimulation with interferon-γ and 
bacterial lipopolysaccharides (LPS; which was measured at two 
different time-points), reported that 51.4% of the eQTLs detected 
before stimulation were not detectable after stimulation, 
sometimes in a time-dependent manner62. Additionally, a study 
assessing the effect of the stimulation of dendritic cells with LPS, 
influenza and interferon-β, showed 121 eQTLs associated with 
changes in gene expression due to these stimuli (response-eQTLs; 
cis-reQTLs)63. Like cell-type specific effects, stimulus dependent 
eQTLs appeared to have a larger distance between the SNP and 
 49
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 52
Maranville, J. C. et al. Interactions between 
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phenotypes. PLoS Genet. 7, e1002162 (2011).
 53
Franco, L. M. et al. Integrative genomic analysis of 
the human immune response to influenza 
vaccination. Elife   2, e00299 (2013).
 54
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the transcript compared to effects shared with unstimulated cells62, 
and can affect specific transcription factor binding sites63. 
Both studies showed that trait-associated SNPs can have  
stimulus dependent effects, which provides further insight in  
the downstream effects of disease associated SNPs62,63.
2.5 RNA-sequencing
 So far, most eQTL mapping studies have measured gene 
expression levels using microarray technology. With the advent  
of NGS, the sequencing of RNA molecules (RNA-seq) has also 
become feasible. RNA-seq has a much larger dynamic range than 
microarray based gene expression quantification, and as such, 
a smaller amount of RNA molecules is required to accurately 
quantify gene expression levels64,65. The initial eQTL mapping 
studies performed using RNA sequencing data on LCLs have  
shown that the gene expression measurements between micro-
arrays and RNA sequencing data generally correlated well (with 
correlations ranging between 0.6 and 0.781)66. As such, cis-eQTLs 
detected using RNA-seq replicated well when using microarray 
data, with up to 70% of the cis-eQTLs detected on microarrays 
being replicated in the Nigerian HapMap population66, and up to 
81% being replicated in a Central European HapMap population67. 
RNA-seq allows for a higher resolution of gene expression 
quantification than microarrays, since RNA-seq is not limited to  
a predefined set of oligonucleotide probes. Consequently, the 
RNA-seq studies on LCLs showed that cis-eQTL effects are not 
limited to annotated genes: in the Nigerian HapMap population, 
for example, the expression of 4031 unannotated transcripts was 
reported66. The higher resolution of RNA-seq also allows for 
better estimation of the correlation structure between exons and 
can thus be used to impute missing gene expression data for exons 
or transcripts67, and it allows for better mapping of cis-eQTLs 
within exons. Comparing RNA-seq with an earlier microarray-
based study on the same samples, RNA-seq-based eQTL mapping 
was better able to detect exon cis-eQTLs, most of which were 
located in genes with a high level of transcription, which indicates 
that RNA-seq is less prone to saturation of the gene expression 
signal, and that splicing complexity is not properly picked up by 
microarray-based studies67. Apart from exon-based cis-eQTLs, 
the relative ratios of different transcript isoforms can also be  
used as a quantitative trait in RNA-seq-based studies, in order  
to detect splicing-QTLs (sQTLs): 187 and 110 significant sQTLs 
were detected in the Nigerian and Central European HapMap 
populations, respecively66,67, 639 genes were detected with 
significant sQTLs in a more recent LCL based study of 462 
individuals68, and 2851 sQTLs were detected in a whole blood 
study of 922 individuals69, which indicates SNPs also regulate gene 
expression through altering different transcript isoforms. 
sQTLs appear to originate from different regulatory variants than 
eQTLs, since sQTL SNPs show less enrichment near the 5’ end of 
genes compared to cis-eQTLs69, but more enrichment in splice 
sites, 3’ untranslated regions (3’ UTR) and promotors68. 
Additionally, 57% of the eQTL genes that also showed an sQTL had 
an independent effect when conditioning for sQTLs, further 
indicating the independence between eQTL and sQTL regulation68. 
Overall, these studies show that genetic variation has a smaller 
influence on splicing than on overall gene expression. Finally, 
different RNA sequencing strategies can be used to answer 
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different biological questions. For example, DeepSAGE, 
a sequencing strategy that uses primer sequences that specifically 
target the 3’ ends of genes, is more suitable for detecting gene 
expression variation near the 3’ ends than conventional RNA-seq, 
which, due to its random hexamer library design, shows larger 
fragmentation near the ends of genes70. A study applying the 
DeepSAGE method showed 12 poly-adenylation QTLs, 
that transcripts more often have an altered 3’UTR length,  
but also showed that different RNA-seq variants can be 
successfully meta-analyzed70 (Chapter 6 of this thesis).
Outline of this thesis
 
 This thesis has two main aims: 1) to present novel computational 
methods that can be used to improve the statistical power to detect 
genetic effects on gene expression, and 2) to assess the effects of 
genotypic variants on gene expression, in order to determine the 
downstream effects of trait-associated and other genetic variants.
Part 1 – Computational methods for eQTL mapping
 Chapter 2 describes the MixupMapper program, which is a 
method to detect sample mix-ups in genetical genomics datasets. 
We applied this method to six published datasets that had both 
genotype and gene expression data, and observed that, on average, 
3% of all samples in these published datasets had been mixed up. 
We modeled the impact of these mix-ups on the power to detect 
genetic effects, and showed that correcting such mix-ups increases 
the number of detectable eQTLs.
 
 Chapter 3 describes additional methods to improve the 
statistical power to detect eQTLs. We used principal component 
analysis to correct the gene expression data for technical artifacts 
and combined two datasets in an eQTL meta-analysis of 1,469 
whole blood samples. We observed an increase of the number of 
detected trans-eQTLs, and showed that independent trait-
associated SNPs can converge on the same genes in trans.
 Chapter 4 describes a method to predict the cell type specificity 
of eQTLs that have been detected in a tissue that consists of many 
different cell types, such as whole blood. The method uses known 
cell type proportions in a training dataset to create proxy 
phenotypes, and uses an interaction model to predict the interaction 
of the genetic effect with the proxy phenotype. Using this approach, 
we created a proxy for neutrophils, which we applied to 5,683 
whole blood samples. Our method predicted that approximately 
7% of the cis-eQTLs in whole blood are specific for neutrophils, 
and validated this hypothesis in six cell-type-specific eQTL 
datasets, and showed that SNPs associated with Crohn’s disease 
preferentially affect gene expression levels within neutrophils.
Part 2 – eQTL association studies
 Chapter 5 describes a study of the genetic effects on the 
expression of large intergenic non-coding RNAs (lincRNA) in  
five different tissues. We showed that variants often alter  




















 Chapter 6 describes an eQTL study using DeepSAGE RNA-
sequencing, which showed that genetic variants can alter the length 
of the poly-adenylation of transcripts. This study also showed that 
the RNA-seq technique is more powerful in detecting eQTL effects 
than microarrays and that different RNA-seq variants can be 
effectively meta-analyzed to further increase the statistical power. 
 Chapter 7 describes a large cis- and trans-eQTL meta-analysis of 
5,311 whole blood samples from seven independent cohorts. This 
study showed that trans-eQTLs can be detected and replicated in 
independent cohorts and showed that trait-associated SNPs are 
enriched for both cis- and trans-eQTLs. This study also identified 
additional convergent effects for trait-associated SNPs and 
indicated that independent trait-associated SNPs that affect the 
same transcription factor in cis can have different effects in trans. 
Part 3 – Discussion
 Chapter 8 places the work described in this thesis in the 
broader perspective of genetical genomics studies. We describe 
the implications of the findings of this thesis with respect to the 
genetics of complex traits and suggest future perspectives for the 
analysis of the genetics of gene expression as well as for functional 
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 Sample mix-ups can arise during sample collection, handling, 
genotyping or data management. It is unclear how often sample 
mix-ups occur in genome-wide studies, as there currently are no 
post-hoc methods that can identify these mix-ups in unrelated 
samples. We have therefore developed an algorithm (MixupMapper) 
that can both detect and correct sample mix-ups in genome-wide 
studies that study gene expression levels.
Results
 We applied MixupMapper to five publicly available human 
genetical genomics datasets. On average, 3% of all analyzed 
samples had been assigned incorrect expression phenotypes: 
in one of the datasets 23% of the samples had incorrect expression 
phenotypes. The consequences of sample mix-ups are substantial: 
when we corrected these sample mix-ups, we identified on average 
15% more significant cis-expression quantitative trait loci 
(cis-eQTLs). In one dataset, we identified three times as many 
significant cis-eQTLs after correction. Furthermore, we show 
through simulations that sample mix-ups can lead to an 
underestimation of the explained heritability of complex traits in 
genome-wide association datasets. 
Availability and implementation





Supplementary information is available online at  
http://www.genenetwork.nl/mixupmapper/
Introduction
 Genome-wide studies have identified many disease-associated 
variants for a wide plethora of complex human diseases1 (such as 
celiac disease2, type 1 diabetes3 and type 2 diabetes4, Crohn’s 
disease5), and complex continuous phenotypes (such as lipid levels6, 
body mass index (BMI)7 and height8). Many of these studies2,4,6–8 
also assess the effect of the identified genetic variants on gene 
expression variation (i.e. genetical genomics9), by mapping 
expression quantitative trait loci (eQTL). As such, these studies 
involve many steps before actual analysis of the data, during each of 
which samples could be accidentally swapped. Since these studies 
are pushing towards larger sample-sizes in order to be able to 
identify ever smaller effects, the presence of sample mix-ups 
becomes almost unavoidable.
 It is known from simulations that sample mix-ups can have an 
effect on the power to detect genetic associations in genome-wide 
studies10–14, which may present a problem to detect variants with 
small effects. However, it is unclear how often such sample 
mix-ups actually occur in studies investigating gene expression.  
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The common method to detect sample mix-ups in genome-wide 
association studies (GWAS) is to check for heterozygous 
genotypes for X-chromosomal markers in males. However, 
this procedure will not identify sample mix-ups between samples of 
identical gender. While it is also possible to use multiple 
phenotypes that can be well predicted based on genetic markers 
(such as eye color15, hair color15 and ABO blood group16), we are 
not aware of any study where this has been applied to identify 
sample mix-ups in GWAS. It is obvious that if there would be a 
considerable number of such phenotypes available, identification of 
nearly all sample mix-ups should become feasible. Another method 
to prevent sample mix-ups that has is commonly used in GWA 
studies involves the genotyping of a small number of variants prior 
to hybridization to the chip. Post-hoc concordance analysis then 
allows to resolve mixed-up samples, although this method does not 
resolve mix-ups that might have been introduced during 
phenotyping. Although these methods are tailored for GWAS, 
they are also applicable to the genetical genomics datasets. 
This however does not apply to the gene expression data, 
for which to our knowledge no methods to detect sample mix-ups 
currently exist.
 Our method (MixupMapper) uses gene expression levels for 
genes which are influenced by genetic variation located near these 
genes (cis-eQTLs). On the basis of such cis-eQTL effects, 
our method measures the difference between actual gene 
expression levels and predicted expression levels that are solely 
based on genotype data of cis-SNPs. Using this distance measure, 
MixupMapper is able to detect and correct sample mix-ups with 
high sensitivity and specificity. In this study, we analyzed five 
publicly available human genome-wide studies on gene expression 
and observe that sample mix-ups are frequent. Subsequently, 
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Choy et al HapMap CHB+JPT 87  Affymetrix HG-U133A  GSE11582  
 HapMap CEU 84  Affymetrix HG-U133A 
 HapMap YRI 85  Affymetrix HG-U133A 
Stranger et al HapMap CHB+JPT 90  Illumina Sentrix Human6 Beadchip GSE6536
 HapMap CEU 90  Illumina Sentrix Human6 Beadchip 
 HapMap YRI 90  Illumina Sentrix Human6 Beadchip 
Zhang et al HapMap CEU 87  Affymetrix Human ST1.0 Exon array GSE9703
 HapMap YRI 89  Affymetrix Human ST1.0 Exon array 
Webster et al Brain 363  Illumina Human Refseq-8  GSE15222
Heinzen et al Brain 93  Affymetrix Human ST1.0 Exon array †
 PBMC 80  Affymetrix Human ST1.0 Exon array 
Wolfs et al Liver 73  Illumina Human HT12v3  GSE22070 *
Trait Population Sample 
size
AccessionPlatform
† Data available through: http://people.genome.duke.edu/~dg48/SNPExpress. * We excluded the 
Wolfs,M.G. et al. (unpublished data) dataset from eQTL mapping, since this dataset was not 
previously published as a genetical genomics dataset.
Table 1.
































































we show that correcting sample mix-ups can yield a substantial 
increase in the number of significant cis-eQTLs. Furthermore, 
we show through simulations that sample mix-ups have large 
effects in genome-wide association studies as well, when detecting 
genome-wide significant associations, which may account for a 
considerable proportion of the missing heritability problem which 
affects many current GWAS studies17.
Methods
Datasets
 We used five genetical genomics studies18–22 to assess the 
prevalence of sample mix-ups (Table 1). To our knowledge, this list 
includes all publicly available datasets that include both genome-
wide genotype and gene expression data (as of October 2010).  
For the various HapMap datasets18,20,22 we confined ourselves to 
the 309,565 SNPs present on the commonly used Illumina 
HumanHap300 platform (to limit the number of calculations).  
The studies that investigated samples from the HapMap project 
concentrated on the Central European (CEU), Chinese (CHB), 
Japanese (JPT) and Yoruban (YRI) populations. We combined the 
CHB and JPT populations since their sample sizes were very small 
and both reflect Asian samples. As such, we analyzed three sample 
sets for the studies that used HapMap samples (CEU, CHB+JPT 
and YRI) for the datasets of Stranger et al and Choy et al. 
We analyzed two sets of samples for Zhang et al’s dataset as they 
had only investigated the CEU and YRI subpopulations. The dataset 
from Heinzen et al consisted of two separate sets of samples from 
peripheral blood mononuclear cells (PBMCs) and brain tissue that 
were analyzed separately. Finally, we included a dataset on brain 
tissue samples from Webster et al. We also assessed a liver dataset 
from Wolfs et al, but did not include eQTL mapping results, as this 
dataset was not published as a genetical genomics dataset before.
Cis-eQTL mapping
 For the sample mix-up analysis, we ran an initial cis-eQTL 
analysis on each dataset. Although we expected the presence of 
sample mix-ups to have a large effect on the ability to detect cis-
eQTLs, we assumed this influence was limited for the cis-eQTLs 
with the strongest effects. Gene expression datasets were quantile 
normalized and log2 transformed, if appropriate, prior to eQTL 
mapping. Cis-eQTL mapping was performed by using Spearman 
rank correlations (minor allele frequency (MAF) > 5%, a Hardy-
Weinberg equilibrium (HWE) P-value ≥ 0.0001, 
SNP call-rate ≥ 95%). Only those SNP-probe pairs were tested 
that were within a vicinity of 250 kilobases (kb). Multiple testing 
correction was performed by controlling the false discovery rate 
(FDR) at 0.05 by permuting the phenotype to genotype sample 
labels (swapping sample phenotype labels, thus preserving the 
correlation structure within both the genotype and expression 
data23) and re-running the eQTL mapping 1,000 times. 
The numbers of cis-eQTLs that we have reported here refer to 
the numbers of unique probes that show a cis-association. It is 
important to note that we did not correct for any potentially false-
positive cis-eQTLs caused by primer polymorphisms within the 
expression probe because they actually assist in determining the 
correct correspondence between genotype and gene expression 
 22
Zhang, W. et al. Identification of common genetic 
variants that account for transcript isoform 
variation between human populations. Hum. Genet. 
125, 81–93 (2009).
 23
Breitling, R. et al. Genetical genomics: spotlight on 
QTL hotspots. PLoS Genet. 4, e1000232 (2008).
24
Figure 1.
A) We observed numerous sample mix-ups in a dataset created by our laboratory (Wolfs,M.G. 
et al., unpublished data), where the chromosome Y expression did not correspond to the genotype-
derived sex (indicated with asterisk). B) Four plots of cis-eQTLs mapped in the dataset from Wolfs,M.G. 
et al. showed samples 36 and 52 as outliers. These samples generally deviated more from the expected 
regression line than the other samples in this dataset (samples 36 and 52 highlighted). If this was a 
general observation over all signifi cant cis-eQTLs for this dataset, we gathered evidence that 
something was wrong with these samples. C) Therefore, for each cis-eQTL, we calculated the mean 
gene expression level (µ) and standard deviation (σ) per genotype (g). This allowed us to determine, 
per individual (i), to what extent the gene expression level (ei) was deviating from the regression line 
using an absolute Z-scorei =|ei −µgi|/σgi. Samples 36 and 52 generally have a higher Z-score compared 
to other samples. By repeating these calculations for all signifi cant cis-eQTLs, and by comparing all 
pairs of gene expression arrays and genotyping arrays, we could identify those samples that were 
likely to be mixed-up. D) When we corrected these mix-ups we observed that the chromosome Y 
expression now corresponded to the sex for most samples: sample mix-ups resolved. (E) Inspection 
of the RNA plate layout indicated that mix-ups had been introduced by pipetting mistakes.
Identification of mixed-up samples
E) Explanation why mix-ups happened:  
 plate layout pipetting mistakes
D) Correction for sample mix-ups:
  Chr. Y expression corresponds to sex for 





















1 2 3 4 5 6
A 100 101 102 103 104 106
B 107 108 109 110 111 112
C 113 115 36 37 40 41
D 42 45 47 48 52 53
E 54 55 58 62 63 64
F 65 66 68 69 70 71

























































Various samples deviate often from cis-eQTL 
regression line (samples 52 and 36 highlighted)





















































A) Wolfs et al, Chromosome Y expression C) Sample mix-up identification 
}}
Repeat for all 
significant eQTLs
Samples 36 and 52 generally have a higher Z-score 
compared to the other samples.  The procedure is 
repeated for all significant eQTLs. 36 and 52 are likely to 
be mixed-up if the the expressionvalues of sample 36 
are generally closer to the genotype mean of sample 52 
and vice versa.
For many samples sex, as determined based on 
chromosome X genotypes does not correspond to 

















Average chromosome Y expression
Females
Males
SNP   rs11191642
Probe   hsa-mir
P-Value   6.53E-10
SNP   rs9258995
Probe   HLA-A
P-Value   1.39E-10
SNP   rs8458
Probe   VAV3
P-Value   2.77E-10
SNP   rs3779356
Probe   ICA1
































































data. This approach was applied to all cis-eQTL mapping 
procedures in this study, unless specified otherwise.
Identifying sample mix-ups
 The concept behind our method to identify sample mix-ups is 
straightforward: for some genes, the expression level is very 
strongly determined by a SNP genotype. For a pair of genotype and 
gene expression arrays, we can determine the concordance 
between the expected gene expression level conditional on the 
putative SNP genotype for such genes (Figure 1C). 
By systematically assessing all sample pairs with such a set of 
cis-eQTLs, we can determine which pairs are likely to be correct 
and which pairs are not. In general, there are several scenarios for 
errors in sample assignment. These include duplicate genotypes, 
duplicate expression arrays, absent genotypes, absent expression 
arrays and sample swaps. We considered each of these scenarios 
indicative of a sample mix-up. We defined the total number of 
sample mix-ups as the number of genotyped samples that have had 
an incorrect expression array assigned.
 To identify sample mix-ups, MixupMapper uses each 
significantly detected cis-eQTL in the dataset. For each of these 
cis-eQTLs we determined the mean (µAA, µAB and µBB) and 
standard deviation (σAA, σAB and σBB) of the gene expression 
values for each of the three genotypes (AA, AB and BB). For this 
purpose we used the genotype and gene expression pairs that 
were initially assumed to be correct. For each pair of genotype and 
gene expression array we determined the SNP genotype (g). 
We calculated the number of standard deviations that the gene 
expression value (e) differed from the expected value associated 
with the SNP genotype using an absolute Z-score (1).
   Z = |e - µg| / σg (1) 
For each sample pair we summed the absolute Z-scores of all 
significant cis-eQTLs and determined the average Z-score for each 
sample pair to account for differences in the number of tested 
eQTLs per sample pair due to missing SNP genotypes. 
 Expression arrays that have been hybridized to lower quality or 
degraded RNA tend to result in higher deviations from the 
individual cis-eQTL regression lines, irrespective of what genotyped 
sample has been tested for such an expression array. 
As a result, such an expression sample will show higher overall 
Z-scores on average for each of the genotyped samples to which it 
is compared. Therefore, in order to standardize the Z-scores for 
each of the expression arrays, we normalized the Z-scores by 
subtracting the average of the overall Z-scores for this expression 
sample and divided it by the standard deviation of the overall 
Z-scores for this expression sample. Similarly, we normalized the 
Z-scores by subtracting the average of the overall Z-scores for this 
genotype sample and divided it by the standard deviation of the 
overall Z-scores for the genotype sample. 
 After these normalizations we determined what the expression 
array was with the lowest overall normalized Z-score for each 
genotyped sample. We considered this expression sample to 
reflect this particular genotyped sample. 
26
 Once the best matching expression sample had been identified 
for each genotyped sample, we compared it to what had been 
initially defined, permitting us to identify which samples were 
mixed-up. 
 It is, however, also conceivable that our method might 
incorrectly suggest the presence of sample mix-ups, because of 
potential overfitting of mean and standard deviations for each of 
the three genotype groups per cis-eQTL. We therefore used a 
post-hoc permutation strategy to check if our results were not 
due to overfitting. We first permuted the phenotype labels and 
subsequently ran a cis-eQTL analysis. As expected, this analysis did 
not lead to the identification of any significant cis-eQTL, although it 
did permit us to identify the list of top cis-eQTLs for this 
permutation. We chose an equal number of cis-eQTLs as identified 
in the initial cis-eQTL analysis (that was based on the non-
permuted data). Using this set of cis-eQTLs and the permuted 
phenotype labels, we then performed the sample mix-up 
identification procedure. This resulted in overall Z-scores for each 
genotype-expression sample pair and a respective distribution that 
indicated what could be expected when running the mix-up 
procedure on randomly permuted data. Based on this distribution, 
we determined the 5th percentile Z-score threshold (low Z-values 
indicating a better agreement). We repeated this permutation 
strategy 1,000 times, resulting in a distribution of 5th percentile 
Z-score thresholds. We decided to select the 5th percentile 
Z-score threshold as what was attained in only 5% of the 1,000 
permutations. Using this strategy we determined a Z-score 
significance threshold for each of the datasets. We used this 
threshold for each of the inferred sample mix-ups and only 
considered the mix-ups significant and real if the mix-up Z-score 
was lower than the Z-score significance threshold.
 Once we had determined the best match for each genotype 
array, we used the following procedure to decide which genotyped 
samples to keep, which to correct, and which to remove 
completely: for each genotyped sample we first checked if the 
overall Z-score of the best matching gene expression array was 
below the permutation Z-score threshold (a lower Z-score 
corresponds to a better match). We discarded the genotyped 
sample completely if no well-matched gene expression sample was 
identified.
 For each of the remaining genotyped samples, we checked if 
the best matching gene expression array corresponded to the one 
that was originally considered to match it. If they corresponded, 
this indicated that the sample had not been mixed-up and it would 
be kept.
 For those genotyped samples with an incorrect gene 
expression array, we applied the following procedure: we first 
determined what other genotyped sample was originally coupled 
to that particular gene expression array. If that other genotype 
sample was not considered a mix-up and thus matched the 
particular gene expression array well, we knew we had to discard 
































































 Alternatively, if the other genotype sample did not correlate 
well with the gene expression array, we knew we could safely 
assign the assessed genotyped sample to this gene expression 
array, because the other genotype sample was likely to be assigned 
to another well matching expression sample.
 Finally, to ensure that each gene expression array was 
eventually assigned to a single genotype array, we checked whether 
there were two genotype samples that were assigned to the same 
gene expression sample. If this was the case, we discarded the 
genotype sample that was the worse match to the expression array 
(i.e. the one with the highest Z-score).
 Using this method, we were able to not only correct for sample 
mix-ups, but also to identify those genotype arrays that clearly did 
not match any gene expression arrays. Such genotype samples 
generally had a worse Z-score than those genotype samples that 
matched a gene expression array well and they were discarded 
from further analyses.
Effects of sample mix-ups in genetical genomics 
studies
 We assessed the effect of sample mix-ups in each of the 
assessed datasets by repeating the cis-eQTL mapping after we had 
corrected the sample mix-ups. We also simulated the effect of 
accidental sample mix-ups in the datasets in which we had not 
identified any mix-ups. The samples were permuted with 
increments of approximately 5%, after which we performed 
cis-eQTL mapping (FDR < 0.05, 100 permutations). We repeated 
this analysis 100 times to get an accurate estimate of the average 
number of significantly detected cis-eQTLs for the different sets of 
increasingly mixed-up samples.
Sensitivity and specificity of sample mix-up method
 For the datasets where we had deliberately introduced sample 
mix-ups, we ascertained how many of these mix-ups could be 
identified by our method to get realistic estimates on its specificity 
and sensitivity. We defined the true positives (TP) as the number 
of mixed-up samples that our method had correctly identified. 
However, we also required that the method had identified the 
correct alternative expression sample. We defined the false 
positives (FP) as the number of samples that were either falsely 
deemed to be a mix-up, or that were mixed-up but not assigned to 
the correct alternative expression sample. We defined the true 
negatives (TN) as the number of samples correctly identified as 
not being mixed-up. This permitted us to determine the true 
positive rate (TPR, sensitivity) as: 
TPR = TP / (Number of introduced mix-ups), and the false positive 
rate (FPR) as: FPR = FP / (TN + FP). We defined the specificity as 
1 – FPR.
Effects of sample mix-ups on GWAS that looked at 
one particular, continuous, phenotype
 We simulated the effect of sample mix-ups on GWAS that 
investigated one particular, continuous, phenotype by first 
generating genotypes for a population of 500,000 individuals, 
each with a minor allele frequency (MAF) of 0.5. On the basis of 
these genotypes, we then generated a random continuous 
28
phenotype, based on an error term and the joint effect of 100, 200 
or 500 unlinked SNPs (each having an equal effect size), and we 
assumed that each of these causal variants had been successfully 
genotyped. Using this method, we created phenotypes that were 
respectively 90%, 80%, 70%, 60% and 50% heritable. From this 
population, we then randomly sampled 10,000 samples, and 
conducted an association analysis. We correlated the phenotype to 
the genotype using Pearson correlation coefficients. By using a 
p-value threshold of 5 x 10-8, which is commonly used to declare 
genome-wide significance, we were able to determine what 
proportion of the causative variants were significant. By repeating 
this procedure 1,000 times, we obtained reliable estimates of how 
many of the variants were declared significant. We then repeated 
this procedure while swapping the phenotypes of an increasing 
number of individuals, to ascertain the effect of sample mix-ups.
Choy et al CHB+JPT 87 138 20 (23%) 79 (90%) 418 (+203%)
 CEU 84 558 0 N/A N/A
 YRI 85 274 2 (2%) 83 (97%) 287 (+5%)
Stranger et al CHB+JPT 90 1,511 0 N/A N/A
 CEU 90 903 0 N/A N/A
 YRI 90 663 1 (1%) 89 (99%) 667 (+1%)
Zhang et al CEU 87 2,581 0 N/A N/A
 YRI 89 1,454 2 (2%) 89 (100%) 1,635 (+12%)
Webster et al Brain 363 1,284 16 (4%) 356 (98%) 1,367 (+6%)
Heinzen et al Brain 93 349 0 N/A N/A
 PBMC 80 297 0 N/A N/A
Study
aIn four out of the five studies, sample mix-ups were present in some of the populations 
investigated by the authors. In a substantial number of cases, these sample mix-ups could be 
resolved if, for instance, we assumed that two expression samples had been accidentally swapped. 
Genotyped samples for which no appropriate expression sample could be identified were 
removed. Numbers of cis-eQTLs are number of unique probes with an significant effect (FDR < 
0.05). N/A, not applicable.
Table 2.

















































































 The issue of sample mix-ups became apparent in a genetical 
genomics dataset of liver tissue that had been generated in our lab, 
as there were various samples for which the chromosome Y 
expression did not correspond to the gender as derived from the 
genotypes (Wolfs et al., unpublished, Figure 1A).
 To identify the exact origin of these sample mix-ups we 
developed a sample mix-up algorithm (MixupMapper) that relies 
upon gene expression phenotypes that are influenced by genetic 
variation (cis-eQTLs). Fig 1B shows four cis-eQTL plots from this 
dataset in which samples 36 and 52 have been highlighted. 
These samples generally deviate substantially from the cis-eQTL 
regression line (Figure 1C), suggesting they have been swapped.
 By applying our mix-up identification method to all pairs of 
genotyped and gene expression samples, we were able to identify 
28 sample mix-ups in this dataset (Figure 1D). These mix-ups were 
later confirmed by the facility involved in generating the data: 
when we compared the results to the plate layout of the RNA 
samples used during pipetting, we observed that some columns had 
been swapped and some rows had been inverted after 
hybridization to the gene expression chip (Fig 1E). We should note 
that the actual mix-up of samples can have occurred during any of 
the steps involved in the generation of this dataset, such as during 
DNA and RNA isolation, aliquoting, and hybridization. 
However, these samples appeared to be mixed-up because of 
pipetting mistakes prior to hybridization on the RNA-chip, as we 
did not observe any indications of errors that occurred in the 
DNA preparation or hybridization process. In total, 30 out of 74 
samples (41%) had been assigned wrong expression phenotypes and 
our method was able to resolve 28 of them.
Sample mix-ups in published datasets
 As we had identified these mix-ups in our own data, we applied 
our method to five publicly available human datasets for which 
both genotype and gene expression data was freely available online 
(Table 1)18–22. Four out of these five datasets contained sample 
mix-ups (Table 2, Figure S1, Table S1) and observed that for 3% of 
all samples, the genotype and expression data did not correspond 
(41 out of 1,238 samples). The number of sample mix-ups was 
highest in the CHB+JPT subset from Choy et al: out of 87 samples, 
20 were incorrect (23%). In total, we were able to correct 21 of 
the 41 samples that had an incorrect expression phenotype.
 We assessed whether the identified mix-ups were not due to 
extreme expression levels (e.g. because of hybridization problems 
that lead to poor normalization) or bad quality genotypes. For this 
purpose, we assessed the variability of all genotype and gene 
expression samples within each dataset using principal component 
analysis (PCA) on the sample correlation matrix: samples that are 
clear outliers in terms of sample quality, show deviations for the 
first two principal components (PCs). To test whether the 
identified sample mix-ups deviated from the remaining samples, 
we performed a Wilcoxon-Mann-Whitney test on the eigenvalues 
for these PCs. As we did not observe any significant differences 
30
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Benovoy, D., Kwan, T. & Majewski, J. Effect of 
polymorphisms within probe-target sequences on 
olignonucleotide microarray experiments. Nucleic 
Acids Res. 36, 4417–23 (2008).
Figure 2.
A) Robustness analyses on the sample mix-up identification method shows that if the fraction of 
mixed-up samples is <25%, most of the sample mix-ups are detected and corrected by our method 
with high specificity and sensitivity. Variability is generally low (shaded areas around graphs), 
especially for the specificity. B) Sample mix-ups were introduced into the six datasets that did not 
initially contain any mix-ups. Deliberately introducing sample mix-ups resulted in a substantial 
decrease in the number of significantly detectable cis-eQTLs (FDR < 0.05). If 3% of the samples had 
an incorrect phenotype assigned, the average number of detectable cis-eQTLs decreased by 13%.
(Bonferroni correction P<0.004), we can conclude that sample 
quality does not confound the results of our method (Fig S2).
Sensitivity and specificity
 We established that our method is highly specific and sensitive, 
by conducting simulations in the datasets in which no mix-ups had 
been identified (Figure 2A). We observed the best performance in 
the Stranger et al. CHB+JPT dataset: even when 40% of the 
samples had been mixed-up, 98% (σ2: 3%) of these ‘errors’ could 
still be successfully identified and successfully corrected. The worst 
performance was observed in the Heinzen et al. post-mortem 
brain dataset: when 10% of the samples in this dataset were 
mixed-up, only 85% (σ2: 15%) of these could be successfully 
identified and corrected. Very few samples were wrongly deemed a 
sample mix-up by our method, indicating our method is highly 
specific: for each of the datasets in which 10% of the samples had 
been mixed-up, we observed only rarely that non-mixed-up 
samples were wrongly deemed to be mixed-up (Specificity > 99.9%, 
Figure 2A).
Effect of correcting sample mix-ups on number of 
detected cis-eQTLs
 Table 2 shows that the number of detected cis-eQTLs increased 
in each of the datasets after we had corrected for the sample 
mix-ups (Table 2, and Figure S3, Figure S4A-S4F, FDR < 0.05, 
1,000 permutations). In total 15% more cis-eQTLs were identified 
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correcting the identified mix-ups increased the number of 
significant cis-eQTLs by 203% (418 cis-eQTLs compared to 138 
cis-eQTLs before correction). This is a considerable increase, 
especially since the effective sample size decreased by 9% 
(79 samples included after correction compared to 87 samples in 
the original dataset). Furthermore, this indicated that the removed 
samples effectively amounted to noise and therefore contributed 
to a decrease in the power to detect cis-eQTL effects, especially 
smaller ones. However, the increase in the number of detected 
cis-eQTLs we describe here could also be explained by an increase 
of the proportion of false positives that are the result of SNPs 
being present in the gene expression probe sequences, directly 
affecting hybridization efficiency24. We therefore checked whether 
the proportion of potential false positives due to probe 
polymorphisms differed before and after sample mix-up correction 
for each dataset and found no differences in the assessed datasets 
(Figure S5).
Replication of detected cis-eQTLs
 We reasoned that we could gain further evidence that the 
identified sample mix-ups were indeed mix-ups by replicating the 
cis-eQTLs that were identified after the correction. It has been 
shown that substantial overlap exists in cis-eQTL effects between 
different populations and also between different tissues20,25,26. 
We therefore compared the datasets that had been run on the 
same expression platform, which amounts to comparing the 
different HapMap populations. For the studies of Choy et al., 
Cox et al. and Stranger et al., we assessed how many of the 
significantly detected cis-eQTLs in one HapMap population had 
also been detected in another HapMap population (Figure S6). 
After correcting the sample mix-ups, the number of shared 
cis-eQTLs increased in each of the population comparisons. 
99.7% of the eQTLs that were shared between at least two 
populations showed identical allelic directions. We observed 
comparable increases in shared cis-eQTLs after mix-up correction, 
when comparing identical HapMap populations that had been run 
on different expression platforms (Figure S7).
Effect of sample mix-ups on GWAS studies on 
continuous traits
 We systematically explored the effect of different proportions 
of sample mix-ups on the power to detect cis-eQTLs. 
We investigated the datasets in which we had not identified any 
sample mix-ups and deliberately introduced sample mix-ups by 
swapping the expression array measurements for an increasing 
number of samples. We observed a considerable decrease of, 
on average, 13% when only 3% of the samples were deliberately 
mixed-up (Figure 2B). 
 Furthermore, we decided to model the influence of sample 
mix-ups on GWAS studies that investigate traits caused by 
hundreds of variants, such as height or body mass index. 
We simulated a trait with several degrees of heritability and 
different numbers of causative variants in a population of 500,000 
individuals. From this population we randomly sampled 10,000 
individuals on which we conducted a linear regression analysis and 
determined the percentage of SNPs that were genome-wide 
significant (P < 5 x 10-8, Figure 3A). To measure the effect of 
 25
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Expression quantitative trait loci detected in cell 
lines are often present in primary tissues. Hum. 
Mol. Genet. 18, 4296–303 (2009).
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sample mix-ups, we then deliberately randomized the trait 
measurements of an increasing number of randomly selected 
individuals (Figure 3B and Figure 3C).
 A very limited number of sample mix-ups had severe 
consequences for traits that have a heritability of 50%, of which 
the heritable fraction is due to 500 causal variants. If 3% of all 
samples had an incorrect phenotype (as observed in the genetical 
genomics datasets), we could only significantly detect 77% of the 
causal variants that we would have identified if no mix-ups had 
been present (at P < 5 x 10-8, Figure 3B). Likewise, we observed a 
decrease in the proportion of the heritability that could be 
explained by the genome-wide significant associations (Figure 3C): 
the explained heritability of genome-wide significant variants 
decreased with 1.24 fold (from 3.7% to 2.8%) when 3% of the 
samples were mixed-up. 
Figure 3.
A) Robustness analyses on the sample mix-up identification method shows that if the fraction of 
mixed-up samples is <25%, most of the sample mix-ups are detected and corrected by our method 
with high specificity and sensitivity. Variability is generally low (shaded areas around graphs), 
especially for the specificity. B) Sample mix-ups were introduced into the six datasets that did not 
initially contain any mix-ups. Deliberately introducing sample mix-ups resulted in a substantial 
decrease in the number of significantly detectable cis-eQTLs (FDR < 0.05). If 3% of the samples had 
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 If these sample mix-ups could be detected and corrected, it 
would be possible to explain 1.24 fold more of the heritability for 
such traits. Methods to detect such sample mix-ups therefore have 
the potential to substantially increase the explained heritability and 
power to detect genetic effects in GWAS on complex phenotypes 
such as height, BMI or some diseases.
Discussion
 We have identified sample mix-ups in four out of five genetical 
genomics studies by applying a novel method (MixupMapper). 
On average, 3% of all samples were mixed-up. After correction for 
these sample mix-ups by our method, we detected on average 15% 
more cis-eQTLs. Correcting mix-ups in one dataset in which 23% 
of the samples were incorrect led to three times as many 
significant cis-eQTLs being detected. The consequences of only 3% 
sample mix-ups on the heritable fraction that can be explained by 
significantly associated variants can also be substantial. For some 
simulated complex traits with a moderate to high heritability, 
`the explained heritability of the genome-wide significant variants 
increased 1.24 fold, when these sample mix-ups could be detected 
and corrected.
 A considerable proportion of the heritability of complex 
diseases and traits is currently ‘missing’. There is debate on 
whether the missing heritability problem is caused by rare variants 
with a large effect, by many more common variants, each with a 
very small effect size, by overestimation of the heritability 
estimates or through other means17,27. As current genome-wide 
studies are pushing towards associating ever smaller effect sizes, 
sample sizes have to increase substantially to discover loci with 
smaller effect sizes28. Our results indicate that especially for these 
small effect size loci, sample mix-ups could have consequences on 
the power to detect such loci for both genetical genomics studies 
as well as GWAS. As such, a proportion of the missing heritability 
could possibly be explained by the presence of sample mix-ups in 
genome-wide datasets.
 However, it remains a question whether the frequency of 
sample mix-ups we observed in genetical genomics samples is a 
realistic estimate for other types of genome-wide datasets. 
Different types of genome-wide datasets require many different 
handling steps, and therefore their frequencies for the presence of 
sample mix-ups may differ. For example for case-control GWAS 
the cases and controls are often collected and processed 
separately from each other. Therefore, the frequency and hence 
the consequence of sample mix-ups in such case-control studies 
might be lower compared to the studies presented here. As such, 
GWAS in general might contain fewer sample mix-ups.
 In the case of genetical genomics datasets, more cis-eQTLs 
could be detected in each of the datasets after correction, 
although the number of included samples had actually decreased 
for three of these datasets. This effectively demonstrates that 
increasing the sample size is not the only way of increasing 
statistical power for determining complex traits; increasing the 
phenotypic accuracy can be equally helpful. In addition to the 
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method described here, phenotypic accuracy may be increased by, 
for example, including relevant co-variates in GWAS, or by using 
principal components analysis in cis-eQTL studies2,29. 
Although these methods are helpful in increasing the phenotypic 
accuracy, they do not help to identify or overcome sample mix-
ups.
 One possible problem with MixupMapper is that it depends on 
an initial set of cis-eQTLs that can be detected in the data. 
Although our method generally shows high sensitivity and 
specificity when large proportions of samples are mixed-up, in an 
extreme scenario, where all genotyped samples are randomly 
assigned to the gene expression samples, the mix-ups cannot be 
resolved since no cis-eQTLs will be initially detectable. However, 
if a set of cis-eQTLs has been independently identified in another 
set of samples for the particular expression platform used, it is also 
be possible to resolve these problems (data not shown).
 We feel it is important to emphasize that the sample mix-ups 
that we detected in the five public datasets do not in any way 
discredit these studies. To our knowledge, we are the first to 
describe a method to identify mix-ups for these kinds of datasets. 
If the authors had been aware of the existence of these mix-ups, 
they would have certainly corrected them, as their goal was to find 
as many eQTLs as possible. Since we observed a substantial 
overlap of detected cis-eQTLs in the three HapMap populations 
before correction of sample mix-ups, we assume the detected 
cis-eQTLs in these datasets are still valid. We are convinced that 
the results and conclusions drawn from these datasets18–22 remain 
appropriate.
 Although our method is intended for genetical genomics 
datasets, it can also be applied to other types of genome-wide 
datasets, as long as there are sufficient numbers of different 
phenotypes available per individual that are each (strongly) 
determined by genetic variants or combinations of variants. 
This requirement will likely be met with the growing interest in 
population-based cohort studies in which hundreds of phenotypes 
are collected from the participants. As a consequence, identifying 
sample mix-ups will then become possible for these datasets as 
well.
 Our results clearly indicate that sample mix-ups occur in many 
labs (including ours). Although a great deal of quality control is 
conducted in GWAS, it is very difficult to prevent the accidental 
mislabeling of some samples. This is particularly problematic in 
studies of unrelated individuals where inheritance patterns cannot 
be investigated. Nevertheless these accidental human mistakes or 
experimental problems can sometimes have far-reaching 
consequences. We therefore recommend rigorous quality control 
of the laboratory and administrative processes in order to prevent 
sample mix-ups from happening. We conclude that fewer sample 
mix-ups will increase the power to detect significant genetic 
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Trans-eQTLs reveal that independent 
genetic variants associated with a complex  
phenotype converge on intermediate genes, 
with a major role for the HLA
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 Many genetic variants have been found associated with diseases. 
However, for many of these genetic variants, it remains unclear 
how they exert their effect on the eventual phenotype. 
We investigated genetic variants that are known to be associated 
with diseases and complex phenotypes and assessed whether these 
variants were also associated with gene expression levels in a set 
of 1,469 unrelated whole blood samples. For several diseases, 
such as type 1 diabetes and ulcerative colitis, we observed that 
genetic variants affect the expression of genes, not implicated 
before. For complex traits, such as mean platelet volume and mean 
corpuscular volume, we observed that independent genetic 
variants on different chromosomes influence the expression of 
exactly the same genes. For mean platelet volume, these genes 
include well-known blood coagulation genes but also genes with 
still unknown functions. These results indicate that, 
by systematically correlating genetic variation with gene expression 
levels, it is possible to identify downstream genes, which provide 
important avenues for further research.
Abstract
  For many complex traits, genetic variants have been found 
associated. However, it is still mostly unclear through which 
downstream mechanism these variants cause these phenotypes. 
Knowledge of these intermediate steps is crucial to understand 
pathogenesis, while also providing leads for potential 
pharmacological intervention. Here we relied upon natural human 
genetic variation to identify effects of these variants on trans-gene 
expression (expression quantitative trait locus mapping, eQTL) in 
whole peripheral blood from 1,469 unrelated individuals. 
We looked at 1,167 published trait- or disease-associated SNPs and 
observed trans-eQTL effects on 113 different genes, of which we 
replicated 46 in monocytes of 1,490 different individuals and 18 in a 
smaller dataset that comprised subcutaneous adipose, visceral 
adipose, liver tissue, and muscle tissue. HLA single-nucleotide 
polymorphisms (SNPs) were 10-fold enriched for trans-eQTLs: 48% 
of the trans-acting SNPs map within the HLA, including ulcerative 
colitis susceptibility variants that affect plausible candidate genes 
AOAH and TRBV18 in trans. We identified 18 pairs of unlinked SNPs 
associated with the same phenotype and affecting expression of 
the same trans-gene (21 times more than expected, P<10 -16). This 
was particularly pronounced for mean platelet volume (MPV): Two 
independent SNPs significantly affect the well-known blood 
coagulation genes GP9 and F13A1 but also C19orf33, SAMD14, VCL, 
and GNG11. Several of these SNPs have a substantially higher effect 
on the downstream trans-genes than on the eventual phenotypes, 
supporting the concept that the effects of these SNPs on 
expression seems to be much less multifactorial. Therefore, these 
trans-eQTLs could well represent some of the intermediate genes 






















































































  For many complex traits and diseases, numerous associated 
single nucleotide polymorphisms (SNPs) have been identified 
through genome-wide association studies (GWAS) through 
genome-wide association studies (GWAS)1. For many of these 
identified variants it is still unclear through which mechanism the 
association between the SNP and the trait or disease phenotype is 
mediated. A complicating factor is that disease-associated variants 
might not be the real causal variants, but are in linkage 
disequilibrium (LD) with the true disease-causing variant, making it 
difficult to accurately implicate the correct gene for a locus in 
disease pathogenesis.
 Within the major histocompatibility locus (MHC) on 6p, many 
SNPs have been found to be associated with complex diseases such 
as celiac disease, inflammatory bowel disease, psoriasis, 
 1 
Hindorff, L. A. et al. Potential etiologic and 
functional implications of genome-wide 
association loci for human diseases and traits. 
Proc. Natl. Acad. Sci. U. S. A. 106, 9362–7 (2009).
 2
Dubois, P. C. A. et al. Multiple common variants 
for celiac disease influencing immune gene 
expression. Nat. Genet. 42, 295–302 (2010).
 3 
Barrett, J. C. et al. Genome-wide association study 
and meta-analysis find that over 40 loci affect risk 
of type 1 diabetes. Nat. Genet. 41, 703–7 (2009).
 4 
Gregersen, P. K. et al. REL, encoding a member of 
the NF-kappaB family of transcription factors, is a 
newly defined risk locus for rheumatoid arthritis. 
Nat. Genet. 41, 820–3 (2009).
Spearman’s correlation threshold P < 1.73 x 10-3 P < 3.6 x 10 -9
Number of tests performed 2,329,207 13,292,122,142
Number of unique eQTL probes 10,872 244
Number of unique eQTL genes 7,589 202
Number of unique eQTL SNPs 48,717 (16.9% of 467 (0.2% of all 
 all tested SNPs) tested SNPs)
Number of unique MHC eQTL SNPs 1,586 (3.3% of  155 (33.2% of
 cis-eQTL SNPs) trans-eQTL SNPs)
Table 1.




For 289,044 SNPs, present on the commonly used Illumina HumanHap300 platform, the false 
discovery rate (FDR) was controlled at 0.05 for both cis- and trans-eQTLs. For the analysis of 1,167 
successfully imputed SNPs that have been found associated with a quantitative trait or disease the 
FDR was controlled at 0.05 for the cis- and trans-eQTLs. We also performed a trans-eQTL analysis 
for these SNPs while controlling the FDR at 0.50 to generate more hypotheses. The number of 
unique genes was determined using Ensembl 52 (NCBI 36.3 release).
trans-eQTLs 
(FDR<0.05)
eQTL analysis on 289,044 
common SNPs
Spearman’s correlation threshold P < 3.7 x 10-3 P < 2.0 x 10-7 P < 1.02 x 10-5
Number of tests performed 15,371 53,629,458 53,629,458
Number of unique eQTL probes 679 130 726
Number of unique eQTL genes 538 113 576
Number of unique eQTL SNPs 472 (40.4% of  67 (5.7% of 462 (39.6% of 
 all tested SNPs) all tested SNPs) all tested SNPs)
Number of unique MHC eQTL SNPs 65 (13.8% of  32 (47.8% of  52 (11.3% of   





eQTL analysis on 1,167 
trait-associated SNPs trans-eQTLs 
(FDR<0.5)
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rheumatoid arthritis, diabetes mellitus, schizophrenia, lung cancer 
and follicular lymphoma2–10. An analysis of the Catalog of Published 
Genome-Wide Association Studies1 revealed that out of 1,167 
unique SNP associations with a reported p < 5 x 10-7, 82 (7.0%) 
were located within the MHC (Fisher’s Exact p < 10-30). Except for 
celiac disease11 it remains largely unclear how MHC variants 
increase disease susceptibility.
 However, common variants have been identified that might 
exert their function by altering gene expression rather than by 
altering protein structure2,12–16 (expression quantitative trait loci, 
eQTLs). Comprehensive eQTL mapping (or genetical genomics17) 
will enable us to assess for every known disease-associated variant 
if it significantly affects gene expression. Genetic variants that 
affect expression of genes that map in their vicinity (cis-eQTLs) can 
potentially pinpoint the true disease gene from an associated locus. 
In addition, genetic variants may also affect expression of genes 
that reside further away or are on different chromosomes 
(trans-eQTLs)18. These trans-eQTLs are especially interesting, 
since they allow us to identify downstream affected disease genes 
which were not implicated by GWAS studies at all, and thereby 
potentially having the ability to reveal previously unknown (disease) 
pathways.
 In this study we performed a comprehensive eQTL mapping to 
explore the downstream effects of SNPs on gene expression by 
analyzing genotype and expression data of 1,469 unrelated samples. 
In addition to a genome-wide analysis, we also performed a 
Figure 1. Disease and trait-associated SNPs are enriched for both  
cis- and trans-eQTLs.
17% of SNPs, present on common SNP platforms, affect gene expression levels in cis or trans (at 
FDR of 0.05). This is substantially different from 1,167 SNPs that have been found associated with 
traits or disease: 40.4% affect gene expression in cis, while 5.7% of these SNPs affect gene 
expression in trans. These eQTL SNPs significantly more often than expected map within the HLA 
(13.8% of cis-eQTLs, 47.8% of trans-eQTLs, extreme value distribution p < 1 x 10 -16).
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focused analysis for disease-and trait-associated SNPs and SNPs 
located within the HLA. We replicated the identified trans-eQTLs 
in a collection of monocyte expression data and expression data 
from subcutaneous adipose, visceral adipose, muscle and liver 
tissue. Principal component analysis (PCA) enabled us to remove 
non-genetic expression variation19,20, resulting in increased power 
to detect eQTLs. A stringent probe-mapping strategy was used to 
filter out false-positive cis-eQTLs due to primer-polymorphisms 
and false-positive trans-eQTLs due to cross-hybridizations. 
Furthermore, a permutation strategy was utilized that corrects for 
multiple-testing, while preventing potential confounders such as 
non-even distribution of SNP markers and expression probe 
markers across the genome, differences in minor allele frequency 
(MAF) between SNPs, linkage disequilibrium (LD) within the 
genotype data, and correlation between expression probes.
Results
Cis- and trans-eQTL mapping
 Results of a genome-wide eQTL analysis on 289,044 common 
SNPs, present on the Illumina HumanHap300 platform in 
peripheral blood expression data of 1,469 unrelated individuals, 
are provided in Table 1, Table S1, Table S2, Figure S1 (controlling 
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Figure 2. Type 1 diabetes associated SNPs both affect genes 
in cis and trans
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 As reported before21–25 we also observed that eQTLs are 
strongly enriched for trait-associated SNPs (SNPs associated with 
a trait or disease phenotype, as reported in the Catalog of 
Published Genome-Wide Association Studies1): We therefore 
concentrated on these variants and imputed (Impute v2.026) 
additional genotype data permitting us to test 1,167 trait-
associated SNPs. After removing false-positive eQTLs due to 
primer-polymorphisms and cross-hybridization 472 (40.4%) of 
these SNPs were cis-eQTLs, affecting the expression of 679 
different transcripts, representing 538 genes (Figure 1, Table 1, 
Figure S2, Table S3).
 67 (5.7%) SNPs were trans-acting on 130 different transcripts, 
representing 113 genes (Table S4). Results on the number of 
detected eQTLs per complex trait are provided in Table S5 and 
Figure S3. For nearly all significant trans-eQTLs the effect was 
present in each of the seven individual patient and controls 
cohorts, making up the total dataset (Table S6).
 These trans-eQTLs provide valuable insight on previously 
unknown functional downstream consequences trait-associated 
SNPs have, e.g. rs2395185 is the strongest susceptibility variant for 
ulcerative colitis27 (UC) but also the strongest SNP, trans-acting on 
Acyloxyacyl hydrolase (AOAH, p = 1.0 x 10 -36), an enzyme that 
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invasion. It is known that defi ciencies in response mechanisms 
against bacterial products like lipopolysaccharide, present on 
gram-negative bacterial cell walls, play an important role in UC 
disease pathogenesis28. Within the peripheral blood we observed 
that AOAH is signifi cantly co-expressed with colony stimulating 
factor 1 receptor (CSF1R, r = 0.21) and major histocompatibility 
complex class II DR alpha (HLA-DRA, r = 0.19). Hyperstimulation of 
CSF1R has been implicated in UC29, while HLA-DRA is one of the 
positional UC candidate genes mapping in very close proximity to 
rs2395185. Another UC HLA variant, rs9268877, was trans-acting 
on T cell receptor beta variable 18 (TRBV18), part of the TCRß 




in peripheral blood (r ≥ 0.19)
trans-eQTL effect  (FDR 0.05)
cis-eQTL effect       (FDR 0.05)
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Figure 3. Human leukocyte antigen (HLA) trait-associated SNPs affect 
gene expression levels in trans.
Thirty-two trait-associated SNPs that map within the HLA are trans-acting on other genes. 
Trans-genes are indicated in red. Peripheral blood co-expression (Pearson correlation coeffi cient 
r�0.19, p<10 -11) between genes is indicated in light grey. Several trans-genes are co-expressed with 
HLA genes.
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For type 1 diabetes (T1D) we observed that 59% (30/51) of the 
known and tested T1D associated SNPs are cis-acting (on in total 
53 unique genes) and 17% (9/50) are trans-acting on 22 unique 
genes (Figure 2). Potentially interesting trans-genes include CCL2, 
CFB, CLN1, KRT19, OSR1 and RARRES1, all strongly co-expressed 
with each other. CCL2 and CFB are known immune response genes 
and have been implicated in T1D before31–33. For breast cancer we 
observed that rs380366234 is trans-acting on origin recognition 
complex subunit 6 (ORC6L). This gene is involved in DNA 
replication and has been frequently used as part of prognostic 
profiles for predicting the clinical outcome in breast cancer35,36.
 We observed a marked enrichment for SNPs within the MHC 
among the cis- and trans-acting trait-associated SNPs: 65 of 472 
cis-acting SNPs (13.8%, EVD p < 1.0 x 10 -16) and 32 of 67 trans-
acting SNPs (47.8%, EVD p < 1.0 x 10 -16) mapped within the MHC 
(Figure 3). These SNPs all map to the Human Leukocyte Antigens 
(HLA) locus: SNPs within the HLA class I region, class II region and 
class III region affect 20, 7 and 2 different genes in trans, 
respectively.
Biological convergence of cis- and trans-eQTLs
 While multiple associated SNPs have been identified for many 
complex diseases, it often remains unclear what the intermediate 
effects of these variants are that eventually lead to disease. 
It is reasonable to assume that for a particular phenotype the 
different associated SNPs eventually converge on the same 
downstream gene(s) or pathways.
 We identified 7 unique pairs of unlinked SNPs that are 
associated with the same phenotype and that also affect the same 
downstream genes in trans or cis (at FDR 0.05, Table 2, Figure 4A). 
In order to establish whether this was more than expected by 
chance, we repeated this analysis, while using a set of trans-eQTLs, 
equal in size to the set of real trans-eQTLs, most significant after 
having permuted the expression sample identifiers. We performed 
this procedure 100 times, and observed on average only 0.15 
unique pairs of unlinked SNPs (range [0, 3], Figure 4B) that showed 
this convergence, which indicates that the observed number of 
converging pairs of SNPs is 47 times more than expected 
(EVD p < 1.0 x 10 -16) and implies a false-positive rate of 0.021.
 Due to this highly significant enrichment of converging pairs  
of SNPs and its low estimated false-positive rate, we also ran an 
analysis where we had relaxed the FDR for trans-eQTLs to 0.50 
(Table S7). Here we observed 18 pairs of SNPs that converge on 
the same genes, whereas in the 100 subsequent permutations  
we observed this only on average for 0.84 SNP-pairs 
(range [0, 5], 21 times more expected by chance, EVD  
p < 1.0 x 10 -16, implying a false-positive rate of 0.047, Table 2, 
Figure 4B).
 Many of these converging downstream genes make biological 
sense: three independent loci, associated with hemoglobin protein 
levels37–39 and β thalassemia susceptibility40, significantly affect 
hemoglobin gamma G (HBG2) gene expression levels (each with 
p < 1.0 x 10-23, Figure 5). For mean corpuscular volume (MCV, 
Figure 5) two unlinked MCV SNPs41,42 also affect HBG2 gene 
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expression levels in trans (at FDR 0.05), while other pairs of MCV 
SNPs converge on ESPN, VWCE, PDZK1IP1 and RAP1GAP.
 For mean platelet volume (MPV) we observed that MPV SNPs 
rs12485738 on 3p26 and rs11602954 on 11p15 affect several 
transcripts in trans. These two SNPs converge on GP9, F13A1, 
C19orf33, SAMD14, VCL and GNG11. As GP9 and F13A1 are known 
blood coagulation genes, C19orf33 is a potential candidate gene, 
involved in coagulation as well. This is substantiated by strong 
co-expression between GP9 and C19orf33 within peripheral blood 
(Pearson r = 0.45, p = 7.0 x 10 -63) and the fact these SNPs 
independently also affect various other blood coagulation genes in 
trans (including CD151, GP1BB, ITGA2B, MMRN1, THBS1 and VWF, 
Figure 4). Many of these are specifi c to megakaryocytes that are 
platelet precursor cells43. As expected, the Gene Ontology term 
‘blood coagulation’ is strongly overrepresented among all these 
trans-genes, Fisher’s exact p = 1.0 x 10-10.We observed that MPV 
SNP rs12485738 (on 3p14.3) was also trans-acting on tropomyosin 
1 (TPM1, 15q22.2, p = 9.7 x 10-9), a gene that is also regulated in cis 
by another MPV variant (rs11071720 on 15q22.2, p = 1.4 x 10-13). 
We observed this for two different expression probes that map 
within different locations of the TPM1 transcript (probes 5560246 
and 610519), and note strong co-expression for these two TPM1 
probes with 46 MPV trans-genes (Pearson r > 0.19, p < 1.0 x 10-11, 
including fi ve known coagulation genes). Although several genes 
reside within the rs11071720 MPV locus, these observations 
strongly implicate TPM1 as the causal MPV gene. For both MPV and 
MCV we observed that the identifi ed cis- and trans-eQTL probes 
Figure 4. Pairs of SNPs that cause the same phenotype more frequently 
than expected also affect the same downstream genes.
Various pairs of unlinked SNPs cause the same phenotype but also converge on the same 
downstream genes. 
A) When using cis- and trans-eQTLs, identifi ed when controlling FDR at 0.05, 7 unique pairs of 
SNPs cause the same phenotype but also affect the same downstream gene. When controlling the 
FDR at 0.50 for the trans-eQTLs, 18 unique pairs of SNPs show this convergence. B) This is 
signifi cantly higher than expected, determined using 100 permutations. 
C) The SNPs that affect these downstream genes in most instances explain a proportion of the 
downstream gene expression variation that is substantially higher than what their effect is on the 
eventual phenotypes.
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Trans-eQTL mapping significance threshold
FDR 0.50  >  18 converging SNP-pairs
FDR 0.05  >   7 converging SNP-pairs
3 1 27 64 136 36 105 148 1,260 2,968
3 3 1 1
1
2



































































































0% 2% 4% 6% 8% 10% 12% 14% 16% 
































































































































generally were more strongly co-expressed in peripheral blood 
than expected (Figure S4, MPV co-expression Wilcoxon P < 10-200, 
MCV co-expression Wilcoxon P = 0.009) substantiating the 
likelihood these genes reflect coherent biological sets. 
We repeated this co-expression analysis after we had regressed 
out all cis- and trans-eQTL effects, and observed that most of this 
co-expression was independent of the eQTL SNP-effect on the 
expression of these genes, which further substantiates that these 
genes are biologically related (MPV co-expression Wilcoxon 
P < 1-200, MCV co-expression Wilcoxon P = 0.018).
Phenotypic buffering
 Although the observed convergence provides insight into 
downstream genes, it is not clear whether the MPV or MCV 
phenotypes are eventually caused through these trans-genes, 
or whether these trans-eQTLs emerged as a result of changes to 
the volume of the platelets or the erythrocytes.
 In order to gain insight into this, we analyzed the effect size of 
these SNP variants on both the expression levels and the 
phenotypes. While the effect sizes of these trait-associated SNPs 
on eventual phenotypes were usually small, their intermediate 
(molecular) effect was often substantially larger. This supports the 
notion that the effect on e.g. MPV and MCV is through these 
trans-genes, and suggests the presence of ‘phenotypic buffering’, 
shown previously in plants44, in humans (Table 2, Figure 4B): 
the effects of the 18 converging pairs of SNPs on gene expression 
levels were often substantially higher than the originally reported 
effect sizes on the trait-phenotypes. For example, several MPV-and 
MCV-associated SNPs explain between 1.41% and 10.99% of 
trans-expression variation within the 1,469 unrelated samples, 
whereas these SNPs only explain between 0.24% and 1.12% of the 
MPV and MCV phenotype variation (and as such required over 
13,000 samples41,42 for identification, Figure 4B).
Replication of trans-eQTLs in monocytes and four 
additional primary tissues
 We analyzed peripheral blood which is a mixture of different 
hematopoietic cell types. In addition, we also assessed whether the 
identified trait-associated trans-eQTLs (detected at FDR 0.05) 
could be replicated in a single cell-type dataset. This is an 
important question, as it is potentially possible that the trans-acting 
SNP are able to alter the amount, volume or ratio of certain blood 
cell types, which might as a consequence result in an indirect net 
effect on the measured gene expression levels within the mix of 
the cells that comprise whole blood.
 We therefore analyzed monocyte expression data from 1,490 
independent samples45 and did not find evidence that this was a 
widespread phenomenon as we could replicate 46 out of the 130 
different trans-eQTLs (each of these with a nominal p < 1.0 x 10-5 
in the monocyte data, Table S8). These replicated eQTLs include 
the genes AOAH, HBG2, GP9, F13A1, SAMD14, CD151, ITGA2B, 
MMRN1, THBS1, VWF and TPM1 mentioned above. Surprisingly we 
could also replicate the trans-eQTL effects on various blood-
coagulation genes for mean platelet volume SNP rs12485738: 
one might argue that rs12485738 primarily increases platelet 
volume, resulting in a relatively higher volume of platelet-RNA 
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ß thalassemia rs766432 rs2071348 3.30%40 3.00%40 HBG2 4010040 2.12x10-29 4.22x10-24 9,72% 7,96%
 rs766432 rs2071348 3.30%40 3.00%40 HBG2a 450537 7.67x10 -37 6.46x10 -24 10,41% 6,72%
 rs766432 rs2071348 3.30%40 3.00%40 HBG2 6400079 6.95x10 -07 3.80x10 -06 10,28% 8,99%
 rs9376092 rs766432 10.50%40 3.30%40 HBG2 4010040 1.73x10-32 2.12x10-29 10,75% 9,72%
 rs9376092 rs2071348 10.50%40 3.00%40 HBG2 4010040 1.73x10-32 4.22x10-24 10,75% 7,96%
 rs9376092 rs766432 10.50%40 3.30%40 HBG2a 450537 9.49x10-39 7.67x10 -37 11,06% 10,41%
 rs9376092 rs2071348 10.50%40 3.00%40 HBG2a 450537 9.49x10-39 6.46x10 -24 11,06% 6,72%
F-cell distribution rs1427407 rs9399137 13.10%38 15.80%38 HBG2 4010040 1.18x10-28 1.70x10 -26 9,51% 8,74%
 rs1427407 rs9399137 13.10%38 15.80%38 HBG2a 450537 1.21x10 -36 1.86x10 -30 10,35% 8,75%
Mean corpuscular volume rs12718597 rs643381 0.26%41 0.50%41 VWCE 1450608 3.39x10 -10 1.74x10 -06 2,65% 1,61%
 rs2540917 rs643381 0.24%41 0.50%41 ESPN 3440630 1.95x10 -15 6.20x10 -07 4,99% 1,99%
 rs4895441 rs2540917 1.12%41 0.24%41 HBG2 4010040 2.74x10-32 2.87x10-19 10,71% 6,32%
 rs4895441 rs2540917 1.12%41 0.24%41 HBG2a 450537 1.31x10-38 3.19x10-18 10,99% 5,29%
 rs4895441 rs643381 1.12%41 0.50%41 RAP1GAPa 4890181 2.46x10-06 5.57x10 -06 1,51% 1,41%
 rs643381 rs4895441 0.50%41 1.12%41 PDZK1IP1 3170270 7.44x10-10 4.27x10 -06 2,55% 1,45%
Mean corpuscular Hb rs628751 rs7776054 0.34%41 1.02%41 PDZK1IP1 3170270 7.74x10-10 8.97x10-07 2,55% 1,65%
Mean platelet volume rs12485738 rs11602954 0.93%42 0.41%42 GP9b 1050292 3.62x10 -17 1.14x10-07 4,82% 1,93%
 rs12485738 rs11602954 0.93%42 0.41%42 GNG11 1580025 9.67x10 -12 2.23x10 -06 3,22% 1,52%
 rs12485738 rs11602954 0.93%42 0.41%42 F13A1 2230241 5.37x10-09 3.13x10-09 2,54% 2,38%
 rs12485738 rs11071720 0.93%42 0.18%42 TPM1 5560246 1.47x10 -08 1.38x10-13 2,58% 4,32%
 rs12485738 rs11071720 0.93%42 0.18%42 TPM1 610519 1.45x10-06 4.41x10-13 1,60% 3,58%
 rs12485738 rs11602954 0.93%42 0.41%42 SAMD14b 5560280 4.08x10 -18 3.10x10 -06 5,05% 1,47%
 rs12485738 rs11602954 0.93%42 0.41%42 C19orf33 630470 6.26x10 -11 1.16x10 -08 2,86% 2,37%
 rs12485738 rs11602954 0.93%42 0.41%42 VCLb 70592 7.49x10-07 6.81x10-06 1,72% 1,39%
Height rs910316 rs10946808 N/A N/A BTN3A2 4610674 5.42x10-06 9.79x10-10 1,40% 2,60%
Multiple sclerosis rs2523393 rs9271366 N/A N/A TGFBR2 2340324 5.15x10-07 1.07x10 -06 2,01% 1,90%
Systolic blood pressure rs3184504 rs2681492 N/A N/A LOC338758 6650035 1.28x10-06 9.17x10-08 1,87% 2,27%
Diastolic blood pressure rs3184504 rs2681472 N/A N/A LOC338758 6650035 1.28x10-06 2.23x10-08 1,87% 2,49%
 rs653178 rs2681472 N/A N/A LOC338758 6650035 1.54x10-06 2.23x10-08 1,85% 2,49%
Type 1 diabetes rs9272346 rs11171739 N/A N/A KRT18 6580270 1.87x10-06 4.72x10 -06 2,06% 1,70%
 rs9272346 rs1701704 N/A N/A KRT18 6580270 1.87x10-06 9.40x10 -06 2,06% 1,39%
Complex trait
Table 2.
Trait-associated SNPs converge on the same downstream genes.
Indicated are 18 pairs of unlinked SNPs that are associated with the same complex phenotype and 
that also affect the expression levels of the same downstream gene(s) in cis (FDR 0.05) or trans 
(FDR 0.50). a Erythrocyte specific gene according to HaemAtlas43. b Megakaryocyte specific gene 
according to HaemAtlas43. c Explained phenotypic variation is shown for traits when reported in 
the original papers (indicated in superscript) that describe these SNP – phenotype association.
SNP1 SNP2
Unlinked SNP-pair Explained trait variance
SNP1 SNP2
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ß thalassemia rs766432 rs2071348 3.30%40 3.00%40 HBG2 4010040 2.12x10-29 4.22x10-24 9,72% 7,96%
 rs766432 rs2071348 3.30%40 3.00%40 HBG2a 450537 7.67x10 -37 6.46x10 -24 10,41% 6,72%
 rs766432 rs2071348 3.30%40 3.00%40 HBG2 6400079 6.95x10 -07 3.80x10 -06 10,28% 8,99%
 rs9376092 rs766432 10.50%40 3.30%40 HBG2 4010040 1.73x10-32 2.12x10-29 10,75% 9,72%
 rs9376092 rs2071348 10.50%40 3.00%40 HBG2 4010040 1.73x10-32 4.22x10-24 10,75% 7,96%
 rs9376092 rs766432 10.50%40 3.30%40 HBG2a 450537 9.49x10-39 7.67x10 -37 11,06% 10,41%
 rs9376092 rs2071348 10.50%40 3.00%40 HBG2a 450537 9.49x10-39 6.46x10 -24 11,06% 6,72%
F-cell distribution rs1427407 rs9399137 13.10%38 15.80%38 HBG2 4010040 1.18x10-28 1.70x10 -26 9,51% 8,74%
 rs1427407 rs9399137 13.10%38 15.80%38 HBG2a 450537 1.21x10 -36 1.86x10 -30 10,35% 8,75%
Mean corpuscular volume rs12718597 rs643381 0.26%41 0.50%41 VWCE 1450608 3.39x10 -10 1.74x10 -06 2,65% 1,61%
 rs2540917 rs643381 0.24%41 0.50%41 ESPN 3440630 1.95x10 -15 6.20x10 -07 4,99% 1,99%
 rs4895441 rs2540917 1.12%41 0.24%41 HBG2 4010040 2.74x10-32 2.87x10-19 10,71% 6,32%
 rs4895441 rs2540917 1.12%41 0.24%41 HBG2a 450537 1.31x10-38 3.19x10-18 10,99% 5,29%
 rs4895441 rs643381 1.12%41 0.50%41 RAP1GAPa 4890181 2.46x10-06 5.57x10 -06 1,51% 1,41%
 rs643381 rs4895441 0.50%41 1.12%41 PDZK1IP1 3170270 7.44x10-10 4.27x10 -06 2,55% 1,45%
Mean corpuscular Hb rs628751 rs7776054 0.34%41 1.02%41 PDZK1IP1 3170270 7.74x10-10 8.97x10-07 2,55% 1,65%
Mean platelet volume rs12485738 rs11602954 0.93%42 0.41%42 GP9b 1050292 3.62x10 -17 1.14x10-07 4,82% 1,93%
 rs12485738 rs11602954 0.93%42 0.41%42 GNG11 1580025 9.67x10 -12 2.23x10 -06 3,22% 1,52%
 rs12485738 rs11602954 0.93%42 0.41%42 F13A1 2230241 5.37x10-09 3.13x10-09 2,54% 2,38%
 rs12485738 rs11071720 0.93%42 0.18%42 TPM1 5560246 1.47x10 -08 1.38x10-13 2,58% 4,32%
 rs12485738 rs11071720 0.93%42 0.18%42 TPM1 610519 1.45x10-06 4.41x10-13 1,60% 3,58%
 rs12485738 rs11602954 0.93%42 0.41%42 SAMD14b 5560280 4.08x10 -18 3.10x10 -06 5,05% 1,47%
 rs12485738 rs11602954 0.93%42 0.41%42 C19orf33 630470 6.26x10 -11 1.16x10 -08 2,86% 2,37%
 rs12485738 rs11602954 0.93%42 0.41%42 VCLb 70592 7.49x10-07 6.81x10-06 1,72% 1,39%
Height rs910316 rs10946808 N/A N/A BTN3A2 4610674 5.42x10-06 9.79x10-10 1,40% 2,60%
Multiple sclerosis rs2523393 rs9271366 N/A N/A TGFBR2 2340324 5.15x10-07 1.07x10 -06 2,01% 1,90%
Systolic blood pressure rs3184504 rs2681492 N/A N/A LOC338758 6650035 1.28x10-06 9.17x10-08 1,87% 2,27%
Diastolic blood pressure rs3184504 rs2681472 N/A N/A LOC338758 6650035 1.28x10-06 2.23x10-08 1,87% 2,49%
 rs653178 rs2681472 N/A N/A LOC338758 6650035 1.54x10-06 2.23x10-08 1,85% 2,49%
Type 1 diabetes rs9272346 rs11171739 N/A N/A KRT18 6580270 1.87x10-06 4.72x10 -06 2,06% 1,70%
 rs9272346 rs1701704 N/A N/A KRT18 6580270 1.87x10-06 9.40x10 -06 2,06% 1,39%
SNP1 SNP2 SNP1 SNP2 SNP1 SNP2
SNP-pair convergences eQTL significance Explained expression variance
50
Figure 5. Trait-associated SNPs show convergence on multiple genes.
For several traits different and unlinked SNPs affect the same genes in cis or trans. For beta 
thalassemia three different loci affect hemoglobin (HBG2) gene expression (one in cis, indicated 
with gray arrow, two in trans (at FDR 0.05), indicated with cyan arrows). For mean corpuscular 
volume (MCV) the same trans-effects on HBG2 (at FDR 0.05) exist, but convergence is also 
apparent on ESPN, VWCE, PDKZ1IP1 and RAP1GAP (at FDR 0.50). For mean platelet volume (MPV) 
numerous trans-effects on genes involved in blood coagulation were identifi ed. Two MPV loci 
(rs12485738 on 3p26.3 and rs11602954 on 11p15.5) both affect GP9, F13A1 and C19orf33 (at FDR 
0.05) and SAMD14, GNG11 and VCL (at FDR 0.50). Peripheral blood co-expression (Pearson 
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when assessing total peripheral blood RNA. If this were to be the 
case, a measurable trans-effect is expected for platelet-specific 
(blood coagulation) genes in whole blood. Such an effect would 
then not actually be an expression-QTL, but rather a ‘cellular-
QTL’. However, the trans-eQTLs for rs12485738 were also present 
in single cell-type monocyte datasets, indicating that the above 
concerns do not apply. Clearly, trans-eQTL effects can manifest 
themselves outside the primary cell-type, in which they are 
expected to operate.
 We also replicated 18 trait-associated trans-eQTLs (including 
AOAH, detected at FDR 0.05) in an independent dataset comprising 
four different non-blood tissues (subcutaneous adipose, visceral 
adipose, liver and muscle, Figure S5, Table S9 and S10). Since this 
dataset comprised only 90 samples, it is very encouraging that 18 
trans-eQTL could be replicated.
Discussion
Here we investigated gene expression in peripheral blood from 
1,469 individuals to identify cis- and trans-effects of common 
variants on gene expression levels. When comparing to other 
genetical genomics studies12–14,16,18,21–24,45,46 we observe an increasing 
percentage of genes that are cis- or trans-regulated (39% of 19,689 
unique genes at FDR 0.05). When eQTL studies further increase 
the sample-sizes and thus increase statistical power, we expect 
that for the far majority of genes the expression levels are to some 
extent determined by genetic variation.
 GWA studies have identified many loci, but it is still often 
unclear what the affected gene in each locus is. Here we showed 
that 39% of trait-associated SNPs affect gene expression in cis 
which is helpful in pinpointing the most likely gene per 
susceptibility locus. However, GWAS do not immediately provide 
insight in the trans-effects of these susceptibility variants on 
downstream genes. Here we identified for 2.6% of all trait-
associated SNPs trans-eQTL effects on in total 113 unique genes. 
While some of these trans-eQTLs are known to be involved in 
these phenotypes (such as HBG2 in hemoglobin protein levels and 
β-Thallasemia), most of these genes have not been implicated 
before in these complex traits, and provide additional insight in the 
downstream mechanisms of these variants. Interestingly, 48% of 
trans-acting trait-associated SNPs map within the HLA, indicating 
the HLA has a prominent role in regulating peripheral blood gene 
expression. This might partly explain why the HLA has been found 
to be associated with so many different diseases.
 While we concentrated on peripheral blood, we could replicate 
35% of the trans-eQTLs in monocytes. Particularly surprising was 
the observation that for SNPs, known to affect the volume of 
platelets or erythrocytes the identified trans-eQTL effects in whole 
blood were also present in these monocytes. Among these 
replicated genes are a considerable number of highly plausible 
trans-genes. For example, for mean platelet volume SNP 
rs12485738 we detected the same trans-eQTL effects on seven 
well-known blood coagulation genes (F13A1, GP1BB, GP9, ITGA2B, 
MMRN1, THBS1 and VWF) in both the peripheral blood data and 
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the monocyte data. Interestingly, in both datasets, trans-effects for 
this SNP on another 31 genes were identified as well, which 
suggests these genes play a role in blood coagulation. It can thus be 
concluded that trans-eQTLs, identified in peripheral blood, 
generally apply to monocytes as well. We assumed these eQTLs 
might therefore also be present in other, non-blood tissues, 
as previously observed for rodents47–49. Indeed we could replicate 
some of these trans-eQTLs in a smaller dataset of four non-blood 
tissues. Importantly, as mentioned before46, the allelic directions 
were nearly always identical to blood, which implies that trans-
eQTLs, if also present in another tissue, work in the same way.
 Our observation that sets of independent SNPs, associated 
with the same complex phenotype sometimes also affect exactly 
the same trans-gene, further substantiates the validity of our 
findings. Based on the reported effect-sizes of these variants on 
these complex phenotypes, we have shown here that the individual 
effects of these SNPs on trans-gene expression can often be 
stronger. This suggests that these down-stream gene expression 
effects do not fully propagate to the eventual phenotype and are 
somehow buffered. This ‘phenotypic buffering’ has been observed 
before in plants44 and suggests that additional compensatory 
mechanisms exist that control these complex phenotypes. 
However, we do realize that accurate estimates on this 
phenomenon requires the availability of both gene-expression and 
phenotype data for these traits. As we did not have these 
phenotypes for our samples, we relied upon estimates from 
literature. Future studies that have collected both genome-wide 
genotype, expression and phenotype data from the same 
individuals will permit answering the question what the extent of 
this phenotypic buffering is. We should emphasize that the number 
of converging pairs of SNPs that we identified must be a very 
strong underestimate, and as such the false-negative rate from this 
analysis is likely to be high: As we observed that on average 40.4% 
of the trait-associated SNPs affect gene expression levels in cis, 
we expect that many of these SNPs will exert effects on gene 
expression in trans. However, these effects are likely to be small 
and due to multiple testing issues our current study identified only 
a relatively small set of trans-eQTL effects. Likewise the number of 
detected converging pairs of SNPs is even smaller. However, as we 
observed this convergence for various pairs of SNPs, future 
genetical genomics studies using larger sample sizes will likely 
reveal many more pairs of converging SNPs, providing better 
insight in the downstream molecular mechanisms that are affected 
by these disorders.
 The convergence and phenotypic buffering we observed might 
also help uncover some of the missing heritability in complex 
disease. As there are probably many SNPs with low marginal 
phenotypic effects50, GWAS currently lack power to detect these. 
However, the effect of these trait-associated SNPs on expression 
seems to be less multifactorial, leading to larger expression effects. 
These numerous expression disturbances will eventually converge 
to a phenotype, explaining the small phenotypic effect of individual 
trait-associated SNPs.
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 Therefore, studying expression as intermediate phenotype will 
be important for disease association studies trying to account for 
the missing heritability of complex diseases. Disease SNPs, already 
found to be disease-associated and marked as eQTL, lead to a set 
of candidate downstream genes. Additional genetic variants that 
also affect the expression of these genes will therefore be powerful 
candidates for disease susceptibility.
Materials and Methods
Peripheral blood genetical genomics study 
populations
 The peripheral blood genetical genomics study population 
contained 1,469 unrelated individuals from the United Kingdom 
and the Netherlands. Some of these are healthy controls while 
others are patient samples. The 49 ulcerative colitis (UC) cases in 
this study are part of the inflammatory bowel disease (IBD) cohort 
of the University Medical Centre Groningen. The 111 celiac disease 
samples were collected within the Barts and the London NHS 
Trust and the Oxford Radcliffe Hospitals NHS Trust. The 453 
chronic obstructive pulmonary disease (COPD) samples were 
collected within the NELSON study. The 856 amyotrophic lateral 
sclerosis (ALS) cases and controls were collected in the University 
Medical Centre Utrecht. All samples were collected after informed 
consent and approved by local ethical review boards. Individual 
sample information is provided in Table S11.
 Peripheral blood (2.5 ml) for all samples was collected with the 
PAXgene system (PreAnalytix GmbH, UK). PAXgene vials were 
chosen to prevent density gradient centrifugation, immortalization 
or in vitro cell culture artifacts changing mRNA profiles. PAXgene 
tubes were mixed gently and incubated at room temperature for 
two hours. After collection, tubes were frozen at 220°C for at 
least 24 hours followed by storage at 280°C. RNA was isolated 
using the PAXgene Blood RNA isolation kit (PreAnalytix GmbH, 
UK). RNA was quantified using the Nanodrop (Nanodrop 
Technolo-gies, USA). Total RNA integrity was analyzed using an 
Agilent Bioanalyzer (Agilent Technologies, USA).
Peripheral blood SNP genotyping
 Peripheral blood samples were either genotyped using the 
Illumina (Illumina, San Diego, USA) HumanHap300, Human-Hap370 
or 610 Quad platform. Genotyping was performed according to 
standard protocols from Illumina. Although the different genotype 
oligonucleotide arrays differ, they share 294,757 SNPs, to which 
the analysis was confined. In addition, SNPs with a minor allele 
frequency of < 5%, or a call-rate < 95%, or deviating from Hardy-
Weinberg equilibrium (exact p-value < 0.001) were excluded, 
resulting in 289,044 SNPs for further analysis. Genotype calling for 
each SNP was performed by a previously described algorithm51.
Peripheral blood Illumina expression profiling
 Anti-sense RNA was synthesized, amplified and purified using 
the Ambion Illumina TotalPrep Amplification Kit (Ambion, USA) 
following the manufacturers’ protocol. Complementary RNA was 
either hybridized to Illumina HumanRef-8 v2 arrays (229 samples, 
further referred to as H8v2) or Illumina HumanHT-12 arrays (1,240 
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samples, further referred to as HT12) and scanned on the Illumina 
BeadArray Reader. Raw probe intensities were extracted using 
Illumina’s BeadStudio Gene Expression module v3.2 
(No background correction was applied, nor did we remove 
probes with low expression). The raw expression data of the 1,240 
HT12 peripheral blood samples were combined with the raw 
expression data of 296 replication samples (described in detail in 
paragraph ‘Trans-eQTL replication dataset’). Both datasets (H8v2 
and HT12) were quantile normalized separately to the median 
distribution and expression values were subsequently 
log2 transformed. Subsequently, the probes were centered to zero 
and linearly scaled such that each probe had a standard deviation of 
one.
Integration of the Illumina H8V2 and HT12 peripheral 
blood expression platform identifiers
 The HT12 and H8v2 arrays share a considerable number of 
probes with identical probe sequences. However, in a considerable 
number of occasions the two platforms use different probe 
identifiers for the same probe sequences. More importantly, 
although probe identifiers are often identical, they sometimes 
represent different probe sequences. In order to permit a meta-
analysis incorporating data from both arrays, we decided on the 
following naming convention: if an H8v2 probe had the same 
sequence as an HT12 probe, the HT12 ‘ArrayAddressID’ probe 
identifier was used. If not, the original H8v2 probe identifier was 
used, but with the prefix ‘‘Human_RefSeq-8_v2-’’ to prevent any 
potential probe identifier ambiguity. A total of 52,061 unique 
probes were used for further analysis, representing 19,609 unique 
genes according to HUGO gene nomenclature.
Initial genomic mapping of Illumina expression probe 
sequences
 Various mapping strategies were used for the expression 
probes to get a mapping location that was as unambiguous as 
possible: if probes have been mapped incorrectly, or cross-
hybridize to multiple genomic loci, it might be that an eQTL will be 
incorrectly deemed a trans-eQTL, while in fact it is a cis-eQTL or 
primer polymorphisms. We used Ensembl database version 52 
(NCBI 36.3 assembly) to obtain, for each annotated gene, 
the transcript with the largest number of exons and included this 
main spliced transcript in our reference set. Second, we added one 
sequence per intron, extending intron boundaries 40 bp on each 
side to allow mapping of the 50 bp probe sequences that 
overlapping exon-intron junctions. Last, a version of the reference 
DNA genome with masked annotated transcripts was included. 
Probe sequences were mapped using NOVOALIGN V2.05.12 for 
all the sequences (main transcript, introns, and non-standard 
exon-exon junctions) originating from the same transcript 
(parameters 2t 150 2v 20 20 200 [.]( [ˆ_]*)_). For each probe it 
was determined whether it was mapping uniquely to one particular 
genomic locus, or, if multiple hits were present whether all these 
mappings resided in each other vicinity (< 250 kb). Probes that did 
not map at all, or mapped to multiple different loci were excluded 
from further analyses. Using this approach, 43,202 of the 48,751 
probes on the HT12 and 21,316 of the 22,185 probes on the H8v2 





















































































 In order to detect cis-eQTLs, analysis was confined to those 
probe-SNP combinations for which the distance from the probe 
transcript midpoint to SNP genomic location was ≤ 250 kb. 
For trans-eQTLs, analysis was confined to those probe-SNP 
combinations for which the distance from probe transcript 
midpoint to SNP genomic location was ≥ 5 Mb (to exclude the 
possibility of accidentally detecting cis-eQTLs due to long ranging 
linkage disequilibrium). Additionally, for the trans-eQTL analysis the 
effects of the significant cis-eQTLs were removed from the expression 
data by keeping the residual expression after linear regression.
 Association for cis- and trans-eQTL was tested with a non-
parametric Spearman’s rank correlation. For directly genotyped 
SNPs we coded genotypes as 0, 1 or 2, while for imputed SNPs we 
used SNP dosage values, ranging between 0 and 2. When a 
particular probe-SNP pair was present in both the HT12 and H8v2 
datasets, an overall, joint p-value was calculated using a weighted 
(square root of the dataset sample number) Z-method.
 To correct for multiple testing, we controlled the false-
discovery rate (FDR) at 0.05: the distribution of observed p-values 
was used to calculate the FDR, by comparison with the distribution 
obtained from permuting expression phenotypes relative to 
genotypes 100 times within the HT12 and H8v2 dataset for both 
the cis- and trans-analyses52.
 In order to increase the number of detectable cis- and trans-
eQTLs we applied a principal component analysis (PCA) on the 
sample correlation matrix. We, among others19,20, argue that the 
dominant PCs, capturing the larger part of the total variation, will 
primarily capture sample differences in expression that reflect 
physiological or environmental variation as well as systematic 
experimental variation (e.g. batch and technical effects). Figure S6 
shows for the 1,240 HT12 samples what per individual the PC 
scores are. It is evident there are, especially among the first PCs, 
strong batch effects are still present after proper quantile-quantile 
normalization. By removing the variation captured by these PCs, 
we expected that the residual expression is more strongly 
determined by genetic variants and the number of significantly 
detected cis- and trans-eQTLs will increase. An aspect to consider 
is that with the removal of more PCs from the data, the degrees of 
freedom of the data will decrease. Furthermore, it is not 
immediately clear which PCs will actually capture physiological, 
environmental, and systematic variation, which might lead to 
removal of genetically determined expression variation as well. 
Therefore a tradeoff has to be made on the number of PCs to 
subtract from the data. We assessed this systematically, 
by removing up to 100 PCs from the genetical genomics dataset (in 
steps of 5).
 Figure S7A shows that the number of significantly detected 
cis-eQTL probes increases two-fold when 50 PCs were removed 
from the expression data. There is a long plateau visible (around 
PC50), where the number of detected cis-eQTLs probes remains 
approximately constant, irrespective of removing for instance 10 
fewer or 10 extra PCs (reported numbers in this figure also include 
false-positive eQTLs due to potential primer polymorphisms, as we 
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here wanted to solely compare the performance of removing 
different numbers of PCs). Figure S7B shows that of the initial 
5,950 significantly detected cis-eQTL probes (no PCs removed), 
4,965 (83.5%) were still detected with 50 PCs subtracted. The 985 
initially detected cis-eQTLs probes, yet no longer detected when 
50 PCs had been removed from the expression data, all had a low 
significance (Figure S8). As we controlled the FDR at 0.05 in all 
analyses it is therefore likely that a considerable amount of these 
reflect false-positives. Figure S8C shows that for all the overlapping 
4,965 detected cis-eQTLs probes between the different analyses, 
the allelic direction was identical, and effect size on expression 
correlate well (Pearson r = 0.95) although these were nearly 
always stronger after having subtracted 50 PCs.
 We assessed this for trans-eQTLs as well. An important aspect 
to consider is that trans-eQTL SNPs might affect multiple genes. If 
these effects are substantial (either in effect size or the number of 
affected genes), it is likely that a certain PC will capture this. 
Removal of such PCs from the expression data will therefore 
unintentionally result in the inability to detect these trans-eQTLs. 
In order to avoid such false-negatives we first performed a QTL 
analysis on the first 50 PCs (that had been removed from the 
expression data for the cis-eQTL analysis) to assess whether some 
of these PCs are under genetic control (genome-wide analysis, 
controlling FDR at 0.05). We did this for the large HT12 and the 
smaller H8v2 expression data separately, as PCA had been applied 
independently to these datasets. We observed that out of the first 
PCs in the HT12 data three PCs and in the H8v2 two PCs were to 
some extent genetically determined (r2 > 5%). This was different 
for PCAs 26–50 in the HT12 data: 11 PCs were under substantial 
genetic control (Figure S9a). We therefore assumed that most 
trans-eQTLs could be detected when removing approximately 25 
PCs. We quantified this systematically, by removing increasing 
amounts of PCs from the expression data and conducting a full 
genome-wide trans-eQTL mapping. Indeed, in these analyses at 
most 244 significant trans-eQTLs could be detected (at FDR 0.05, 
with potential false-positives due to cross-hybridizations removed), 
when removing 25 PCs (Figure S9b). The overlap with the 
expression with no PCs removed was substantial: 62 of the 82 
trans-eQTLs (77%), detected in the original analysis were detected 
as well in the analysis with 25 PCs removed (Figure S9c), all with 
identical allelic directions (Figure S9d).
Identification of false eQTLs due to primer 
polymorphisms and cross-hybridization
 One should be aware that sequence polymorphisms can cause 
many false cis-eQTLs53. Such false cis-eQTLs do not reflect actual 
expression differences caused by sequence polymorphisms in 
cis-acting factors that affect mRNA levels. Instead they indicate 
hybridization differences caused by sequence polymorphisms in the 
mRNA region that is targeted by the microarray expression 
probes. Therefore, SNP-probe combinations were excluded from 
the cis-eQTL analysis when the 50 bp long expression probe 
mapped to a genomic location that contained a known SNP that 
was showing at least some LD (r2 > 0.1) with the cis-SNP. We used 
SNP data from the 1000 Genomes Projects, as it contains LD 
information for 9,633,115 SNPs (April 2009 release, based on 57 
CEU samples of European descent).
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 Detected trans-eQTLs might also reflect false-positives, 
although we initially had attempted to map the expression probes 
as accurately as possible, by using the aforementioned three 
different mapping strategies: it is still well possible that some of the 
identified, putative trans-eQTLs in fact reflect very subtle cross-
hybridization (e.g. pertaining to only a small subsequence of the 
probe). We therefore tried to falsify each of the putative trans-
eQTLs by attempting to map each trans-probe into the vicinity of 
the SNP probe location, by using a highly relaxed mapping 
approach. All putative Illumina trans-expression probes were 
mapped using SHRiMP54, which uses a global alignment approach, 
to the human reference genome (NCBI 36.3 build). The mapping 
settings were chosen very loosely to permit the identification of 
nearly all potential hybridization locations: match score was 10, 
the mismatch score was 0, the gap open penalty was 2250, the gap 
extension penalty was 2100, Smith and Waterman minimum 
identical alignment threshold was 30.0%, while other SHRiMP 
parameters were left at default. Using these settings all mappings 
with a minimum overlap of 15 bases, or with 20 matches with one 
mismatch, or 30 matches with 2 mismatches, or full-length (50 bp) 
probe hybridizations with no more than 15 mismatches were 
accepted. Any trans-eQTL was discarded, if the expression probe 
had a mapping that was within 2 Mb of the SNP that showed the 
trans-eQTL effect. Once these potential false-positive trans-eQTLs 
had been removed from the real, non-permuted data, we repeated 
the multiple testing correction (again controlling the FDR at 0.05).
 Using this strategy we observed several instances where only 
20 out the 50 bases of a probe sequence mapped in the vicinity of 
the trans-SNP (data not shown). For these trans-eQTLs the 
Spearman’s rank correlation p was often lower than 10-100, 
which would imply these SNPs explain over 25% of the total 
expression variation of the corresponding trans-genes. Given the 
small amount of trans-eQTLs we detected in total, such effect sizes 
are quite unlikely and therefore provide circumstantial evidence 
these indeed reflect cross-hybridization artifacts.
 We also assessed whether any of the Illumina SNPs that 
constitute trans-eQTLs might map to a different position than what 
is reported in dbSNP. As such we mapped the 50 bp Illumina SNP 
probe sequences to the genome assembly, permitting up to four 
mismatches per 50 bp SNP probe sequence. We did not observe 
any SNP that could map (with some mismatches) to the same 
chromosome of the trans-probe.
 It is still possible that some of the trans-eQTLs for which we 
did not find any evidence of cross-hybridization, still are false 
positives, by missing some cross-hybridizations due to 
imperfections in the NCBI v36 assembly we used. Although we 
have identified numerous occasions where a SNP affects two 
different probes within the same gene in trans, substantiating the 
likelihood these trans-eQTLs are real, providing unequivocal 
evidence that all our reported trans-eQTLs are real is not 
straightforward.
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Enrichment analysis of trait-associated SNPs and 
SNPs located within the HLA region
 To assess enrichment of trait-associated SNPs, we used a 
collection of 1,262 unique SNPs from ’A Catalog of Published 
Genome-Wide Association Studies’ (accessed 09 February 2010, 
and each having at least one reported association p-value < 5.0 x 
10-7). We could successfully impute the genotypes for 1,167 of 
these SNPs and therefore confined all analyses to these SNPs. Of 
these SNPs 572 had been directly genotyped on the Illumina 
HumanHap300 platform, with a MAF < 0.05, an HWE exact 
p-value < 0.0001 and call-rate < 95%.
 To ascertain whether these SNPs are more often constituting 
an eQTL than expected, we used a methodology that is not 
affected by the following potential confounders: non-even 
distribution of SNP markers and expression probe markers across 
the genome, differences in MAF between SNPs and LD structure 
within the genotype date and correlation between probes in the 
expression data. Additionally, this methodology is also not 
confounded by the fact that for certain traits different SNPs in 
strong LD can have been reported, due to differences in the 
platforms that were used to identify these loci. We first 
determined how many unique eQTL SNPs had been identified in 
the original eQTL mapping (with an FDR < 0.05) and how many of 
these are trait-associated. Subsequently we permuted the 
expression phenotypes relative to the genotypes (thus keeping the 
correlation structure within the genotype data and the correlation 
structure within the expression data intact, yet assigning the 
genotypes of a sample to the expression data of a randomly chosen 
sample) and reran the eQTL mapping, sorting all tested eQTLs on 
highest significance. We then took an equal number of top 
associated, but permuted, eQTL SNPs and determined how many 
of these permuted eQTL SNPs are trait-associated. By performing 
100 permutations we obtained an empiric distribution of the 
number of trait-associated SNPs expected by chance. 
We subsequently fitted a generalized extreme value distribution 
(EVD, using the EVD add-on package for R), permitting us to 
estimate realistic enrichment significance estimates (called EVD p 
throughout the manuscript).
 For the MHC enrichment analysis the followed procedure was 
identical, with the difference that we looked for enrichment for 
SNPs within the MHC, defined as SNPs physically mapping 
between 20 Mb and 40 Mb on chromosome 6 (NCBI 36 assembly).
Trans-eQTL replication datasets
 Replication of the detected eQTLs was performed in monocytes 
from 1,490 different samples45 and in an independent population of 
86 morbidly obese individuals that underwent elective bariatric 
surgery (Department of general surgery, Maastricht University 
Medical Centre, the Netherlands).Both these datasets also used 
the same Illumina HumanHT-12 expression platform.
 For the 1,490 monocyte samples eQTL P-Values summary 
statistics were available for all monocyte trans-eQTLs with a 
nominal p < 1.0 x 10-5. We ascertained how many of the trans-
eQTLs we had found in our peripheral blood data had a nominal 



















































































 We also assessed trans-eQTLs in four different tissues from the 
86 morbidly obese individuals that underwent bariatric surgery. 
DNA was extracted from blood samples using the Chemagic 
Magnetic Separation Module 1 (Chemagen) integrated with a 
Multiprobe II Pipeting robot (PerkinElmer). All samples were 
genotyped using both Illumina HumanCytoSNP-12 BeadChips and 
Illumina HumanOmni1-Quad BeadChips (QC was identical as was 
applied to the peripheral blood samples). We imputed HapMap 2 
genotypes using Impute version 2.0. In addition expression profiling 
was performed for four different tissues for each of these 
individuals using the Illumina HumanHT-12 arrays. Wedge biopsies 
of liver, visceral adipose tissue (VAT, omentum majus), 
subcutaneous adipose tissue (SAT, abdominal), and muscle 
(musculus rectus abdominis) were taken during surgery. RNA was 
isolated using the Qiagen Lipid Tissue Mini Kit (Qiagen, UK, 
74804). Assessment of RNA quality and concentration was done 
with an Agilent Bioanalyzer (Agilent Technologies USA). Starting 
with 200 ng of RNA, the Ambion Illumina TotalPrep Amplification 
Kit was used for anti-sense RNA synthesis, amplification, 
and purification according to the protocol provided by the 
manufacturer (Ambion, USA). 750 ng of complementary RNA was 
hybridized to Illumina HumanHT12 BeadChips and scanned on the 
Illumina BeadArray Reader. Expression data preprocessing was as 
mentioned before. We first attempted to replicate the trait-
associated trans-eQTLs per tissue, using an FDR of 0.05 and 100 
permutations. Subsequently we conducted a meta-analysis, 
combining the four tissues. Per trans-eQTL we used a weighted 
Z-method to combine the four individual p-values. However, these 
four datasets are not independent, as they reflect the same 
individuals. We resolved this by conducting the permutations in 
such a way that in every permutation round the samples were 
permuted in exactly the same way for each of the four tissues. 
By doing this we retained the correlations that exist between the 
different tissues per sample, and were able to get a realistic 
empiric (null-) distribution of expected test-statistics.
Convergence analysis
 Per trait we assessed all the SNPs that have been reported to 
be associated with that particular trait. We analyzed per trait all 
possible SNP-pairs. If a pair of SNPs was not in LD (r2 < 0.001) we 
assessed whether they affected the same gene in cis or trans. 
When using the trait-associated cis- and trans-eQTLs that had been 
identified when controlling the FDR at 0.05, we identified 7 unique 
pairs of SNPs that caused both the same phenotype and also 
affected the same gene(s). When using a somewhat more relaxed 
set of trans-eQTLs, identified when controlling the FDR at 0.5, 
we identified 18 unique pairs of SNPs that affect the same 
downstream gene.
 We assessed whether these numbers were significantly higher 
than expected, by using the same strategy that we had used to 
assess the enrichment of trait-associated SNPs and the HLA; 
we ran 100 permutations. We kept per permutation the cis-eQTL 
list as it was, but generated a permuted set of trans-eQTLs, equal 
in size to the original set of non-permuted trans-eQTLs. 
This enabled us to determine per permutation round how many 
unique pairs of SNPs converge on the same gene(s). 
We subsequently fitted a generalized extreme value distribution, 
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permitting us to estimate realistic enrichment significance 
estimates.
Co-expression between genes, based on HT12 
peripheral blood co-expression
 If a particular SNP is cis-or trans-acting on multiple genes, it is 
plausible that those genes are biologically related. Co-expression 
between these genes provides circumstantial evidence this is the 
case, strengthening the likelihood such cis- and trans-eQTLs are 
real. We assessed this in the peripheral blood data, by using the 
expression data of the 1,240 samples, run on the comprehensive 
HT12 expression platform. As we had removed 25 PCs (to remove 
physiological, environmental variation, and systematic experimental 
variation) for the trans-eQTL analyses, we decided to confine 
co-expression analyses to this expression dataset. As there are 
43,202 HT12 probes that we mapped to a known genomic location, 
43,202 * 43,201/2 = 933,184,801 probe-pairs exist. Given 1,240 
samples, a Pearson correlation coefficient r ≤ 0.19 corresponds to 
a p < 0.05 when applying stringent Bonferroni correction for these 
number of probe-pairs.
Accession numbers
Expression data for both the peripheral blood and the four 
non-blood datasets have been deposited in GEO with accession 
numbers GSE20142 (1,240 peripheral blood samples, hybridized to 
HT12 arrays), GSE20332 (229 peripheral blood samples, hybridized 
to H8v2 arrays) and GSE22070 (subcutaneous adipose, visceral 
adipose, muscle and liver samples).
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Abstract
 The functional consequences of trait associated SNPs are often 
investigated using expression quantitative trait locus (eQTL) 
mapping. While trait-associated variants may operate in a cell-type 
specific manner, eQTL datasets for such cell-types may not always 
be available. We performed a genome-environment interaction 
(GxE) meta-analysis on data from 5,683 samples to infer the cell 
type specificity of whole blood cis-eQTLs. We demonstrate that 
this method is able to predict neutrophil and lymphocyte specific 
cis-eQTLs and replicate these predictions in independent cell-type 
specific datasets. Finally, we show that SNPs associated with 
Crohn’s disease preferentially affect gene expression within 
neutrophils, including the archetypal NOD2 locus.
Author summary
 
 Many variants in the genome, including variants associated with 
disease, affect the expression of genes. These so-called expression 
quantitative trait loci (eQTL) can be used to gain insight in the 
downstream consequences of disease. While it has been shown 
that many disease associated variants alter gene expression in a 
cell-type dependent manner, eQTL datasets for specific cell types 
may not always be available and their sample size is often limited. 
We present a method that is able to detect cell type specific 
effects within eQTL datasets that have been generated from whole 
tissues (which may be composed of many cell types), in our case 
whole blood. By combining numerous whole blood datasets 
through meta-analysis, we show that we are able to detect eQTL 
effects that are specific for neutrophils and lymphocytes 
(two blood cell types). Additionally, we show that the variants 
associated with some diseases may preferentially alter the gene 
expression in one of these cell types. We conclude that our 
method is an alternative method to detect cell type specific eQTL 
effects, that may complement generating cell type specific eQTL 
datasets and that may be applied on other cell types and tissues as 
well.
Introduction
 In the past seven years, genome-wide association studies 
(GWAS) have identified thousands of genetic variants that are 
associated with human disease1. The realization that many of the 
disease-predisposing variants are non-coding and that single 
nucleotide polymorphisms (SNPs) often affect the expression of 
nearby genes (i.e. cis-expression quantitative trait loci; cis-eQTLs)2 
suggests these variants have a predominantly regulatory function. 
Recent studies have shown that disease-predisposing variants in 
humans often exert their regulatory effect on gene expression in a 
cell-type dependent manner3–5. However, most human eQTL 
studies have used sample data obtained from mixtures of cell types 
(e.g. whole blood) or a few specific cell types (e.g. lympoblastoid 
cell lines) due to the prohibitive costs and labor required to purify 
subsets of cells from large samples (by cell sorting or laser capture 
micro-dissection). In addition, the method of cell isolation can 
trigger uncontrolled processes in the cell, which can cause biases. 
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In consequence, it has been difficult to identify in which cell types 
most disease-associated variants exert their effect.
 Here we describe a generic approach that uses eQTL data in 
mixtures of cell types to infer cell-type specific eQTLs (Figure 1). 
Our strategy includes: (i) collecting gene expression data from an 
entire tissue; (ii) predicting the abundance of its constituent cell 
types (i.e. the cell counts), by using expression levels of genes that 
serve as proxies for these different cell types (since not all datasets 
might have actual constituent cell count measurements). We used 
an approach similar to existing expression and methylation 
deconvolution methods6–11; (iii) run an association analysis with a 
term for interaction between the SNP and the proxy for cell count 
to detect cell-type-mediated or -specific associations, and (iv) test 
whether known disease associations are enriched for SNPs that 
show the cell-type-mediated or -specific effects on gene 
expression (i.e. eQTLs). 
Figure 1. Method overview
I) Starting with a dataset that has cell count measurements, determine a set of probes that have a 
strong positive correlation to the cell count measurements. Calculate the correlation between 
these specific probes in the other datasets, and apply principal component analysis to combine 
them into a single proxy for the cell count measurement. II) Apply the prediction to other 
datasets lacking cell count measurements. III) Use the proxy as a covariate in a linear model with 
an interaction term in order to distinguish cell-type-mediated from non-cell-type-mediated eQTL 
effects.
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II Apply classifier to other cohorts with no 
neutrophil granulocyte percentage 
information available
I Identify probes that strongly correlate with neutrophil 
granulocyte percentage in whole peripheral blood: 58 
probes in EGCUT (each r > 0.55). Build classifier on 58 
probes (r = 0.74 in EGCUT, n = 826)
Replicate classifier based on these 58 probes in 
independent cohort (SHIP-TREND; n = 962, r = 0.82) 
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Results
 We applied this strategy to 5,863 unrelated, whole blood 
samples from seven cohorts: EGCUT12, InCHIANTI13, Rotterdam 
Study14, Fehrmann2, SHIP-TREND15, KORA F416, and DILGOM17. 
Blood contains many different cell types that originate from either 
the myeloid (e.g. neutrophils and monocytes) or lymphoid lineage 
(e.g. B-cells and T-cells). Even though neutrophils comprise ~62% 
of all white blood cells, no neutrophil eQTL data have been 
published to date, because this cell type is particularly diffi cult to 
purify or culture in the lab18. 
 For the purpose of illustrating our cell-type specifi c analysis 
strategy in the seven whole blood cohorts, we focused on 
neutrophils. Direct neutrophil cell counts and percentages were 
only available in the EGCUT and SHIP-TREND cohorts, requiring 
us to infer neutrophil percentages for the other fi ve cohorts.
We used the EGCUT cohort as a training dataset to identify a list 
of 58 Illumina HT12v3 probes that correlated positively with 
neutrophil percentage (Spearman’s correlation coeffi cient
R > 0.55). We then summarized the gene expression levels of these 
58 individual probes into a single neutrophil percentage estimate, 
by applying principal component analysis (PCA) and using the fi rst 
principal component; an approach that is similar to existing 
expression and methylation deconvolution methods6-11. We then 
used this procedure in the other cohorts to predict the neutrophil 
percentage (see Figure 2 for confi rmation of the accuracy of 
prediction in the SHIP-TREND cohort; Spearman R = 0.81).
 Here we limit our analysis to 13,124 cis-eQTLs that were 
previously discovered in a whole blood eQTL meta-analysis of a 
comparable sample size19 (we note that these 13,124 cis-eQTLs 
were detected while assuming a generic effect across cell-types, 
and as such, genome-wide application of cell-type specifi city 
strategy might result in the detection of additional cell-type-
specifi c cis-eQTLs). To infer the cell-type specifi city of each of 
these eQTLs, we performed the eQTL association analysis with a 
term for interaction between the SNP marker and the proxy for 
cell count within each cohort, followed by a meta-analysis of the 
Figure 2. Validation of neutrophil proxy
There is a strong correlation between the neutrophil proxy and the actual neutrophil percentage 
measurements in the training dataset (EGCUT, r = 0.74). Validation of neutrophil prediction in the 
SHIP-TREND cohort shows a strong correlation (r = 0.81) between the neutrophil proxy and 
actual neutrophil percentage measurements in this dataset. 
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Figure 3. Validation of neutrophil and lymphoid specific cis-eQTLs in 
purified cell type eQTL datasets
A) We validated the neutrophil- and lymphoid-mediated cis-eQTL effects in four purified cell type 
datasets from the lymphoid lineage (B-cells, CD4+ T-cells, CD8+ T-cells and lymphoblastoid cell 
lines) and in two datasets from the myeloid lineage (monocytes and neutrophils). Compared to 
generic cis-eQTLs, large effect sizes were observed for neutrophil-mediated cis-eQTLs in myeloid 
lineage cell types, and small effect sizes in the lymphoid datasets. Conversely, lymphoid-mediated 
cis-eQTL effects had large effect sizes specifically in the lymphoid lineage datasets, while having 
smaller effect sizes in myeloid lineage datasets. These results indicate that our method is able to 
reliably predict whether a specific cis-eQTL is mediated by cell type.
B) Comparison between average gene expression levels between different purified cell type eQTL 
datasets shows that neutrophil mediated cis-eQTLs have, on average a lower expression in cell 
types derived from the lymphoid lineage, and a high expression in myeloid cell types, while the 
opposite is true for lymphocyte mediated cis-eQTLs.
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interaction term (weighted for sample size) across all the cohorts. 
We identified 1,117 cis-eQTLs with a significant interaction effect 
(8.5% of all cis-eQTLs tested; false discovery rate (FDR) < 0.05; 
1,037 unique SNPs and 836 unique probes; Supplementary Tables 1 
and 2). Out of the total number of cis-eQTLs tested, 909 (6.9%) 
had a positive direction of effect, which indicates that these 
cis-eQTLs show stronger effect sizes when more neutrophils are 
present (i.e. ‘neutrophil-mediated cis-eQTLs’; 843 unique SNPs and 
692 unique probes). Another 208 (1.6%) had a negative direction of 
effect (196 unique SNPs and 145 unique probes), indicating a 
stronger cis-eQTL effect size when more lymphoid cells are 
present (i.e. ‘lymphocyte-mediated cis-eQTLs’; since lymphocyte 
percentages are strongly negatively correlated with neutrophil 
percentages, Figure 1). Overall, the directions of the significant 
interaction effects were consistent across the different cohorts, 
indicating that our findings are robust (Supplementary Figure 1).
 We validated the neutrophil- and lymphoid-mediated 
associations we detected in six small, purified cell-type gene 
expression datasets that had not been used in our meta-analysis. 
We generated new eQTL data from two lymphoid cell types 
(CD4+ and CD8+ T-cells) and one myeloid cell type (neutrophils, 
see online methods) and used previously generated eQTL data on 
two lymphoid cell types (lymphoblastoid cell lines and B-cells) and 
another myeloid cell type (monocytes, Supplementary Table 3). 
As expected, compared to cis-eQTLs without a significant 
interaction term (‘generic cis-eQTLs’, n = 12,007) the 909 
neutrophil-mediated cis-eQTLs did indeed show very strong 
cis-eQTL effects in both of the myeloid datasets (Wilcoxon 
P-value ≤ 4.9 x 10-31), and small effect sizes in the lymphoid 
datasets. Conversely, the 208 lymphoid-mediated cis-eQTLs had a 
pronounced effect in each of the lymphoid datasets (Wilcoxon 
P-value ≤ 7.8 x 10-14; Figure 3A), while having small effect sizes in 
the myeloid datasets. These results indicate that our method is 
able to reliably predict whether a cis-eQTL is mediated by a 
specific cell type. Unfortunately, the cell type that mediates the 
cis-eQTL is not necessarily the one in which the cis-gene has the 
highest expression (Figure 3B), making it impossible to identify 
cell-type-specific eQTLs directly on the basis of expression levels.
 Myeloid and lymphoid blood cell types provide crucial 
immunological functions. Therefore, we assessed five immune-
related diseases for which genome-wide association studies 
previously identified at least 20 loci with a cis-eQTL in our meta-
analysis. We observed a significant enrichment only for Crohn’s 
disease (CD), (binomial test, one-tailed P = 0.002, Supplementary 
Table 4): out of 49 unique CD-associated SNPs showing a cis-eQTL 
effect, 11 (22%) were neutrophil-mediated. These 11 SNPs affect 
the expression of 14 unique genes (ordered by size of interaction 
effect: IL18RAP, CPEB4, RP11-514O12.4, RNASET2, NOD2, CISD1, 
LGALS9, AC034220.3, SLC22A4, HOTAIRM2, ZGPAT, LIME1, 
SLC2A4RG, and PLCL1). CD is a chronic inflammatory disease of the 
intestinal tract. While impaired T-cell responses and defects in 
antigen presenting cells have been implicated in the pathogenesis of 
CD, so far little attention has been paid to the role of neutrophils, 
because its role in the development and maintenance of intestinal 
inflammation is controversial: homeostatic regulation of the 































neutrophils in the intestinal submucosal space can lead to 
inflammation. On the one hand, neutrophils are essential in killing 
microbes that translocate through the mucosal layer. The mucosal 
layer is affected in CD, but also in monogenic diseases with 
neutropenia and defects in phagocyte bacterial killing, such as 
chronic granulomatous disease, glycogen storage disease type I, 
and congenital neutropenia, leading to various CD phenotypes20. 
On the other hand, an increase in activated neutrophils that 
secrete pro-inflammatory chemokines and cytokines (including 
IL18RAP which has a neutrophil specific eQTL) maintains 
inflammatory responses. Pharmacological interventions for the 
treatment of CD have been developed to specifically target 
neutrophils and IL18RAP, including Sagramostim21 and 
Natalizumab22. Our new analysis shows clear neutrophil-mediated 
eQTL effects for many of the known CD genes, including the 
archetypal NOD2 gene, and our results provide deeper insight into 












































Figure 4. Effect of sample size on power to detect cell type specific 
cis-eQTLs
We systematically excluded datasets from our meta-analysis in order to determine the effect of 
sample size on our ability to detect significant interaction effects. The number of significant 
interaction effects was rapidly reduced when the sample size was decreased (the number of 
unique significant probes given a Bonferroni corrected P-value < 8.1 x 10-6 is shown). In general, 
due to their low abundance in whole blood, lymphoid-mediated cis-eQTL effects are harder to 
detect than neutrophil-mediated cis-eQTL effects.
 20
Uhlig, H. H. Monogenic diseases associated with 
intestinal inflammation: implications for the 
understanding of inflammatory bowel disease. Gut 
62, 1795–805 (2013).
 21
Korzenik, J. R., Dieckgraefe, B. K., Valentine, J. F., 
Hausman, D. F. & Gilbert, M. J. Sargramostim for 
active Crohn’s disease. N. Engl. J. Med. 352, 
2193–201 (2005).
 22
Ghosh, S. et al. Natalizumab for active Crohn’s 
disease. N. Engl. J. Med. 348, 24–32 (2003).
71
 Large sample sizes are essential in order to find cell-type-
mediated cis-eQTLs (Figure 4): when we repeat our study on fewer 
samples (ascertained by systematically excluding more cohorts 
from our study), the number of significant cell-type-mediated 
eQTLs decreased rapidly. This was particularly important for the 
lymphoid-mediated cis-eQTLs, because myeloid cells are 
approximately twice as abundant as lymphoid cells in whole blood. 
Consequently, detecting lymphoid-mediated cis-eQTLs is more 
challenging than detecting neutrophil-specific cis-eQTLs. As whole 
blood eQTL data is easily collected, we were able to gather a 
sufficient sample size in order to detect cell-type-mediated or 
-specific associations without requiring the actual purification of 
cell types. 
Discussion
 Here we have shown that it is possible to infer in which blood 
cell-types cis-eQTLs are operating from a whole blood dataset. 
Cell-type proportions were predicted and subsequently used in a 
G x E interaction model. Hundreds of cis-eQTLs showed stronger 
effects in myeloid than lymphoid cell-types and vice versa.
 These results were replicated in 6 individual purified cell-type 
eQTL datasets (two reflecting the myeloid and four reflecting the 
lymphoid lineage). This indicates our G x E analysis provides 
important additional biological insights for many SNPs that have 
previously been found to be associated with complex (molecular) 
traits.
 Here, we concentrated on identifying cis-eQTLs that are 
preferentially operating in either myeloid or lymphoid cell-types. 
We did not attempt to assess this for specialized cell-types within 
the myeloid or lymphoid lineage. However, this is possible if 
cell-counts are available for these cell-types, or if these cell-counts 
can be predicted by using a proxy for those cell-counts. As such, 
identification of cell-type mediated eQTLs for previously unstudied 
cell-types is possible, without the need to generate new data. 
However, it should be noted that these individual cell-types 
typically have a rather low abundance within whole blood 
(e.g. natural killer cells only comprise ~2% of all circulating white 
blood cells). As a consequence, in order to have sufficient 
statistical power to identify eQTLs that are mediated by these 
cell-types, very large whole blood eQTL sample-sizes are required, 
specific cell types should be variable between individuals (which is 
analogous to the difference in the number of identified lymphoid 
mediated cis-eQTLs, as compared to the number of neutrophil 
mediated cis-eQTLs, which is likely caused by their difference in 
abundance in whole blood).
 We confined our analyses to a subset of cis-eQTLs for which 
we had previously identified a main effect in whole peripheral 
blood19: for each cis-eQTL gene, we only studied the most 
significantly associated SNP. Considering that for many cis-eQTLs 
multiple, unlinked SNPs exist that independently affect the gene 
expression levels, it is possible that we have missed myeloid or 
































 The method we have applied to predict the neutrophil 
percentage in the seven whole blood datasets involves correlation 
of gene expression probes to cell count abundances and 
subsequent combination of gene expression probes into a single 
predictor using PCA. This approach is comparable to other 
deconvolution methods for methylation and gene expression 
data6-11. Although we have shown that the proxy that is created by 
our method is able to predict neutrophil percentage accurately, 
this may not be the case for all cell types available in whole blood, 
which may be greatly dependent upon the ability of individual gene 
expression probes to differentiate between cell types. 
 However, we anticipate that the (pending) availability of large 
RNA-seq based eQTL datasets, statistical power to identify 
cell-type mediated eQTLs using our approach will improve: 
since RNA-seq enables very accurate gene expression level 
quantification and is not limited to a set of preselected probes that 
interrogate well known genes (as is the case for microarrays), 
the detection of genes that can serve as reliable proxies for 
individual cell-types will improve. Using RNA-seq data, it is also 
possible to assess whether SNPs that affect the expression of 
non-coding transcripts, affect splicing23 or result in alternative 
polyadenylation24 are mediated by specific cell-types.
 Although we applied our method to whole blood gene 
expression data, our method can be applied to any tissue, 
alleviating the need to sort cells or to perform laser capture micro 
dissection. The only prerequisite for our method is the availability 
of a relatively small training dataset with cell count measurements 
in order to develop a reliable proxy for cell count measurements. 
Since the number of such training datasets is rapidly increasing and 
meta-analyses have proven successful2,19, our approach provides a 
cost-effective way to identify cell-type-mediated or -specific 
associations that can supplement results obtained from purified 




 This eQTL meta-analysis is based on gene expression 
intensities measured in whole blood samples. RNA was isolated 
with either PAXgene Tubes (Becton Dickinson and Co., Franklin 
Lakes, NJ, USA) or Tempus Tubes (Life Technologies). To measure 
gene expression levels, Illumina Whole-Genome Expression 
Beadchips were used (HT12-v3 and HT12-v4 arrays, Illumina Inc., 
San Diego, USA). Although different identifiers are used across 
these different platforms, many probe sequences are identical. 
Meta-analysis could thus be performed if probe-sequences were 
equal across platforms. Integration of these probe sequences was 
performed as described before19. Genotypes were harmonized 
using HapMap2-based imputation using the Central European 
population25. In total, the eQTL genotype x environment 
interaction meta-analysis was performed on seven independent 
cohorts, comprising a total of 5,863 unrelated individuals. Mix-ups 
between gene expression samples and genotype samples were 
corrected using MixupMapper26. Gene expression normalization 
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was performed as described before19, removing up to 40 principal 
components (PCs). Additionally, we corrected for possible 
confounding factors due to arrays of poor RNA quality, by 
correlating the sample gene expression measurements against the 
first PC that was determined from the sample correlation matrix. 
Samples with a correlation < 0.9 were removed from further 
analysis.
Gene expression normalization
 Each cohort performed gene expression normalization 
individually: gene expression data was quantile normalized to the 
median distribution then log2 transformed. The probe and sample 
means were centered to zero. Gene expression data was then 
corrected for possible population structure by removing four 
multi-dimensional scaling components (MDS components obtained 
from the genotype data using PLINK) using linear regression. 
Because normalized gene-expression data still contains large 
amounts of non-genetic variation2,27, principal component analysis 
(PCA) was performed on the sample correlation matrix, and up to 
40 principal components (PCs) were then removed from the gene 
expression data using linear regression19. 
 In order to improve statistical power to detect cell-type 
mediated eQTLs, we corrected the gene expression for technical 
and batch effects (here we applied principal component analysis 
and removed per cohort the 40 strongest principal components 
that affect gene expression). Such procedures are commonly used 
when conducting cis-eQTL mapping2,5,19,23,24,28. To minimize the 
amount of genetic variation removed by this procedure, we 
performed QTL mapping for each principal component, to 
ascertain whether genetic variants could be detected that affected 
the PC. If such an effect was detected, we did not correct the gene 
expression data for that particular PC19. We chose to remove 40 
PCs based on our previous study results, which suggested that this 
was the optimum for detecting eQTLs19. We would like to stress 
that while PC-corrected gene expression data was then used as 
the outcome variable in our gene x environment interaction 
model, we used gene expression data that was not corrected for 
PCs to initially create the neutrophil cell percentage proxy.
Creating a proxy for neutrophil cell percentage from 
gene expression data
 To be able to determine whether a cis-eQTL is mediated by 
neutrophils, we reasoned that such a cis-eQTL would show a larger 
effect size in individuals with a higher percentage of neutrophils 
than in individuals with a lower percentage. However, this required 
the percentage of neutrophils in whole blood to be known, and 
cell-type percentage measurements were not available for all of the 
cohorts. We therefore created a proxy phenotype that reflected 
the actual neutrophil percentage that would also be applicable to 
datasets without neutrophil percentage measurements. In the 
EGCUT dataset, we first quantile normalized and log2 transformed 
the raw expression data. We then correlated the gene expression 
levels of individual probes with the neutrophil percentage, and 
selected 58 gene expression probes showing a high positive 
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 In each independent cohort, we corrected for possible 
confounding factors due to arrays with poor RNA quality, by 
correlating the sample gene expression measurements against the 
first PC determined from the sample correlation matrix. Only 
samples with a high correlation (r ≥ 0.9) were included in further 
analyses. Then, for each cohort, we calculated a correlation matrix 
for the neutrophil proxy probes (the probes selected from the 
EGCUT cohort). The gene expression data used was quantile 
normalized, log2 transformed and corrected for MDS components. 
Applying PCA to the correlation matrix, we then obtained PCs 
that described the variation among the probes selected from the 
EGCUT cohort. As the first PC (PC1) contributes the largest 
amount of variation, we considered PC1 as a proxy-phenotype for 
the cell type percentages. 
Determining cell-type mediation using an interaction 
model
 Considering the overlap between the cohorts in this study and 
our previous study, we limited our analysis to the 13,124 cis-eQTLs 
having a significant effect (false discovery rate, FDR < 0.05) in our 
previous study19. This included 8,228 unique Illumina HT12v3 
probes and 10,260 unique SNPs (7,674 SNPs that showed the 
strongest effect per probe, and 2,586 SNPs previously associated 
with complex traits and diseases, as reported in the Catalog of 
Published Genome-Wide Association Studies 1, on 23rd 
September, 2013).
We defined the model for single marker cis-eQTL mapping as 
follows:
Y ≈ I + β1*G + e
where Y is the gene expression of the gene, β1 is the slope of the 
linear model, G is the genotype, I is the intercept with the y-axis, 
and e is the general error term for any residual variation not 
explained by the rest of the model.
 We then extended the typical linear model for single marker 
cis-eQTL mapping to include a covariate as an independent 
variable, and captured the interaction between the genotype and 
the covariate using an interaction term:
Y ≈ I + β1*G + β2*P + β3*P:G + e
where P (cell-type proxy) is the covariate, and P:G is the 
interaction term between the covariate and the genotype. 
We used gene expression data corrected for 40 PCs as the 
predicted variable (Y). The interaction terms were then meta-
analyzed over all cohorts using a Z-score method, weighted for the 
sample size29.
Multiple testing correction
 Since the gene-expression data has a correlated structure (i.e. 
co-expressed genes) and the genotype data also has a correlated 
structure (i.e. linkage disequilibrium between SNPs), a Bonferroni 
correction would be overly stringent. We therefore first estimated 
the effective number of uncorrelated tests by using permuted 
eQTL results from our previous cis-eQTL meta-analysis19. 
 29
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The most significant P-value in these permutations was 8.15 x 10 -5, 
when averaged over all permutations. As such, the number of 
effective tests = 0.5 / 8.15 x 10 -5 ≈ 6134, which is approximately 
half the number of correlated cis-eQTL tests that we conducted 
(=13,124). Next, we controlled the FDR at 0.05 for the interaction 
analysis: for a given P-value threshold in our interaction analysis, 
we calculated the number of expected results (given the number of 
effective tests and a uniform distribution) and determined the 
observed number of eQTLs that were below the given P-value 
threshold (FDR = number of expected p-values below 
threshold / number of observed p-values below threshold). At an 
FDR of 0.05, our nominal p-value threshold was 0.009 
(corresponding to an absolute interaction effect Z-score of 2.61).
Cell-type specific cis-eQTLs and disease
 For each trait in the GWAS catalog, we pruned all SNPs with a 
GWAS association P-value below 5 x 10-8, using an r2 threshold of 
0.2. We only considered traits that had more than 20 significant 
eQTL SNPs after pruning (irrespective of cell-type mediation). 
Then, we determined the proportion of pruned neutrophil-
mediated cis-eQTLs for the trait relative to all the neutrophil-
mediated cis-eQTLs. The difference between both proportions was 
then tested using a binomial test.
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Abstract
 Recently it has become clear that only a small percentage (7%) 
of disease-associated single nucleotide polymorphisms (SNPs) are 
located in protein-coding regions, while the remaining 93% are 
located in gene regulatory regions or in intergenic regions. 
Thus, the understanding of how genetic variations control the 
expression of non-coding RNAs (in a tissue-dependent manner) 
has far-reaching implications. We tested the association of SNPs 
with expression levels (eQTLs) of large intergenic non-coding 
RNAs (lincRNAs), using genome-wide gene expression and 
genotype data from five different tissues. We identified 112 
cis-regulated lincRNAs, of which 45% could be replicated in an 
independent dataset. We observed that 75% of the SNPs affecting 
lincRNA expression (lincRNA cis-eQTLs) were specific to lincRNA 
alone and did not affect the expression of neighboring protein-
coding genes. We show that this specific genotype-lincRNA 
expression correlation is tissue-dependent and that many of these 
lincRNA cis-eQTL SNPs are also associated with complex traits 
and diseases.
Author Summary
 Large intergenic non-coding RNAs (lincRNAs) are the largest 
class of non-coding RNA molecules in the human genome. Many 
genome-wide association studies (GWAS) have mapped disease-
associated genetic variants (SNPs) to, or in, the vicinity of such 
lincRNA regions. However, it is not clear how these SNPs can 
affect the disease. We tested whether SNPs were also associated 
with the lincRNA expression levels in five different human primary 
tissues. We observed that there is a strong genotype-lincRNA 
expression correlation that is tissue-dependent. Many of the 
observed lincRNA cis-eQTLs are disease-or trait-associated SNPs. 
Our results suggest that lincRNA-eQTLs represent a novel link 
between non-coding SNPs and the expression of protein-coding 
genes, which can be exploited to understand the process of 
gene-regulation through lincRNAs in more detail.
Introduction
 It is now evident that most of the human genome is transcribed 
to produce not only protein-coding transcripts but also large 
numbers of non-coding RNAs (ncRNAs) of different size1,2. 
Well-characterized short ncRNAs include microRNAs, small 
interfering RNAs, and piwi-interacting RNAs, whereas the large 
intergenic non-coding RNAs (lincRNAs) make up most of the long 
ncRNAs. LincRNAs are non-coding transcripts of more than 200 
nucleotides long; they have an exon-intron-exon structure, similar 
to protein-coding genes, but do not encompass open-reading 
frames3. The recent description of more than 8,000 lincRNAs 
makes these the largest subclass of the non-coding transcriptome 
in humans4.
 Evidence is mounting that lincRNAs participate in a wide-range 
of biological processes such as regulation of epigenetic signatures 























































differentiation of embryonic stem cells8. In addition, several 
individual lincRNAs have also been implicated in human diseases. 
A well-known example is a region on chromosome 9p21 that 
encompasses an antisense lincRNA, ANRIL (antisense lincRNA of 
the INK4 locus). Genome-wide association studies (GWAS) have 
shown that this region is significantly associated with susceptibility 
to type 2 diabetes, coronary disease, and intracranial aneurysm as 
well as different types of cancers9 and some of the associated SNPs 
have been shown to alter the transcription and processing of ANRIL 
transcripts10. Similarly, increased expression of lincRNA HOTAIR 
(HOX antisense non-coding RNA) in breast cancer is associated 
with poor prognosis and tumor metastasis10. Another example is 
MALAT-1 (metastasis associated in lung adenocarcinoma transcript) 
where the expression is three-fold higher in metastasizing tumors 
of non-small-cell lung cancer than in non-metastasizing tumors11.
 In addition, over the last decade, more than 1,200 GWAS have 
identified nearly 6,500 disease- or trait-predisposing SNPs, but 
only 7% of these are located in protein-coding regions12,13. 
The remaining 93% are located within non-coding regions14, 
suggesting that GWAS-associated SNPs regulate gene transcription 
levels rather than altering the protein-coding sequence or protein 
structure. Even though there is growing evidence to implicate 
lincRNAs in human diseases15,16, it is unknown whether disease-
associated SNPs could affect the expression of non-coding RNAs. 
We hypothesized that GWAS-associated SNPs can affect the 
expression of lincRNA genes, thereby proposing a novel disease 
mechanism.
 To test this hypothesis, we performed eQTL mapping on 2,140 
human lincRNA-probes using genome-wide gene expression and 
genotype data of 1,240 peripheral blood samples (discovery 
cohort)17. The lincRNA cis-eQTLs identified were then tested for 
replication in an independent cohort containing 891 peripheral 
blood samples (replication cohort). Since lincRNAs are considered 
Table 1.
Some of the lincRNA cis-eQTLs are disease-associated SNPs. Chr chromosome, SAT Saturated 
adipose tissue, VAT Visceral adipose tissue
rs13278062 4.31 x 10-32 rs13278062 8 Exudative age-related macular degeneration XLOC_006742 Blood
rs11066054 4.09 x 10-11 rs6490294 12 Mean platelet volume XLOC_010202 Blood
rs206942 3.63 x 10-5 rs206936 6 Body mass index XLOC_005690 Blood
rs11065766 6.67 x 10-5 rs10849915 12 Alcohol consumption XLOC_009878 Blood
 6.67 x 10-5 rs10774610 2 Drinking behavior  
rs1465541 1.84 x 10-4 rs11684202 2 Coronary heart disease XLOC_002026 Blood
rs12125055 1.84 x 10-4 rs7542900 1 Type 2 diabetes XLOC_000922 Blood
rs199439 8.25 x 10-6 rs199515 17 Parkinson’s disease XLOC_012496 SAT
  rs415430 17 Parkinson’s disease  SAT
  rs199533 17 Parkinson’s disease  SAT
rs17767419 1.05 x 10-8 rs17767419 16 Thyroid volume XLOC_011797 SAT, VAT
  rs3813582 16 Thyroid function  SAT, VAT
Cis-eQTL  eQTL P Proxies Chr Trait/Disease eQTL affected eQTL 
SNP on lincRNA associated   lincRNA tissue 
  with disease
  (R2>0.8)
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to be more tissue-specific than protein-coding genes4, we set-out 
to identify tissue-dependent cis-eQTLs for lincRNAs using data 
from another four different primary tissues from the subset of 85 
individuals in our primary cohort18. Subsequently, we tested 
whether SNPs that affect the levels of lincRNA expression are 
associated with diseases or traits. Finally, we predicted the most 
likely function(s) of a subset of cis-eQTL lincRNAs by using 
co-regulation information from a compendium of approximately 
80,000 expression arrays (www.GeneNetwork.nl).
Results
Commercial microarrays contain probes for a subset 
of non-coding RNA
 Whole-genome gene expression oligonucleotide arrays have 
played a crucial role in our understanding of gene regulatory 
networks. Even though most of the currently available commercial 
microarrays are designed to capture all known protein-coding 
transcripts, they still include subsets of probes that capture 
transcripts of unknown function (sometimes abbreviated as TUF). 
We investigated whether the TUF probes present on the Illumina 
Human HT12v3 array, overlap with lincRNA transcripts that were 
recently described in the lincRNA catalog4. The lincRNA catalog 
contained a provisional set of 14,393 transcripts mapping to 8,273 
lincRNA genes and a stringent set of 9,918 transcripts mapping to 
4,283 lincRNA genes. We identified 2,140 unique probes that map 
to 1,771 different lincRNAs from the provisional set and 1,325 
unique probes that map to 1,051 lincRNA genes from the stringent 
set. We chose 2,140 unique probes that mapped to lincRNAs from 
the provisional set for further eQTL analysis.
Genetic control of lincRNAs expression in blood
 It is known that in general lincRNAs are less abundantly 
expressed compared to protein-coding transcripts4. To test the 
expression levels of the 2,140 lincRNA probes in 1,240 peripheral 
blood samples (discovery cohort), we compared the quantile-
normalized, log scale transformed mean expression intensity as 
well as expression variation of the lincRNA probes to probes 
mapping to protein-coding transcripts. We indeed observed a 
significant difference in the expression levels, where lincRNA 
probes are less abundant (mean expression = 6.67) than probes 
mapping to protein-coding transcripts (mean expression = 6.92, 
Wilcoxon Mann Whitney P < 2.2 x 10 -16; Figure S1). We also 
observed a highly significant difference in the expression variation 
between lincRNA probes and probes mapping to protein-coding 
transcripts (Wilcoxon Mann Whitney P < 3.85 x 10 -96). Next, 
we tested whether the expression of these 2,140 lincRNA probes 
is affected by SNPs in cis, by performing eQTL mapping in these 
1,240 peripheral blood samples for which genotype data was also 
available. We confined our analysis to SNP-probe combinations for 
which the distance from the center of the probe to the genomic 
location of the SNP was ≤ 250 kb. In the end, at a false-discovery 
rate (FDR) of 0.05, we identified 5,201 significant SNP-probe 
combinations, reflecting 4,644 different SNPs; these affected the 
expression of 112 out of 2,140 different lincRNA probes. The 112 
lincRNA probes mapped to 108 lincRNA genes and comprised 
5.2% of all tested lincRNA probes, with a nominal significance 
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ranging from P < 2.8 x 10-4 to 9.81 x 10-198 in peripheral blood 
(Table S1).
Replication of lincRNA cis-eQTLs in an independent 
blood dataset
 We then performed a replication analysis to test the 
reproducibility of the identifi ed 112 lincRNA cis-eQTLs using an 
independent dataset of 891 whole peripheral blood samples. 
We took the 112 lincRNA-probes (or 5,201 SNP-probe pairs) that 
were signifi cantly affected by cis-eQTLs in the discovery cohort 
and tested whether these eQTLs were also signifi cant in the 
replication dataset (at FDR 0.05). We could replicate 45% of the 
112 lincRNA cis-eQTLs at an FDR < 0.05, of which all the eQTLs 
had an identical allelic direction (Figure S2). The smaller sample 
size of the replication cohort compared to the discovery cohort 
makes it inherently diffi cult to replicate all the cis-eQTLs that we 
have detected in the discovery cohort.
Figure 1. The number of detected cis-eQTLs is dependent on the 
expression levels of the transcripts.
A) Quantile-normalized average expression intensity and B) number of cis-eQTL affected probes 
in percentage, for 2,140 lincRNA probes, 2,140 non-lincRNA (matched for 2,140



























































Number of cis-eQTLs is dependent on expression 
levels of transcripts
 Our observation that 5.2% of all tested lincRNAs are cis-
regulated (Table S1) might seem disappointing, compared to our 
earlier observation that 25% of the protein-coding probes in this 
dataset are cis-regulated18. However, we reasoned that the 
generally lower expression levels of lincRNAs compared to 
protein-coding genes might make it more difficult to detect 
cis-eQTLs for lincRNAs, as the influence of background noise 
becomes substantial for less abundant transcripts, making accurate 
expression quantification difficult (Figure S1A).
 Indeed, we found significantly higher expression levels for the 
112 cis-eQTL lincRNA probes (mean expression = 6.80) compared 
to the 2,028 non-eQTL lincRNA probes (mean expression = 6.66 
Wilcoxon Mann Whitney P = 3.88 x 10-15; Figure S3) and also 
observed a significant difference in expression variance between 
the 112 cis-eQTL lincRNAs compared to the 2,028 non-cis-eQTL 
lincRNAs (Wilcoxon Mann Whitney P = 1.067 x 10 -8), indicating 
that lower overall expression levels do make identification of 
cis-eQTLs more difficult.
 To further confirm the relationship between average 
expression levels of probes and the number of detectable cis-
eQTLs, we first mapped cis-eQTLs for an equal set of 2,140 probes 
that were instead protein-coding and were the most abundantly 
expressed of all protein-coding probes. We also conducted 
cis-eQTL mapping for a set of 2,140 protein-coding probes that had 
been selected to have an identical expression intensity distribution 
as the 2,140 lincRNA probes (i.e. matched for mean expression 
intensity and standard deviation), using the same 1,240 blood 
samples (Figure 1A). We indeed observed a profound relationship 
between average expression levels of protein-coding transcripts 
and the number of detectable cis-eQTLs. Eighty percent of the 
2,140 most abundantly expressed protein-coding probes showed a 
cis-eQTL effect, whereas only 10% of the protein-coding probes 
that had been matched for an expression intensity of the 2,140 
lincRNA-probes were affected by cis-eQTLs (Figure 1B).
 Hence it is possible that if we can accurately quantify all 
lincRNAs in large RNA-sequencing datasets, we will be able to 
identify cis-eQTLs for a larger proportion of all lincRNAs. 
Most SNPs that affect lincRNA expression do not alter the 
expression of protein-coding genes. It could be possible that the 
SNPs that affect lincRNA expression actually operate by first 
affecting protein-coding gene expression levels, which in turn affect 
lincRNA expression. If this were to be the case, our identified 
lincRNA cis-eQTLs would merely be a by-product of protein-
coding cis-eQTLs. To ascertain this, we tested whether the 112 
lincRNA-eQTL SNPs were also significantly affecting neighboring 
protein-coding genes. By keeping the same significance threshold 
(at FDR < 0.05 level, the value threshold was 2.4 x 10-4), 
we observed that nearly 75% (83 out of 112) of the lincRNA-
eQTLs were affecting only lincRNAs, even though the interrogated 
neighboring protein-coding genes were generally more abundantly 
expressed than the lincRNAs themselves (Figure S4). Genetic 
























































 We found 29 cis-eQTLs to be associated with the expression of 
both lincRNA and protein coding genes. For 50% of these 29 
cis-eQTLs, we found that the expression of lincRNAs and protein-
coding genes was in the opposite direction, whereas for the other 
50% of cis-eQTLs, both types of transcripts were co-regulated in 
the same direction (Figure S5). We tested whether these 29 
cis-eQTLs are the strongest eQTLs for both lincRNA and protein-
coding genes. Although these 29 cis-eQTLs were the strongest 
eQTLs for lincRNAs, only 5 among 29 were also the strongest 
eQTLs for protein-coding genes. This observation further 
highlights the direct regulation of lincRNA expression through 
genetic variants.
Some lincRNA cis-eQTLs are tissue-dependent
 There is considerable interest in mapping eQTLs in disease-
relevant tissue types. We reasoned that since expression of the 
lincRNAs seems to be much more tissue-specific than the 
expression of protein-coding genes4, mapping lincRNA-eQTLs in 
different tissues could reveal additional, tissue-specific lincRNA-
eQTLs. To test this, we analyzed gene expression and genotype 
data of 74 liver samples, 62 muscle samples, 83 subcutaneous 
adipose tissue (SAT) samples, and 77 visceral adipose tissue (VAT) 
samples from our primary cohort of 85 unrelated, obese Dutch 
individuals18. Upon cis-eQTL mapping we detected 35 cis-eQTL-
probes, of which 18 were specific in the four different non-blood 
tissues, resulting in a total of 130 lincRNA-eQTLs in the combined 
set of all five tissues (Table S1). Five cis-eQTLs identified in blood 
tissue were also significantly replicated in at least one other 
non-blood tissue (Table S1). While we could replicate 45% of the 
cis-eQTLs in the substantial whole peripheral blood replication 
cohort, the replication rate in the very small cohorts for fat, liver 
and muscle tissue was, as expected, much lower. We were able to 
observe tissue-specific lincRNA eQTLs in muscle (1), liver (4), SAT 
(9) and blood (107) (Figure S6). Since the four non-blood tissue 
expression levels were from the same individuals, these results do 
indeed provide evidence that some of the lincRNAs are regulated 
by genetic variants in a tissue-specific manner.
 LincRNA tissue specific cis-eQTLs are disease-associated SNPs
Figure 2. Distribution of lincRNA cis-eQTLs with respect to different 
transcripts. 
(A) The majority of the lincRNA cis-eQTLs are located within the non-coding part of the genome 
and less than 6% of lincRNA cis-eQTLs are located within mRNA. 
B) Distribution of lincRNA cis-eQTLs with respect to distance to the lincRNA transcripts. 
The x-axis displays the 250 kb window used for cis-eQTL mapping and the y-axis displays the 
fraction of lincRNA cis-eQTLs located within this window.
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As most of the GWAS-associated SNPs are located within non-
coding regions, we tested whether the 130 lincRNA-eQTLs 
identified in five different tissues are also GWAS-associated 
variants. To do this, we intersected trait-associated SNPs 
(at reported nominal P < 9.9 x 10 -6, retrieved from the catalog of 
published genome-wide association studies per 26 July 2012)14 with 
the 130 top lincRNA cis-eQTLs and their proxies (proxies with R2 
> 0.8 using the 1000 Genome CEU population as reference). 
We identified 12 GWAS SNPs or their proxies, that were also a 
lincRNA cis-eQTLs of eight different lincRNA genes (Table 1). 
All except one of the 12 SNPs were exclusively associated with 
lincRNA expression and thus did not affect the expression levels of 
neighboring protein-coding genes (Table 1), suggesting a causative 
role of altered lincRNA expression for these phenotypes. Notably 
SNP rs13278062 at 8p21.1, associated with exudative age-related 
macular degeneration (AMD) in the Japanese population, 
was reported to alter the transcriptional levels of TNFRSF10A 
(Tumor necrosis factor receptor superfamily 10A) protein-coding 
gene19. Here we identified SNP rs13278062 as a highly significant 
cis-eQTL of lincRNA XLOC_006742 (LOC389641; P = 4.31 x 10-32) 
rather than for TNFRSF10A (P = 4.21 x 10-4) protein-coding gene 
(Figure S7). Furthermore, SNP rs13278062 is located in exon 1 of 
lincRNA XLOC_006742, which encompasses an ENCODE 
(Encyclopedia of DNA elements) enhancer region characterized by 
H3K27 acetylation and DNaseI hypersensitive clusters20 
(Figure S8).
 Another interesting example is at 17q21.31 where three 
Parkinson’s disease associated SNPs were in strong linkage 
disequilibrium (R2 > 0.8) with top cis-eQTL SNP rs199439, which 
affects lincRNA XLOC_012496 expression exclusively in SAT (Table 
1). Weight loss due to body-fat wasting is a very common but 
poorly understood phenomenon in Parkinson’s disease patients21. 
In this regard, it is intriguing to note that the Parkinson’s disease 
associated SNPs affects lincRNA expression exclusively in fat tissue 
(Table 1). Hence, identifying lincRNA-eQTLs in disease-relevant 
tissue types using larger groups of individuals may open up new 
avenues towards achieving a better understanding of disease 
mechanisms.
LincRNA function predictions using a co-expression 
network of ~ 80,000 arrays: a mechanistic link 
between disease and lincRNA
 Our observations suggest a role for lincRNAs in complex 
diseases and other phenotypes. The next, rather daunting task is 
to elucidate the function of these ncRNAs. We recently developed 
a co-regulation network (GeneNetwork, www.genenetwork.nl/ 
genenetwork, manuscript in preparation), to predict the function 
of any transcript based on co-expression data extracted from 
approximately 80,000 Affymetrix microarray experiments 
(see Methods). We interrogated the GeneNetwork database to 
predict the function of eQTL-affected lincRNAs. Among the 130 
cis-eQTL lincRNAs that we had identified in the five different 
tissues, 43 were represented by expression probe sets on 
Affymetrix arrays for which we could predict the function (Table 
S2). These 43 probes include four out of eight disease-associated 
lincRNAs described above (Table 1) and function prediction for 
these probes provided relevant biological explanations.
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LincRNA co-expression analysis: disease-associated 
lincRNAs are co-expressed with neighboring protein-
coding genes
 It has been reported that some transcribed long ncRNAs 
function as enhancers that regulate the expression of neighboring 
genes3 and may thereby contribute to the disease pathology. 
We found that the AMD-associated lincRNA XLOC_006742 
(LOC389641) (by virtue of SNP rs13278062 which exhibits a 
significant eQTL effect) (Figure S7) is in strong co-expression with 
TNFRSF10A based on our GeneNetwork database (Table S3). 
AMD is a leading cause of blindness among elderly individuals 
worldwide and recent studies, both in animal models and in 
humans, provide compelling evidence for the role of immune 
system cells in its pathogenesis22. The gene TNFRSF10A, which 
encodes TRAIL receptor 1 (TRAIL1), has been implicated as a 
causative gene for AMD19. It has been shown that binding of TRAIL 
to TRAILR1 can induce apoptosis through caspase 8 activation23 
and using GeneNetwork we also predict a role in apoptosis for 
lincRNA XLOC_006742 (Table S2). Another trait-associated SNP, 
rs11065766, is the top cis-eQTL of lincRNA XLOC_009878 
(ENSG00000185847 or RP1-46F2.2 or LOC100131138) and it is in 
strong linkage disequilibrium with two SNPs associated with 
alcohol drinking behavior (Table 1). We found that the lincRNA 
XLOC_009878 is strongly co-expressed with the neighboring 
protein-coding gene MYL2 (Table S4) and, according to our 
predictions, lincRNA XLOC_009878 is involved in striated muscle 
contraction (P = 1.22 x 10 -26). Chronic alcohol abuse can lead to 
striking changes in skeletal muscle structure, which in turn plays a 
role in the development of alcoholic myopathy and/or 
cardiomyopathy24. It has also been reported that alcohol can 
reduce the content of skeletal muscle proteins such as titin and 
nebulin to affect muscle function in rats25. We found lincRNA 
XLOC_009878 to be co-expressed with titin and many other 
skeletal muscle proteins necessary for the structural integrity of 
the muscle (Table S4). Thus, it needs to be tested whether 
deregulation of lincRNA XLOC_009878 expression might alter an 
individual’s ability to metabolize alcohol due to changes in the 
muscle functional property.
Figure 3. Localization of lincRNA cis-eQTLs in regulatory regions.
(A) A plot to indicate the location of lincRNA cis-eQTLs in cell-specific enhancers. The x-axis 
shows the different cell lines analyzed and the y-axis shows the fold enrichment of enhancers. 
(B) A plot to show the difference in fold enrichment of enhancers for real lincRNA cis-eQTLs 
compared to permuted lincRNA cis-eQTLs. The significance of the difference in fold enrichment 
was tested by T-test. The HaploReg database was used to analyze the fold enrichment of 
enhancers.
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Localization of lincRNA cis-eQTLs in regulatory 
regions
 We found that more than 70% of the lincRNA cis-eQTLs from 
both blood and non-blood tissues were located in intergenic 
regions with respect to protein-coding genes (Figure 2A). We also 
found high frequencies of lincRNA cis-eQTLs to be located around 
transcriptional start site (Figure 2B), suggesting that these cis-
eQTLs may affect the expression of lincRNAs through similar gene 
regulatory mechanisms as those seen for protein-coding cis-eQTLs. 
Thus, in order to understand the mechanism of how lincRNA 
cis-eQTLs affect lincRNA expression, we intersected the location 
of top 112 lincRNA cis-eQTLs and their proxies (r2 = 1) in blood 
with regulatory regions using the HaploReg database26. The results 
suggested that indeed most of the lincRNA cis-eQTLs (69%) were 
located in functionally important regulatory regions (Figure S8), 
which contained DNAse I regions, transcription factor binding 
regions, and histone marks of promoter and enhancer regions. 
Furthermore, these cis-eQTLs were found to be located more 
often within blood cell-specific enhancers (K562 and GM12878) 
(Figure 3A), suggesting that some of these cis-eQTLs regulate 
lincRNA expression in a tissue-specific manner through altering 
these enhancer sequences. Since we observed enrichment of 
cell-specific enhancers for lincRNA cis-eQTLs within blood cells 
(K562 and GM12878), we compared the fold enrichment of 
enhancers in these two cell types to see whether lincRNA cis-
eQTLs are more often located in functionally important regions 
than any random set of SNPs. We found a significant difference in 
the enrichment of enhancers in which more than a 4-fold 
enrichment was seen for real cis-eQTLs both in K562 cells 
(P = 0.0004) and GM12878 cells (P = 0.011) compared to permuted 
SNPs. These findings suggest that some of the identified lincRNA 
cis-eQTLs are indeed functional SNPs.
Discussion
 Even though it may have been expected that lincRNA 
expression would be under genetic control, this is the first study, 
to our knowledge, to comprehensively establish this link. We were 
able to identify cis-eQTLs in five different tissues and have 
demonstrated that common genetic variants regulate the 
expression of lincRNAs alone. It is intriguing that around 75% of 
lincRNA cis-eQTLs are specific to lincRNAs alone, but not to 
protein-coding genes. Recent data from the ENCODE project 
suggests that combinations of different transcription factors are 
involved in regulating gene-expression in different cell types and 
non-coding RNAs tend to be regulated by certain combinations of 
transcription factors more often than others27. Thus, it could still 
be possible that some transcription factors specifically regulate 
lincRNA expression. We also observed a strong relationship 
between whether or not a transcript is affected by cis-eQTLs and 
its expression levels, where highly abundant transcripts were more 
often affected by cis-eQTLs. This relationship was comparable 
between lincRNA and protein-coding probes, although protein-
coding probes (matched for expression levels of lincRNA probes) 
tend to show more cis-eQTLs (Figure 1B; 5.2% versus 10%). 
Although this difference is not drastic, it may suggest that 
lincRNAs exhibit another layer of gene regulation which is more 
 26
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tissue-specific. Thus, we may expect to identify many more 
lincRNA cis-eQTLs once larger datasets of different tissues 
become available.
 One limitation of our study is the lack of probes to 
comprehensively map eQTLs to all the reported lincRNAs, as we 
relied upon microarrays. Future analyses using RNA-sequencing 
datasets will undoubtedly provide much more insight into how 
genetic variants affect lincRNA expression. So far, two landmark 
RNA-sequencing based eQTL studies have been published using 60 
(Montgomery et al.)28 and 69 samples (Pickrell et al.)29, respectively. 
While Pickrell et al. did not mention lincRNAs with a cis-eQTL 
effect, Montgomery et al identified six cis-regulated lincRNAs 
(at a slightly higher FDR of 0.17). We re-analyzed these two 
datasets and found that we could replicate one of the 112 cis-eQTL 
lincRNAs effects that we detected using arrays (with an identical 
allelic direction; Figure S10). These results indicate that cis-eQTL 
lincRNAs detected using conventional microarrays can be 
replicated in sequencing-based datasets. However, it also indicates 
that sample size is currently a limiting factor in finding many more 
cis-eQTL lincRNAs in sequencing-based datasets.
 Nevertheless, our results clearly indicate that there is a strong 
genotype-lincRNA expression correlation that is tissue-dependent. 
A considerable number of the observed lincRNA cis-eQTLs are 
disease-or trait-associated SNPs. Since lincRNAs can regulate the 
expression of protein-coding genes either in cis3 or in trans8, 
lincRNA-eQTLs represent a novel link between non-coding SNPs 
and the expression of protein-coding genes. Our examples show 
that this link can be exploited to understand the process of 
gene-regulation in more detail, which may assist us in 
characterizing lincRNAs as another class of disease biomarkers.
Methods
Ethics statement
 This study was approved by the Medical Ethical Board of 
Maastricht University Medical Center (four non-blood tissues), 
and local ethical review boards (1,240 peripheral blood samples) in 
line with the guidelines of the 1975 Declaration of Helsinki. 
Informed consent in writing was obtained from each subject 
personally. The subject information is provided in Table S5.
Mapping probes to lincRNAs
 A detailed mapping strategy of Illumina expression probe 
sequences has been described previously17. We extracted 43,202 
expression probes mapping to single genomic locations (hg18 build) 
and excluded those that did not map or that mapped to multiple 
different loci. LincRNA chromosomal coordinates (hg19 build) 
were obtained from the lincRNA catalog (http://www.
broadinstitute.org/genome_bio/human_lincrnas/?q=lincRNA_
catalog) and converted to hg18 coordinates using UCSC’s LiftOver 
application (http://genome.ucsc.edu/cgi-bin/hgLiftOver). 
Subsequently, we extracted probes mapping to lincRNA exonic 
regions by employing BEDtools30.
 28
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 29
Pickrell, J. K. et al. Understanding mechanisms 
underlying human gene expression variation with 
RNA sequencing. Nature 464, 768–72 (2010).
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Blood dataset of 1,240 samples
 The blood dataset and a detailed eQTL mapping strategy have 
been described previously17. Briefly, 1,240 peripheral blood samples 
from unrelated, Dutch control subjects were investigated (Table 
S5). Genotyping of these samples was performed according to 
Illumina’s standard protocols (Illumina, San Diego, USA), using 
either the HumanHap370 or 610-Quad platforms. Because the 
non-blood samples (see below) were genotyped using Illumina 
HumanOmni1-Quad BeadChips, we applied IMPUTE v231 to impute 
the genotypes of SNPs that were covered by the Omni1-Quad chip 
but that were not included on the Hap370 or 610-Quad 
platforms31. Anti-sense RNA was synthesized using the Ambion 
Illumina TotalPrep Amplification Kit (Ambion, New York, USA) 
following the manufacturer’s protocol. Genome-wide gene 
expression data was obtained by hybridizing complementary RNA 
to Illumina’s HumanHT-12v3 array and subsequently scanning these 
chips on the Illumina BeadArray Reader.
Replication blood dataset of 891 samples
 We used a dataset comprising peripheral blood samples of 891 
unrelated individuals from the Estonian Genome Centre, 
University of Tartu (EGCUT) biobank cohort of 53,000 samples 
for replication. Genotyping of these samples was performed 
according to Illumina’s standard protocols, using Illumina 
Human370CNV arrays (Illumina Inc., San Diego, US), and imputed 
using IMPUTE v231, using the HapMap CEU phase 2 genotypes 
(release #24, build 36). Whole peripheral blood RNA samples 
were collected using Tempus Blood RNA Tubes (Life Technologies, 
NY, USA), and RNA was extracted using Tempus Spin RNA 
Isolation Kit (Life Technologies, NY, USA). Quality was measured 
by NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, 
DE, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, CA, 
USA). Whole-Genome gene-expression levels were obtained by 
Illumina Human HT12v3 arrays (Illumina Inc, San Diego, US) 
according to manufacturers’ protocols.
Four non-blood primary tissues
 Previously we described tissue-dependent eQTLs in 74 liver 
samples, 62 muscle samples, 83 SAT samples and 77 VAT samples 
from a cohort of 85 unrelated, obese Dutch individuals (all four 
tissues were available for 48 individuals)18 (Table S5). 
These samples were genotyped according to standard protocols 
from Illumina, using Illumina HumanOmni-Quad BeadChips 
(Omni1). Genome-wide gene expression data of all samples was 
assayed by hybridizing complementary RNA to the Illumina 
HumanHT-12v3 array and then scanning it on the BeadArray 
Reader.
Cis-eQTL mapping
 The method for normalization and principal component 
analysis-based correction of expression data, along with the 
methods to control population stratification and SNP quality, 
were described previously17,18. The cis-eQTL analysis was 
performed on probe-SNP combinations for which the distance 
from the center of the probe to the genomic location of the SNP 
was ≤ 250 kb. Associations were tested by non-parametric 
Spearman’s rank correlation test and the P values were corrected 
for multiple testing by false-discovery rate (FDR) at P < 0.05, 
 30
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in which the distribution was obtained from permuting expression 
phenotypes relative to genotypes 100 times within the HT12v3 
dataset and comparing those with the observed P-value 
distribution. At FDR = 0.05 level, the P-value threshold was 2.4 x 
10-4 for significantly associated probe-SNP pairs in blood, 1.5 x 10 -5 
in SAT, 5.21 x 10 -6 in VAT, 6.3 x 10-6 in liver and 1.8 x 10 -6 in 
muscle.
LincRNA function prediction
 To predict the function(s) for lincRNAs, we interrogated the 
GeneNetwork database (www.genenetwork.nl/genenetwork) that 
has been developed in our lab (manuscript in preparation). 
In short, this database contains data extracted from approximately 
80,000 microarray experiments that is publically available from the 
Gene Expression Omnibus; after extensive quality control, 
it contains data on 54,736 human, 17,081 mouse and 6,023 rat 
Affymetrix array experiments. Principal component analysis was 
performed on probe-set correlation matrices of each of four 
platforms (two human platforms, one mouse and one rat platform), 
resulting in 777, 377, 677 and 375 robust principal components, 
respectively. Jointly these components explain between 79% and 
90% of the variance in the data, depending on the species or 
platform. Many of these components are well conserved across 
species and enriched for known biological phenomena. Because of 
this, we were able to combine the results into a multi-species gene 
network with 19,997 unique human genes, allowing us to utilize the 
principal components to accurately predict gene function by using 
a ‘guilt-by-association’ procedure (a description of the method is 
available at www.genenetwork.nl/genenetwork). Predictions were 
made based on pathways and gene sets from Gene Ontology, 
KEGG, BioCarta, TransFac and Reactome.
Functional annotation of lincRNA cis-eQTLs
 We employed the HaploReg web tool26 to intersect SNPs 
(and their perfect proxies, r2 = 1 using the CEU samples from the 
1000 Genomes project) with regulatory information and also to 
calculate the fold enrichment of cell-type specific enhancers. 
In order to ascertain whether this enrichment was higher than 
expected, we took eQTL results from 100 permutations (shuffling 
the gene expression identifier labels): for each permutation we 
determined the top 112 eQTL probes and took the corresponding 
top SNPs and their perfect proxies (r2 = 1). We extracted the fold 
enrichment of enhancers from HaploReg for these 100 sets of 
SNPs as well, which then permitted us to estimate the significance 
of enrichment of the real eQTL analysis, determined by fitting a 
normal distribution on the 100 log-transformed permutation 
enrichment scores.
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Supplemental Information
Figure S1
LincRNA probes show different expression characteristics 
compared to other transcripts. The figure shows the difference in 
quantile-normalized average expression intensity between lincRNA 
probes and non-lincRNA probes. The significance of difference in 
expression intensity was tested by the Wilcoxon Mann Whitney 
test.
Figure S2
Replicated lincRNA cis-eQTLs show identical allelic direction of 
effect in the both the discovery and replication datasets. 
We compared the z-scores (association strength) of each 
significantly associated probe-SNP pair in the discovery dataset 
(Groningen HT12v3; N = 1,240) with the replication dataset 
(EGCUT; N = 891).
Figure S3
lincRNA probes with cis-eQTL effect show higher expression levels 
compared to lincRNA probes without cis-eQTL effect. 
The significance of difference in expression intensity was tested by 
the Wilcoxon Mann Whitney test.
Figure S4
LincRNA cis-eQTL SNPs mostly affect lincRNA transcripts alone. 
Quantile-normalized average expression intensity of cis-eQTL 
lincRNAs and their neighboring protein coding genes without 
cis-eQTL.
Figure S5
Distribution of Z-scores of co-regulated lincRNA and protein-
coding genes. We compared the z-scores (association strength) of 
each significantly associated probe-SNP pair for the 29 cis-eQTLs 
that affect both lincRNAs and protein-coding genes.
Figure S6
Number of specific and overlapping cis-eQTL lincRNAs identified 
across five different tissues. 
Figure S7
Plots to show the association of age-related macular degeneration 























































protein-coding gene TNFRSF10A in blood (N = 1,249). The x-axis 
shows the number of samples according to the genotypes at 
rs13278062 and the y-axis is the average expression intensity of 
probes.
Figure S8
UCSC genome browser screen shot (http://genome.ucsc.edu) to 
show the location of age-related macular degeneration SNP, 
rs13278062. The x-axis is the chromosome location in the hg19 
build and indicates the location of transcripts and regulatory 
elements identified by ENCODE on chromosome 8.
Figure S9
A plot to show the number of lincRNA cis-eQTLs on the y-axis 
within different regulatory regions on the x-axis.
Figure S10
Plots to show the cis-eQTL effect on lincRNA XLOC_00197 from 
both microarray data (Groningen HT12v3; N = 1,240) and RNA-
sequencing data (Montgomery et al.; N = 60). The x-axis shows the 
number of samples according to the genotypes at rs1120042 and 
rs2279692 (LD between these two SNPs, R2 = 0.96) in microarray 
data and RNA-sequencing data, respectively.
Table S1
LincRNA cis-eQTLs in blood and four other non-blood tissues.
Table S2
Function prediction of lincRNAs affected by cis-eQTLs using 
GeneNetwork.
Table S3
Identification of co-expressed genes for lincRNA LOC389641 using 
GeneNetwork.
Table S4
Identification of co-expressed genes for lincRNA LOC100131138 
using GeneNetwork.
Table S5
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 Many disease-associated variants affect gene expression levels 
(expression quantitative trait loci, eQTLs) and expression profiling 
using next generation sequencing (NGS) technology is a powerful 
way to detect these eQTLs. We analyzed 94 total blood samples 
from healthy volunteers with DeepSAGE to gain specific insight 
into how genetic variants affect the expression of genes and 
lengths of 3’-untranslated regions (3’-UTRs). We detected 
previously unknown cis-eQTL effects for GWAS hits in disease- 
and physiology-associated traits. Apart from cis-eQTLs that are 
typically easily identifiable using microarrays or RNA-sequencing, 
DeepSAGE also revealed many cis-eQTLs for antisense and other 
non-coding transcripts, often in genomic regions containing 
retrotransposon-derived elements. We also identified and 
confirmed SNPs that affect the usage of alternative polyadenylation 
sites, thereby potentially influencing the stability of messenger 
RNAs (mRNA). We then combined the power of RNA-sequencing 
with DeepSAGE by performing a meta-analysis of three datasets, 
leading to the identification of many more cis-eQTLs. Our results 
indicate that DeepSAGE data is useful for eQTL mapping of known 
and unknown transcripts, and for identifying SNPs that affect 
alternative polyadenylation. Because of the inherent differences 
between DeepSAGE and RNA-sequencing, our complementary, 
integrative approach leads to greater insight into the molecular 
consequences of many disease-associated variants.
Author Summary
 Many genetic variants that are associated with diseases also 
affect gene expression levels. We used a next generation 
sequencing approach targeting 3’ transcript ends (DeepSAGE) to 
gain specific insight into how genetic variants affect the expression 
of genes and the usage and length of 3’-untranslated regions. 
We detected many associations for antisense and other non-coding 
transcripts, often in genomic regions containing retrotransposon-
derived elements. Some of these variants are also associated with 
disease. We also identified and confirmed variants that affect the 
usage of alternative polyadenylation sites, thereby potentially 
influencing the stability of mRNAs. We conclude that DeepSAGE is 
useful for detecting eQTL effects on both known and unknown 
transcripts, and for identifying variants that affect alternative 
polyadenylation.
Introduction
 Genome-wide association studies (GWAS) have associated 
genetic variants, such as single nucleotide polymorphisms (SNPs) 
and copy number variants (CNVs), with numerous diseases and 
complex traits. However, the mechanisms through which genetic 
variants affect disease phenotypes or physical traits often remain 
unclear. To gain insight into these mechanisms, we have combined 
genotype data with gene expression data by conducting expression 
quantitative trait locus (eQTL) mapping. Previously, the level of 
gene expression was primarily assessed using oligonucleotide 













































































































































































































transcriptome1–6. But recently, high-throughput next generation 
sequencing (NGS) has become available, which allows 
quantification of expression levels by counting mRNA fragments 
(RNA-seq) or sequence tags (including serial analysis of gene 
expression (SAGE), cap analysis of gene expression (CAGE), 
and massively parallel signature sequencing (MPSS))7.
 To date, two NGS eQTL studies have been published8,9, both of 
which used RNA-seq. Although RNA-seq is a versatile technique, 
the coverage in the ultimate 3’-end is usually lower due to the 
fragmentation and random hexamer priming steps involved in the 
sample preparation10 (Figure 1B). DeepSAGE technology11,12, 
however, concentrates on capturing information on the 3’-end of 
transcripts. In DeepSAGE, enzymatic cDNA digestions generate 
one specific tag of 17 nucleotides at the most 3’-CATG sequence of 
each transcript (Figure 1A). The majority of these 21-mer tags 
(‘CATG’ + 17 nucleotides) can be uniquely mapped to the genome 
to identify the genes expressed.
 There are several features of NGS-based expression 
quantification methods that are especially important for eQTL 
mapping. While oligonucleotide arrays target a predefined set of 
transcripts or exons, both RNA-seq and DeepSAGE are capable of 
detecting novel and unannotated transcripts. If such a novel gene 
later turns out to be cis-regulated by trait- or disease-associated 
SNPs, it can represent an interesting causal candidate gene for the 
trait or disease under investigation. RNA-seq is extremely 
versatile, as it can quantify the expression of alternative 
transcripts, which makes it possible to detect SNPs regulating the 
choice between alternative transcripts. DeepSAGE, however, 
is generally not suited to detecting alternative splicing because of 
the 3’ bias of the tag locations13. Because only sequence data is 
generated for these short tags, the read depth per tag is generally 
much greater than with RNA-seq, permitting accurate 
quantification of these tags11,14. Thus, this 3’ emphasis makes 
DeepSAGE suitable for transcript variants that differ in 3’-UTRs 
and also for detecting alternative polyadenylation events, 
a widespread phenomenon that generates variation in 3’-UTR 
length15,16. Shortening or lengthening of the 3’-UTR may result in 
Figure 1. Comparison of typical DeepSAGE and RNA-seq data 
generation steps. 
A) DeepSAGE data preparation consists of the following basic steps: after RNA extraction 
the polyadenylated mRNA fraction is captured with oligo-dT beads. While RNA is still 
bound to the beads, double- stranded cDNA synthesis is performed. Next, cDNA is 
digested by NlaIII restriction enzyme (an anchoring enzyme), which cuts the DNA at CATG 
recognition sequences, leaving only the fragment with the most distal (3’) CATG site 
associated with the beads. Subsequently, a GEX adapter is attached to the 5’ end. This 
adapter contains a recognition sequence for the MmeI restriction enzyme that cuts the 
sequence 17 bp downstream of the CATG site. After ligation of a second GEX adapter, 
fragments containing 21 bp tags (17 unknown nucleotides + CATG) are ready for sequencing. 
B) A typical protocol for RNA-seq data preparation has the following steps: after RNA 
extraction the polyadenylated mRNA fraction is captured with oligo- dT beads. Captured 
RNA is fragmented and for each fragment cDNA synthesis is performed using random 
hexamer primers. Sequencing adapters are then ligated to each fragment. This is followed 
by size selection of the DNA fragments and PCR amplification. Then one end of the 
fragment is sequenced (single-end sequencing) or both ends (paired-end sequencing).
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the loss or gain of regulatory elements, such as miRNA binding 
sites or binding sites for proteins that can stabilize or destabilize 
the transcript17,18. Several SNPs that influence the choice for 
alternative polyadenylation sites have been detected by RNA-seq 
on a small number of individuals19. Here, we analyzed this 
phenomenon in more depth by performing cis-eQTL mapping on 
DeepSAGE data from total blood samples of 94 individuals.
Results
DeepSAGE dataset
 For cis-eQTL mapping, we used DeepSAGE sequencing of 21 bp 
tags (16±7 million tags) from total blood samples from 94 healthy, 
unrelated individuals from the Netherlands Twin Register (NTR) 
and the Netherlands Study of Depression and Anxiety (NESDA)20. 
Sequence reads were mapped to the reference genome hg19 using 
Bowtie21 and assigned to transcripts. We mapped 85±5% of tags to 
the genome and found that 77±9% of these mapped to exonic 
regions. Although 66±18% of these reads mapped to hemoglobin-
alpha or –beta (HBA1, HBA2, HBB) genes, we were left with 
sufficient sequencing depth to detect a total of 9,562 genes at a 
threshold of at least two tags per million.
Cis-eQTL mapping
 Once reads had been mapped, we quantified the expression 
levels of sequenced tags and performed cis-eQTL mapping, 
evaluating only those combinations of SNPs and tags that were 
located within a genomic distance of 250 kb, while using a 
Spearman rank correlation test (tag-level false discovery rate 
(FDR) controlled at 0.05). We identified 540 unique cis-regulated 
tags.
 To subsequently increase the statistical power of eQTL 
detection, we used principal component analysis (PCA) to correct 
for technical and known and unknown biological confounders. 
The first principal components (PC) generally capture a high 
percentage of the expression variation, and these PCs mostly 
reflect technical, physiological and environmental variability. 
Figure 2. Fraction of cis-regulated genes in bins by mean gene expression 
levels for DeepSAGE and Affymetrix data. 
For each dataset, all genes were sorted by their mean gene expression levels, and divided into ten 
equal bins. The X-axis reflects these bins, which are sorted by increasing mean gene expression 
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Removing this variation allows for the detection of more 
eQTLs6,22,23. In our data the first principal component significantly 
correlated with sample GC content, and principal components 
7 and 11 correlated with various blood cell count parameters 
(for details see Text S1, Figures S1 and S2). When using the PC 
corrected data, we observed an almost two-fold increase in the 
number of significant cis-eQTLs (1,011 unique cis-regulated tags, 
corresponding to 896 unique cis-regulated genes at tag-level 
FDR < 0.05). The list of detected eQTLs is given in Table S1.
Comparison with microarray results
 We then compared the DeepSAGE cis-eQTLs with cis-eQTLs 
that we had identified using the Affymetrix HG-U219 expression 
microarrays on the same 94 samples. In that analysis we detected 
cis-eQTLs for only 274 genes (FDR < 0.05), only a third of what we 
identified using DeepSAGE.
 We observed that this substantial difference could mostly be 
explained by the fact that the cis-eQTLs detected using Affymetrix 
microarrays nearly always reflected genes that are highly expressed 
in blood, whereas for DeepSAGE the detected cis-eQTL genes had 
expression levels that could be much lower (Figure 2). Although we 
only concentrated on tags that were expressed, there was no clear 
relationship between the mean tag level expression and the 
probability of showing a significant cis-eQTL. As such, DeepSAGE 
is much more capable of identifying cis-eQTLs for genes showing 
low expression than conventional microarrays.
 It was therefore not a surprise that only 39% of the identified 
DeepSAGE cis-eQTLs could also be significantly detected in the 
microarray-based dataset (with identical allelic direction; 
Figure S3). Indeed, the cis-eQTLs that were not replicated in the 
microarray-based dataset generally had a much lower expression 
than the replicating cis-eQTLs (Wilcoxon Mann Whitney 
P < 2 x 10-3). And vice versa, we could significantly replicate 75% of 
the detected Affymetrix cis-eQTLs with the same allelic direction 
in the DeepSAGE data (Figure S3), indicating that DeepSAGE 
shows overlapping results with array-based data. At the same time, 
this provides insight into the regulation of gene expression by SNPs 
at many more loci.
 We estimated the reduction that could be made in the sample 
size of the sequencing-based dataset to get the same number of cis 
regulated genes as in microarray-based data. We observed that the 
DeepSAGE sample size could be reduced by almost half 
(to 55 samples) to get the same number of significant cis-regulated 
genes as identified in the microarray analysis of the 94 samples. 
As such, these results clearly indicate that DeepSAGE has higher 
statistical power than microarrays.
Cis-eQTL effects on non-coding genes
 While most microarray platforms interrogate mainly the 
protein-coding part of the transcriptome, NGS-based expression 
profiling will detect the majority of all expressed transcripts. 
Indeed, we detected eQTLs for known, but non-protein coding, 
genes: 8 antisense genes and 31 lincRNAs (Figure 3).
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 We also expected to find a number of cis-eQTL effects on 
previously unknown transcripts. Of the 1,011 tags with a significant 
cis-eQTL effect, 230 did not map to known transcripts. Many of 
these tags map to retrotransposon-derived elements in the 
genome, which are known to be a source of novel exons24: 
73 DeepSAGE tags with significant cis-eQTLs that did not map to 
annotated genes mapped to 72 unique LINE, SINE and LTR 
elements in the genome (Table 1).
New regulatory roles for disease- and trait-
associated SNPs
 We checked how many of our cis-acting SNPs were associated 
with complex traits or complex diseases (‘trait-associated SNPs’), 
as published in the Catalog of Published Genome-Wide Association 
Studies. 104 of the 6,446 unique trait-associated SNPs were 
significant cis-eQTLs in our data (Table S2).
 We were interested to determine whether the DeepSAGE data 
had revealed cis-eQTL effects for trait-associated SNPs that had 
been missed when using conventional arrays on much larger 
cohorts. We therefore compared our results to a re-analysis of a 
large-scale, array-based cis-eQTL mapping that we had conducted 
in whole peripheral blood samples when using a much larger 














Figure 3. Mapping regions of cis-regulated tags.
The gene biotypes and exon/intron locations of unique cis-regulated tags, according to Ensembl 
v.69 annotation, are shown. The numbers indicate the number of tags mapping in the genes of the 
corresponding type.
Table 1.





Type of genomic region Number of cis-regulated tags
 24
Cordaux, R. & Batzer, M. A. The impact of 
retrotransposons on human genome evolution. 
Nat. Rev. Genet. 10, 691–703 (2009).
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 We identified 13 trait-associated SNPs that did show a 
significant cis-eQTL effect in DeepSAGE eQTL mapping, but which 
did not show a cis-eQTL effect in the large, array-based, blood 
dataset (Table 2). This indicates that many trait-associated SNPs 
have regulatory effects that will, so far, likely have been missed 
using microarrays. While some of the tags map in the exons of 
annotated transcripts, we also found three cis-regulated tags in 
introns (sense direction), two tags antisense to the known 
transcripts, and two tags outside the annotated transcripts. 
These results indicate that several trait-associated SNPs affect the 
expression of previously unknown transcripts, adding functional 
relevance to SNPs and transcripts that are so far without 
annotation.
 Some newly discovered eQTLs provide novel insights into 
genome-wide association hits for diseases or physiological traits, 
e.g. SNP rs216345, which has been associated with bipolar 
disorder. While it is located just downstream of PRSS3, we now 
saw that it also affects the expression of UBE2R2. There are many 
links between the ubiquitin system and bipolar disorder reported 
in the literature25,26, making UBE2R2 a more plausible candidate 
gene for bipolar disorder than PRSS3.
Genes with multiple SAGE tags and opposite allelic 
direction
 In DeepSAGE, 21-bp-long cDNA fragments begin at the ‘CATG’ 
closest to the polyadenylation site (Figure 1). These individual ‘tags’ 
represent transcripts sharing the same polyadenylation site. 
If a SNP increases the abundance of one tag of a gene and 
decreases the abundance of another tag of the same gene, 
this indicates that the SNP is acting like a switch between 
transcripts with different 3’-UTRs or between alternative 
polyadenylation sites19 (Figure 4).
Table 2.
Trait-associated SNPs affecting DeepSAGE tags of 94 peripheral blood samples, but not detected 
in an array-based eQTL dataset of 1,469 peripheral blood samples.
rs6704644 2 234380527 DGKD 3’-UTR sense None  Bilirubin levels
rs9875589 3 14196086 XPC intron antisense LINE L1MB3 Ovarian reserve
rs4580814 5 1050754 SLC12A7 3’-UTR sense None Hematological and biochemical traits 
rs3194051 5 35884591 IL7R - noncoding LINE L2C Ulcerative colitis
rs4917014 7 50472441 IKZF1 3’-UTR sense None Systemic lupus erythematosus
rs10092658 8 131017411 FAM49B intron sense None Protein quantitative trait loci
rs216345 9 33917317 UBE2R2 3’-UTR sense None Bipolar disorder
rs12219125 10 20519590 PLXDC2 intron sense SINE AluJb Diabetic retinopathy
rs7181230 15 40325714 EIF2AK4 intron antisense None Dehydroepiandrosterone sulphate levels
rs4924410 15 40328035 SRP14 3’-UTR sense None Ewing sarcoma
rs12594515 15 45995320 lincRNA RP11-718O11.1 noncoding LTR MLT1A Waist circumference, weight
rs6504218 17 62400467 PECAM1 3’-UTR antisense None Coronary heart disease
 17 62397000 PECAM1 3’-UTR antisense LINE L1ME4A Coronary heart disease
rs4072910 19 8640274 MYO1F intron sense LINE MER1B  Height
SNP Tag Tag In / near Location Sense / Repeat  Associated trait 
 chr. position gene in gene antisense masker 
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 Twelve genes with highly significant cis-eQTLs (p-value < 10-7) 
contained tags that were regulated in opposite directions (Table 3). 
Most of the tags regulated in opposite direction could be explained 
by switches in alternative polyadenylation sites, as the tags were 
observed in the same last exon. The effect on alternative 
polyadenylation in IRF5 has been found before19,27 and was also 
validated in our cohort by RT-qPCR with primers in the proximal 
and distal parts of the 3’-UTR (Figure 5). As a further confirmation 
of the observed switches in using polyadenylation sites, we tested 
genotype-dependent alternative polyadenylation in two other 
RNA-seq datasets8,9. In these datasets, we confirmed the effect of 
two cis-regulating SNPs on THEM4 and F11R. However, we could 
not confirm the effect of other SNPs on targets validated 
experimentally, including IRF5. This shows the limitation of 
RNA-seq data in detecting alternative polyadenylation events, 
likely due to limited and unequal coverage of the 3’-UTR. For only 
two genes, OAS1 (also reported earlier28) and RP11-493L12.2, 
the observed opposite allelic effect originated from transcripts 
with different last exons, likely due to alternative splicing.
 As we had identified several SNPs that affect alternative 
polyadenylation, we subsequently used a more permissive strategy, 
which required that, for a given SNP, only one eQTL tag should 
pass the FDR < 0.05 significance threshold while the other tag 
could be less significant. However, for such SNP-tag pairs, we then 
Table 3.
Cis-regulating SNPs significantly affecting multiple tags of the same gene in opposite directions. 
Only significant eQTLs with FDR,0.05 for both cis-regulated tags were used.
rs12568757 G/A G 1 150782318 4.404 ARNT Alternative polyadenylation 
   1 150782604 -4.314  
rs12566232 A/C C 1 151846229 -6.859 THEM4 Alternative polyadenylation
   1 151846628 4.292  
rs1062826 G/C C 1 160965239 -4.46 F11R Alternative polyadenylation
   1 160966976 8.012  
rs13160562 G/A A 5 96110323 -7.883 ERAP1 Alternative polyadenylation
   5 96111908 5.555  
rs3185733 A/C A 5 112320282 4.027 DCP2 Alternative polyadenylation
   5 112356357 -4.46  
rs6948928 T/C T 7 128589824 8.451 IRF5 Alternative polyadenylation
   7 128589265 -7.31  
rs2111903 G/C C 12 47603121 5.143 RP11-493L12.2 Different exon
   12 47599911 -4.676  
rs841718 A/G G 12 57489368 5.506 STAT6 Alternative polyadenylation 
   12 57489809 -7.002  
rs2285934 G/T T 12 113357275 4.931 OAS1 Different exon
   12 113355465 -5.191  
rs168822 C/T T 16 55616984 7.37 LPCAT2 Alternative polyadenylation
   16 55620233 -4.664  
rs922446 T/C T 16 56395733 -4.966 AMFR Alternative polyadenylation
   16 56396100 4.392  
rs1674159 C/T T 19 5915589 -7.103 CAPS Alternative polyadenylation 
   19 5916143 6.126  
SNP SNP Allele Probe Probe Overall HGNC Annotation 
Name Type assessed chr. center Z-score name 
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genotype effects on gene expression in primary 
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tested whether the allelic directions were opposite and if the 
difference between correlation coefficients was significant. 
With a differential correlation significance p-value threshold of 
10-7, we detected 41 unique genes showing regulation in opposite 
directions (Table S3). Of these, 23 (56%) showed opposite 
regulation of two tags in the same annotated 3’-UTR and a further 
7 genes (17%) showed opposite regulation of tags in the same 
exons, both indicative of a switch in polyadenylation sites. 
Of these we picked HPS1, and validated a genotype-determined 
switch in preferred polyadenylation site usage by RT-qPCR analysis 
(Figure 5), indicating that the more permissive list also holds 
genuine changes in polyadenylation sites. The remaining 11 genes 
showed significant genotype-determined switches in expression of 
alternative transcripts not sharing the final exon. Thus, switches 
between shorter and longer 3’-UTRs occur more frequently than 
switches between transcripts with different 3’-UTRs.
 To check whether such results appeared by chance, we took an 
equal number of top hits from a permuted eQTL run (shuffling the 
phenotype labels of the expression data, thus breaking the 
relationship between genotype and expression, but retaining 
linkage disequilibrium (LD) structure and structure in the 
expression data) and performed the same analysis as above 
(assessing an equal number of top eQTLs from the permuted 
analysis as we had investigated in the real analysis). Using the 
differential correlation significance threshold of 10 -7 and conducting 
this permutation analysis ten times, we did not find any SNP that 
affected two tags in the same gene in a significantly different way, 
indicating this method is robust.
 Since the eQTL SNPs are usually in strong LD with multiple 
SNPs, it is difficult to conclude whether a SNP is causal or which 














Figure 4. The number of cis-regulated tags per gene.
The percentages of cis-regulated tags mapping into the same gene are indicated (781 genes 
overall). For nearly half of the genes (48%) only one tag shows an eQTL effect. If multiple tags map 
within the same gene, only one eQTL tag should pass the FDR < 0.05 significance threshold while 
the other tag could be less significant. For these eQTLs the allelic direction is shown: same allelic 
direction (multiple tags within the same gene are cis-regulated by a SNP in the same direction), 
significantly opposite allelic direction (multiple tags within the same gene are cis-regulated 
by a SNP but with opposite directions and the difference between the correlation coefficients is 
significant), or opposite allelic direction but not significant (if the difference between correlation 










































































we assessed whether any of these SNPs caused changes in poly-
adenylation site usage. A direct effect on alternative poly-
adenylation can be explained by a change in the polyadenylation 
site (corresponding to the cleavage site) or in the polyadenylation 
signal (a six-nucleotide motif located between 10–30 bases 
upstream of the cleavage site). 
 We searched for likely causative SNPs in linkage disequilibrium 
with the polyA-QTL SNP (R2 ≥ 0.8). We did not find any strong 
evidence for SNPs influencing the cleavage site and focused on 
cis-regulating SNPs located within polyadenylation signals. 
Considering the length and the motif of canonical and non-
canonical polyadenylation signals15, we performed a motif analysis 
in the sequence surrounding each cis-regulating SNP. We identified 
five SNPs that likely affect polyadenylation because there was a 
change in the polyadenylation signal (Table 4). As previously shown, 
rs10954213 causes the formation of a stronger polyadenylation 
signal in IRF5. Similar changes from non-canonical to stronger, 
canonical polyadenylation signals were observed for rs1062827 in 
F11R and rs6598 in GIMAP5. Moreover, rs12934747 creates a new 
canonical AATAAA polyadenylation signal in LPCAT2. The presence 
of this alternative polyadenylation signal at the beginning of the 
3’-UTR leads to a decrease in transcripts containing the full length 
3’-UTR, as observed by DeepSAGE (Figure 6). An opposite effect is 
observed for rs7063 in the ultimate 3’-end of the ERAP1 gene, 
where the SNP causes the disruption of the strong canonical motif, 
and results in the use of a more proximal polyadenylation signal. 
Unfortunately we were not able to identify likely causative SNPs 
for each of these eQTLs. This could have several reasons: 
we imposed strict thresholds (R2 ≥ 0.8) on the LD between the 
detected cis-eQTLs and the putative causative SNPs; by imputing 
to the 1000 genomes dataset we may have missed causative SNPs 
unique to the Dutch population; and the list of experimentally 
validated polyadenylation sites is not exhaustive, because their 
detection depends on the expression level and cell type analyzed.
Figure 5. The choice of proximal/distal polyadenylation site in genes IRF5 
and HPS1 depends on the genotypes of rs10488630 and rs11189600, 
respectively.
The ratio between the abundance of transcripts with proximal and distal 3’-UTR RT-qPCR 
products in IRF5 (left) and HPS1 (right) depends on the genotypes of cis-regulating SNPs 
rs10488630 and rs11189600, respectively. N denotes the number of individuals included in the 


















































0.01 ≤ p ≤ 0.05 p ≤ 0.01
0.01 ≤ p ≤ 0.05
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Table 4.
SNPs that likely affect polyadenylation due to a change in the polyadenylation signal. * This SNP 
was reported in 27 and is validated by our data.
Formation/activation of polyA signal
rs6948928 rs10954213 0.76* G/A IRF5 AATGAA AATAAA 15 Shortening
rs168822 rs12934747 0.87 C/T LPCAT2 AACAAA AATAAA 27 Shortening
rs1062826 rs1062827 0.99 G/A F11R AGTAAA AATAAA 21 Shortening
rs759011 rs6598 1 G/A GIMAP5 AATAGA AATAAA 13 Shortening
Disruption of polyA signal 
rs13160562 rs7063 1 T/A ERAP1 AATAAA AAAAAA 23 Shortening
Cis- Causal R2 SNP Gene Reference Alternative Distance Effect on 
regulating SNP  Type  sequence polyA to polyA 3’-UTR 
SNP      signal site (bp) length
 Seven of the SNPs affecting polyadenylation are reported in the 
GWAS catalog as associated with diseases (Table S3), including 
rs2188962 and rs12521868, which are associated with Crohn’s 
disease. We found that these SNPs were associated with a switch 
in the polyadenylation site of IRF1. This may reinforce previous 
evidence that IRF1 is the gene in the IBD5 locus responsible for its 
association with Crohn’s disease29. IRF1 is a family member of the 
IRF5 gene. Thus, in the family of interferon regulatory factors, 
we found two members with genetic regulation of alternative 
polyadenylation sites, likely explaining susceptibility for Crohn’s 
disease and systemic lupus erythematosus, respectively.
 Another example is rs3194051, located in the IL7R gene. 
This SNP was not found in the analysis described above since it 
affects the expression of a tag on the same strand, downstream of 
IL7R in a LINE element (Table 2). However, this tag may represent 
an alternative 3’-UTR for IL7R. The SNP is associated with ulcerative 
colitis and IL7R may be another example of a gene in the inflammatory 
response pathway demonstrating alternative poly-adenylation.
Meta-analysis with RNA-seq data
 In order to increase the statistical power to detect associations 
of SNPs with gene expression, we performed a first-of-its-kind 
eQTL mapping meta-analysis, combining DeepSAGE data with two 
published RNA-seq datasets. We used paired-end sequencing of 
mRNA derived from lymphoblastoid cell lines from HapMap 
individuals of European origin8 and 35 and 46 bp single-end 
sequencing of mRNA derived from lymphoblastoid cell lines from 
HapMap individuals of Yoruba origin9. Sequence reads were 
mapped to the reference genome hg19 using Tophat30 and assigned 
to transcripts. A consistently high percentage of reads 
(86–87% of aligned reads) mapped to exonic regions (Table 5).
 We first performed eQTL mapping separately in all three 
datasets (Table 6), summarizing expression on the transcript level 
to permit comparisons between the datasets. The numbers of 
cis-regulated genes detected in transcript-wise analysis was lower 
than in tag-wise analysis, possibly because we missed resolution on 
alternative splicing- and alternative polyadenylation events. 
Again, PC correction greatly improved the number of cis-eQTLs 
detected (Table 6).
 29
Huff, C. D. et al. Crohn’s disease and genetic 
hitchhiking at IBD5. Mol. Biol. Evol. 29, 101–11 
(2012).
 30
Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: 
discovering splice junctions with RNA-Seq. 
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Figure 6. rs12934747*T creates a poly(A) signal in LPCAT2 and leads to 
alternative polyadenylation site usage. 
The y-axis represents the number of counts for the DeepSAGE tags. Two samples with different 
genotypes for SNP rs12934747, CC (reference allele) and TT (alternative allele), are shown as 
different traces. Below the coverage tracks, the position of rs12934747 is shown, together with 
the position of all reported polyadenylation sites from polyA_DB. An enlargement of the region 
containing the SNP is shown below. rs12934747 is located at the beginning of the 3-untranslated 
region (3’-UTR) of LPCAT2, 27 nucleotides upstream a reported and experimentally validated 
polyadenylation site. This SNP changes the sequence, creating a polyadenylation signal that leads 
to the usage of the reported polyadenylation site. The square block indicates the sequence of the 
polyadenylation signal created by rs12934747. The creation of this signal shortens the 3’-UTR, as 
indicated by the higher abundance of the proximal DeepSAGE just upstream of the 
polyadenylation signal, and the nearly absent distal DeepSAGE, in the sample with the TT 
genotype (both tags indicated by arrows). Tag 2 was fi ltered out because it was expressed in less 
than 90% of individuals. There is an additional tag 3 inbetween the proximal and distal tags, which 
is not cis-regulated.
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 We applied PC correction to the individual datasets. As for the 
DeepSAGE analysis, the first PC correlated strongly with the mean 
GC-percentage in the two RNA-seq datasets (Figure S1). We then 
assessed the robustness of the identified cis-eQTLs: we checked 
whether those in one dataset could be significantly replicated in 
the other two datasets. We observed that in each of the RNA-seq 
datasets approximately one-third of cis-eQTLs could be replicated 
in the other dataset (Table S4). The overlap between RNA-seq and 
DeepSAGE was smaller, reflecting differences in the two 
technologies, in cell types and in populations. In each comparison, 
we observed a very high concordance in the allelic direction of 
cis-eQTLs that could be replicated in another dataset.
 We also looked at the replication of RNA-seq eQTLs in 
corresponding micro-array-based datasets. 80–88% of such eQTLs 
could be replicated in microarray data (Table S5). As we could 
cross-replicate many cis-eQTLs, we decided to conduct a meta-
analysis to increase the statistical power. We calculated joint 
p-values using a weighted Z-score method. The number of cis-
regulated genes then increased to 1,207 unique genes 
(Table 6; a list of detected eQTLs is given in Table S6), indicating 
that a meta-analysis of different types of sequencing based eQTL 
datasets reveals many more cis-regulated genes than the individual 
analyses.
 For our meta-analysis results we determined the number of 
disease- and trait-associated SNPs using the Catalog of Published 
Genome-Wide Association Studies in the same way as for the 
DeepSAGE dataset. 107 of the 6,446 unique trait-associated SNPs 
Table 5.
Description of RNA next generation sequencing datasets.
Montgomery et al.  Paired-end RNA-seq LCL 60 37 bp 9.5 ± 3 56 87
Pickrell et al. Yale Single-end RNA-Seq LCL 72 35 bp 8.1 ± 2.3 85 86
Pickrell et al. Argonne Single-end RNA-Seq LCL 72 46 bp 8.1 ± 1.8 80 86
NTR-NESDA  DeepSAGE Total blood 94 21 bp 16 ± 7  85 88
Dataset Sequencing Cell Number Read Million Average % Average % 
 type tissue of length reads of mapped mapped reads 
  type samples  per sample reads in exons
Table 6.
Number of detected cis-eQTLs in transcript-wise analysis of three harmonized RNA NGS 
datasets.
Montgomery et al. (paired-end RNA-seq) 94 145
Pickrell et al. (single-end RNA-seq) 199 438
NTR-NESDA transcript-wise (DeepSAGE) 292 579
Meta-analysis 651 1,207












































































showed a significant cis-eQTL effect in the meta-analysis. 
The overlap with 104 trait-associated SNPs detected in tag-wise 
DeepSAGE eQTL mapping was 37, indicating that the DeepSAGE 
transcript end quantification revealed other trait-associated 
cis-eQTLs than a meta-analysis on the level of whole transcripts. 21 
of the 107 SNPs showed a significant cis-eQTL effect in the 
sequencing-based meta-analysis, but did not show a cis-eQTL effect 
in the large array-based blood dataset (Table 7).
Discussion
 We have described the results from cis-eQTL mapping on 
DeepSAGE sequencing, a technique that is different from RNA-seq 
since it mainly targets the 3’-end of transcripts. We identified 1,011 
unique cis-regulated tags (significant at tag-level FDR < 0.05). 
We performed eQTL mapping on the microarray expression data 
of the same samples and the number of detected cis-eQTLs was 
much smaller than in the DeepSAGE data, indicating the higher 
power of DeepSAGE in eQTL mapping. Moreover, for 220 of the 
cis-eQTLs SNPs detected by DeepSAGE we did not detect a 
significant cis-eQTL in a much larger microarray-based study in 
1,469 whole peripheral blood samples6. 13 of these SNPs were 
reported as disease- or trait-associated in the GWAS catalog.
Table 7.
Trait-associated SNPs detected in the sequencing-based transcript-wise meta-analysis, but not 
detected in array-based eQTL dataset of 1,469 peripheral blood samples.
rs1052501 3 41963564 ULK4 Multiple myeloma
rs347685 3 141782879 TFDP2 Chronic kidney disease
rs4580814 5 1081324 SLC12A7 Hematological and biochemical traits
rs4947339 6 28911984 C6orf100 Platelet aggregation
rs2517532 6 31024818 HCG22 Hypothyroidism
rs2844665 6 31024818 HCG22 Stevens-Johnson syndrome and toxic 
    epidermal necrolysis (SJS-TEN)
rs6457327 6 31024818 HCG22 Follicular lymphoma
rs3130501 6 31324124 HLA-B Stevens-Johnson syndrome and toxic 
    epidermal necrolysis (SJS-TEN)
rs2858870 6 32434437 HLA-DRB9 Nodular sclerosis Hodgkin lymphoma
rs3129889 6 32434437 HLA-DRB9 Multiple sclerosis
rs3135388 6 32434437 HLA-DRB9 Multiple sclerosis
rs477515 6 32434437 HLA-DRB9 Inflammatory bowel disease
rs9271100 6 32524134 HLA-DRB6 Systemic lupus erythematosus
rs9273349 6 32632106 HLA-DQB1 Asthma
rs3807989 7 116183034 CAV1 PR interval
rs12680655 8 135604552 ZFAT Height
rs4929923 11 8642408 TRIM66 Menarche (age at onset)
rs12785878 11 71161461 RP11-660L16.2 Vitamin D insufficiency
rs12580100 12 56436876 RPS26 Psoriasis
rs4924410 15 40329664 SRP14 Ewing sarcoma
rs7364180 22 42184613 MEI1 Alzheimer’s disease biomarkers
SNP Chr. Transcript Cis-regulated Associated trait 
name  position gene 
  (midpoint)
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 We observed that the number of cis-eQTLs detected in 
microarray data was higher in highly expressed genes, whereas for 
DeepSAGE the detected cis-eQTL genes had expression levels that 
could be much lower (Figure 2). This means that DeepSAGE is 
much better at identifying cis-eQTLs for genes showing low 
expression than conventional microarrays. This is because gene 
expression quantification using microarrays is more difficult as 
there is always a background signal present that needs to be 
accounted for. This is not the case for next-generation sequencing: 
although stochastic variation plays a major role in determining 
what RNA molecules will eventually be sequenced (especially for 
transcripts of low abundance), detection of such an RNA molecule 
is direct proof that it is being expressed.
 Clearly, DeepSAGE can capture events that are likely to be 
missed by RNA-seq and conventional microarrays. It is not 
surprising, due to the different emphasis of DeepSAGE, that we 
could only replicate 39% of the DeepSAGE cis-eQTLs in the 
microarray data with a consistent allelic direction (Figure S3). 
The limited overlap between DeepSAGE- and microarray-based 
eQTL studies may be partly explained by the fixed thresholds 
applied, the interrogation of different transcript variants, and by 
the smaller dynamic range of microarrays. In addition, we found 
that more highly expressed genes were more often replicated than 
lower expressed ones.
 Moreover, DeepSAGE allows for the detection of non-coding 
and novel transcripts not present on the microarrays. We showed 
that genetic variation affects the expression of a substantial 
number of lincRNAs and antisense genes, some of which have been 
linked to clinical traits. This suggests that clinical traits may be 
modified by expression of antisense transcripts or alternative 
3’-UTR selection, which are not separately quantified in the 
microarray-based studies or in most RNA-seq, where standard 
protocols are still not strand-specific.
 We also noticed a relatively high proportion of eQTLs with 
DeepSAGE tags mapping in SINE, LINE and LTR elements. 
These transposable elements contribute to the evolution and 
inter-individual variation of the human genome and to the 
diversification of the transcriptome, the latter facilitated by their 
inherent potential to be transcribed and the presence of cryptic 
splice acceptor and donor sites24,31,32. Some of the DeepSAGE tags 
we identified may be located in entirely new transcripts, but the 
majority is likely to represent alternative exons or 3’-UTRs of 
known transcripts, in accordance with the observed preferential 
location in introns or near genes.
 Associations with transcripts and transcript variants not yet 
annotated may help to discover a function for these transcripts, 
as they are likely to play a role in the physiological and clinical 
traits associated with the SNP. Moreover, this will complement our 
knowledge of the pathways associated with these physiological and 
clinical traits.
 
 In our study, we have demonstrated that genotype-dependent 
switches in the preference of alternative polyadenylation sites are 
common. One of these events has been well characterized: SNP 
 31
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rs10954213 creates an alternative polyadenylation site in IRF5, 
shortens the 3’-UTR, stabilizes the mRNA, and increases IRF5 
expression, explaining its genetic association with systemic lupus 
erythematosus19,27. We have now discovered more examples where 
SNPs create or disrupt polyadenylation motifs. Amongst others, 
we identified a new, similar, genotype-dependent switch in 
preferred polyadenylation site for family member IRF1, with a 
probable link to Crohn’s disease. Alternative polyadenylation 
associated with shortening of 3’-UTRs is a prominent event in the 
activation of immune cells18. Thus, genetically determined use of a 
proximal polyadenylation sites may predispose to inflammatory 
disorders such as Crohn’s disease. The opposite correlations that 
we observed for most genes were slightly less pronounced than for 
IRF5. This indicates that mechanisms other than the creation or 
disruption of canonical polyadenylation motifs may also play a role. 
For example, SNPs in miRNA or protein-binding sites may 
specifically affect the stability of the transcript variant with the 
long 3’-UTR.
 We subsequently conducted a cis-eQTL meta-analysis on the 
heterogeneous types of data using methods extended from those 
we developed for microarray-based eQTL meta-analysis6. 
We identified 1,207 unique cis-regulated genes. This number is 
substantially higher than in each of the datasets separately and 
indicates that different protocols for digital gene expression 
generally deliver consistent results. Nevertheless, the overlap at a 
fixed FDR of 0.05 is rather small, in particular between DeepSAGE 
and RNA-seq data. While this is partly attributable to using a 
strong threshold, there are other important reasons: firstly, 
the RNA-seq and DeepSAGE technologies frequently interrogate 
different transcript variants. Secondly, the RNA-seq studies were 
done on lymphoblastoid cell lines (LCLs) while the DeepSAGE 
study was on total blood, and some cis-eQTLs may be tissue-
specific33,34. Finally, the DeepSAGE technology is strand-specific but 
the RNA-seq technologies evaluated here are not: where 
DeepSAGE will evaluate the expression of sense and antisense 
transcripts separately, RNA-seq will sum them. These reasons 
could explain why the percentage of RNA-seq-derived eQTLs that 
can be replicated by DeepSAGE is higher than the percentage of 
DeepSAGE-derived eQTLs that can be replicated by RNA-seq.
 We conclude that DeepSAGE technology is useful to determine 
cis-eQTLs, as it is able to quantify the expression of novel 
transcripts, and to detect alternative polyadenylation effects and 
alternative 3’-UTR selection. It is complementary to other 
sequencing-based approaches, as they each reveal slightly different 
regulatory effects of genetic variants. Different sequencing-based 
eQTL analyses generally deliver consistent results, allowing for 
meta-analyses across different technologies. Future eQTL mapping 
studies based on DeepSAGE and other next generation sequencing 
strategies, using larger cohorts and different techniques, will likely 
reveal a more comprehensive picture of how far genetic variation 
affects the expression of protein-coding genes and non-coding 
RNAs.
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 The medical ethical committee of the VUMC, Amsterdam, 
the Netherlands, approved the collection and analysis of material 
blood, DNA and RNA from the 94 participants from the 
Netherlands Twin Registry (NTR) and the Netherlands Study of 
Depression and Anxiety (NESDA).
NTR-NESDA dataset
 We analyzed 21 bp DeepSAGE data from total blood RNA of 
94 unrelated individuals who participated in NTR or NESDA. 
RNA was isolated using PaxGene tubes20,35,36. DeepSAGE sample 
preparation protocols, and alignment approaches were described 
in37. One sample was run on one lane of the Illumina GAII 
instrument. Data are available in ArrayExpress under accession 
number E-MTAB-1181.
 The NTR-NESDA data was imputed using Beagle v3.1.0, 
with HapMap2 release 24 as a reference.
Tag mapping and expression estimation
 Tags from DeepSAGE sequencing were aligned to the NCBI 
build 37 reference genome using Bowtie v. 0.12.7 allowing for a 
maximum of 1 mismatch and a maximum of 2 possible alignments 
(-n 1 -k 1 -m 2 --best --strata options).
 The expression values were both quantified on an individual tag 
and transcript level. For the tag-wise analysis, the total number of 
occurrences of each unique tag in each sample was counted. 
We only included tags that were present in > 90% of samples. 
Tags with SNPs in the CATG recognition sequence (according to 
dbSNPv135) and the transcripts containing those tags were 
removed before eQTL analysis, since these SNPs can affect the 
position of the SAGE tag in the transcript. For the transcript-wise 
analysis, the tag counts for tags overlapping the exons of a 
transcript by at least half of the tag length were summed. 
Coordinates of LINE, SINE, LTR elements were derived from 
UCSC’s RepeatMasker track (update: 2009-04-24).
GC content bias estimation
 To calculate the GC content per individual for DeepSAGE data, 
GC frequencies for all mapped tags were summed after excluding 
the twenty most abundant tags, since their high abundance would 
give biased estimates.
Cis-eQTL mapping and correction for confounding 
effects through principal component analysis
 Before eQTL mapping, transcript and tag expression values 
were quantile normalized. To perform cis-eQTL mapping, 
association of SNPs with the expression levels of tags or 
transcripts within a distance of 250 kb (as this is the average size of 
linkage regions) of the midpoint of the transcript or tag were 
tested with a non-parametric Spearman’s rank correlation. 
Multiple testing correction was performed, controlling the false 
discovery rate (FDR) at 0.05. To determine the FDR, we created a 
null distribution by repeating the cis-eQTL analysis after permuting 
the sample labels 10 times38.
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 We argue that gene expression levels from NGS-based datasets 
are, like micro-array based data, derived from genetic, technical 
and environmental effects. As such, compensating for these 
non-genetic effects would increase the power to detect cis-eQTL 
effects. To mitigate the effects of non-genetic sources of variability, 
we first log2 transformed the data and centered and scaled each 
tag, and subsequently applied PCA on the sample correlation 
matrix. We then used the first PCs as covariates, and re-did the 
non parametric cis-eQTL mapping on the residual expression data 
(using the procedure described by6).
Validation of genotype-dependent alternative 
polyadenylation in RNA-seq datasets
 The genomic coordinates of the 3’-UTR, obtained from Refseq 
Genes, were split into two separate regions (distal and proximal 
3’-UTRs) according to the position of the DeepSAGE tags with 
opposite directions, the position of LongSAGE tags from CGAP, 
and the position of reported and predicted polyadenylation sites 
from polyA_DB database. To calculate the coverage in proximal 
and distal regions in RNA-seq datasets, we created a coverage 
histogram from each .bam alignment file using coverageBed tool 
from BEDTools package (version 2.17.0)39. Subsequently, a custom 
Python script was used to convert the histogram in number of 
nucleotides mapped per region, normalized by the length of the 
region. The ratio between the number of counts in the proximal 
region and the distal region was then calculated.
qPCR validation of alternative polyadenylation
 Expression of short and long variants of HPS1 and IRF5 was 
quantified by qRT-PCR, which was performed on a subset of RNA 
samples used for the DeepSAGE sequencing. cDNA was 
synthesized from 400 ng of total RNA using BioScript MMLV 
Reverse Transcriptase (Bioline) with 40 ng of random hexamer and 
oligo(dT)18 primers following manufacturer’s instructions 
(for the list of primer sequences see Table S7). Primers specific to 
short or long variants of HPS1 were designed using Primer3Plus 
program, primers for IRF5 were designed as previously described40. 
qRT-PCR was performed on the LightCycler 480 (Roche) using 26 
SensiMix reagent (Bioline). 45 cycles of two-step PCR were 
performed for HPS1, and 55 cycles of three-step PCR 
(95°C for 15 s, 48°C for 15 s, and 60°C for 40 s) for IRF5. 
Each measurement was performed in duplicates. PCR efficiency 
was determined using the LinRegPCR program41 v.11.1 according to 
the described method42. Ratios between distal and proximal PCR 
products were then calculated and significance was tested 
performing a T-test.
Identifying causal SNPs affecting polyadenylation
 We obtained all the proxy SNPs for all SNPs identified as 
cis-regulating the choice of polyadenylation site. To do this we used 
bi-allelic SNPs that pass QC from the 1000G European panel 
(v3.20101123) and took all SNPs that were in linkage disequilibrium 
with the query SNPs (R2 ≥ 0.8, distance between SNPs within 250 
kb).
 From this list of cis-regulating SNPs in linkage disequilibrium, 
we kept only SNPs, which were located in the cis-regulated genes. 
The filtering was performed by intersecting .bed files containing 
 38
Breitling, R. et al. Genetical genomics: spotlight on 
QTL hotspots. PLoS Genet. 4, e1000232 (2008).
 39
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible 
suite of utilities for comparing genomic features. 
Bioinformatics 26, 841–2 (2010).
 40
Graham, R. R. et al. Three functional variants of 
IFN regulatory factor 5 (IRF5) define risk and 
protective haplotypes for human lupus. Proc. Natl. 
Acad. Sci. U. S. A. 104, 6758–63 (2007).
 41
Ramakers, C., Ruijter, J. M., Deprez, R. H. L. & 
Moorman, A. F. M. Assumption-free analysis of 
quantitative real-time polymerase chain reaction 
(PCR) data. Neurosci. Lett. 339, 62–6 (2003).
 42
Ruijter, J. M. et al. Amplification efficiency: linking 
baseline and bias in the analysis of quantitative 
PCR data. Nucleic Acids Res. 37, e45 (2009).
115
SNPs coordinates and coordinates of cis-regulated genes from the 
RefSeq database, using the table browser tool in the UCSC genome 
browser and the overlap intervals tool in Galaxy (version 1.0.0).
 Intersection of SNPs with validated and predicted 
polyadenylation sites was performed using annotation in the 
PolyA-DB database (PolyA_DB 1 and PolyA_SVM) on UCSC (table 
browser tool). Detection of SNPs within polyadenylation signals 
was performed by extracting the strand specific sequence five 
nucleotide upstream and downstream each SNP (using table 
browser tool in UCSC) and performing a motif search using 
custom Perl script. Canonical and non-canonical polyA motifs 
searched were AATAAA, ATTAAA, TATAAA, AGTAAA, 
AAGAAA, AATATA, AATACA, CATAAA, GATAA, AATGAA, 
TTTAAA, ACTAAA, and AATAGA. For every SNP located in a 
putative polyadenylation signal motif, the distance to validated and 
predicted polyadenylation sites from PolyA-DB was calculated. 
Only motifs within a distance of 30 nucleotides from a 
polyadenylation site were considered true polyadenylation signals. 
Newly formed polyadenylation signals were detected by changing 
the reference allele of the SNP with the alternative allele, followed 
by the same polyadenylation signal motif search using custom Perl 
scripts.
 For the cis-regulated genes where the SNP is located within a 
true polyadenylation signal, we retrieved the coverage of every 
SAGE tag upstream and downstream the putative affected 
polyadenylation site and calculated the ratio between proximal and 
distal tags for the different genotypes to confirm the expected 
effects of polyadenylation site formation or disruption.
RNA-seq datasets
 For the meta-analysis we combined DeepSAGE data with two 
published RNA-seq datasets. The first dataset was 37 bp paired-
end RNA-sequencing data from HapMap individuals8 
(ArrayExpress:E-MTAB-197): RNA from lymphoblastoid cell lines 
of 60 HapMap CEPH individuals was sequenced on the Illumina 
GAII sequencer, while genotype data had already been generated 
within the HapMap project.
 The second dataset was single-end RNA-sequencing data from 
HapMap individuals9,43 (GEO:GSE19480 and at http://eqtl.uchicago.
edu/RNA_Seq_data/): RNA was sequenced from lymphoblastoid 
cell lines of 72 HapMap Yoruba individuals from Nigeria on the 
Illumina GAII platform in two sequencing centers: 
Yale (using 35 bp reads) and Argonne (using 46 bp reads).
 Since the Montgomery et al. paper used genotype data for 
some individuals that were not in the HapMap3 panel (NA0851, 
NA12004, NA12414 and NA12717), we imputed these individuals 
using Beagle v3.1.0, with HapMap2 release 24 as a reference.
RNA-seq read mapping
 Reads from single- and paired-end RNA-sequencing were 
mapped to the human genome NCBI build 37 (reference 
annotation from Ensembl GRCh37.65) using Tophat v. 1.3.330 – a 
splice-aware aligner that maps RNA-seq reads to the reference 
genome using Bowtie21. We used default settings (maximum 2 
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mismatches, 20 possible alignments per read) with a segment 
length value of 17 bp. Reads that corresponded to the flag 1796 in 
the .bam alignment file (read unmapped, not primary alignment, 
read fail quality check, read is PCR or optical duplicate) were 
filtered out. The numbers of raw and mapped reads for each 
dataset are given in Table 5.
Read quantification
 To estimate expression levels in RNA-seq data, reads that 
overlapped with exons from known transcripts (GRCh37.65) were 
quantified using the coverageBed method from BEDTools suite39.
 For transcript level quantification the read count C for sample s 
for transcript tr was calculated as a sum of expression values over 
all exons contained in this transcript: 
Cs,tr = 10
6 x � (ne * Be)
 
where ne is number of reads overlapping exon e by not less than 
half of read’s length, and Be is the breadth of coverage for exon e 
(% of exon length covered by the reads mapping to that exon).
 In case a read mapped to multiple transcripts, the read was 
counted for all transcripts, since the short reads are difficult to 
assign to a specific transcript. Multiplication by breadth of coverage 
was performed to help in distinguishing between different isoforms 
by assigning higher weight to exons fully covered by reads in 
contrast to alternative exons covered only partly.
 Because different methods have different capacity to identify 
alternative splicing events, we subsequently summarized our eQTL 
results to unique genes.
Meta-analysis
 Meta-analysis was conducted by using a weighted Z-method, 
weighing each of the datasets by the square root of the number of 
samples per dataset6.
Microarray datasets
 We compared the results to corresponding microarray dataset 
eQTL mapping results. For each of the 94 individuals from NTR 
NESDA study, Affymetrix HG-U219 expression data were 
generated at the Rutgers University Cell and DNA Repository 
(RUCDR, http://www.rucdr.org). NTR and NESDA samples were 
randomly assigned to plates with seven plates containing subjects 
from both studies to better inform array QC and study 
comparability. Gene expression data were required to pass 
standard Affymetrix QC metrics (Affymetrix expression console) 
before further analysis. Probe sets were removed when their 
mapping location was ambiguous or if their location intersected a 
polymorphic SNP (dropped if the probe oligonucleotide sequence 
did not map uniquely to hg19 or if the probe contained a 
polymorphic SNP based on HapMap344 and 1000 Genomes45 
project data). Expression values were obtained using RMA 
normalization implemented in Affymetrix Power Tools 
(APT, v 1.12.0). MixupMapper revealed no sample mix-ups46.
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 For RNA-seq data we used corresponding microarray datasets 
that were available for most of the individuals present in RNA-seq 
datasets. We used Illumina expression data provided by Stranger et 
al.3 of the 72 HapMap YRI individuals (56 of which were also 
present in RNA-seq dataset from Pickrell et al.) and 60 HapMap 
CEU individuals provided by Montgomery et al. (58 of which were 
also present in RNA-seq dataset from Montgomery et al.).
 The same normalization procedure was performed as for the 
sequencing-based datasets: quantile normalization, and subsequent 
probe set centering to zero, z-score transformation, and scaling to 
a standard deviation of one.
Data access
 The newly generated DeepSAGE data for NTR-NESDA dataset 
is available in ArrayExpress under accession number E MTAB-1181 
(ENA: ERP001544).
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Supplementary Information
Figure S1
Correlation of GC content with principal component 1 (PC1) 
eigenvector coefficients for all the three datasets. Pearson 
correlation coefficient and corresponding p-value are shown in the 
plot.
Figure S2
Blood cell counts in DeepSAGE data captured by the eigenvector 
coefficients on principal components PC7 (left) and PC11 (right). 
Experimentally determined blood cell counts at the time of RNA 
isolation were available for 36/94 samples. Blood cell counts are 
expressed as (number of cells) x 109/L. Pearson correlation 
coefficients and corresponding p-values are shown in the plot.
Figure S3
Replication of Affymetrix eQTLs in DeepSAGE dataset and 
DeepSAGE eQTLs in Affymetrix data. The numbers of unique 











































































List of detected eQTLs in tag-wise eQTL mapping.
Table S2
Trait-associated SNPs affecting the expression of DeepSAGE tags 
of 94 peripheral blood samples.
Table S3
List of candidate genes with alternative polyadenylation event 
detected using a permissive strategy.
Table S4
Replications between RNA-seq and DeepSAGE eQTLs.
Table S5
Replication of RNA-seq eQTLs in microarray-based datasets.
Table S6
List of detected eQTLs in the meta-analysis.
Table S7
Primer sequences for qPCR validation.
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 Identifying the downstream effects of disease-associated SNPs 
is challenging. To help overcome this problem, we performed 
expression quantitative trait locus (eQTL) meta-analysis in non-
transformed peripheral blood samples from 5,311 individuals with 
replication in 2,775 individuals. We identified and replicated 
trans-eQTLs for 233 SNPs (reflecting 103 independent loci) that 
were previously associated with complex traits at genome-wide 
significance. Some of these SNPs affect multiple genes in trans that 
are known to be altered in individuals with disease: rs4917014, 
previously associated with systemic lupus erythematosus (SLE)1, 
altered gene expression of C1QB and five type I interferon 
response genes, both hallmarks of SLE2–4. DeepSAGE RNA 
sequencing showed that rs4917014 strongly alters the 3’-UTR levels 
of IKZF1 in cis, and chromatin immunoprecipitation and sequencing 
analysis of the trans-regulated genes implicated IKZF1 as the causal 
gene. Variants associated with cholesterol metabolism and type 1 
diabetes showed similar phenomena, indicating that large-scale 
eQTL mapping provides insight into the downstream effects of 
many trait-associated variants.
 Genome-wide association studies (GWAS) have identified 
thousands of variants that are associated with complex traits and 
diseases. However, because most variants are noncoding, 
it is difficult to identify causal genes. Several eQTL-mapping 
studies5–8 have shown that disease-predisposing variants often 
affect the gene expression levels of nearby genes (cis-eQTLs). 
A few recent studies have also identified trans-eQTLs5,9–13, showing 
the downstream consequences of some variants. However, 
the total number of reported trans-eQTLs is low, mainly owing to 
the multiple-testing burden. To improve statistical power, 
we performed an eQTL meta-analysis in 5,311 peripheral blood 
samples from 7 studies (EGCUT14, InCHIANTI15, 
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Figure 1. 
Trans-eQTL SNPs are enriched for functional elements. We investigated whether trans-eQTL 
SNPs are enriched for certain functional elements using the online tools SNPInfo, SNPNexus and 
HaploReg that rely on data from, among others, the ENCODE Project. 
A) Trans-eQTL SNPs are enriched for mapping within miRNA binding sites.
B) Trans-eQTL SNPs show strong enrichment (as annotated using HaploReg) for enhancer regions 
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Trans-eQTL SNP enhancer enrichment
using HaploReg
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Rotterdam Study16, Fehrmann5, HVH17–19, SHIP-TREND20 and 
DILGOM21) and replication analysis in another 2,775 samples. 
We aimed to ascertain to what extent SNPs affect genes in cis and 
in trans and to determine whether eQTL mapping in peripheral 
blood could identify downstream pathways that might be drivers of 
disease processes.
 Our genome-wide analysis identified cis-eQTLs for 44% of all 
tested genes (6,418 genes at probe-level false discovery rate (FDR) 
< 0.05 and 4,690 genes with a more stringent Bonferroni multiple-
testing correction; Table 1, Supplementary Figures 1–3 and 
Supplementary Tables 1–3). Our trans-eQTL analysis focused on 
4,542 SNPs that have been implicated in complex disease or traits 
(derived from the Catalog of Published GWAS; see URLs). 
In the discovery data set, we detected 1,513 significant trans-eQTLs 
that included 346 unique SNPs (FDR < 0.05; 8% of all tested SNPs; 
Table 1, Supplementary Figure 4 and Supplementary Table 4) 
affecting the expression of 430 different genes (643 trans-eQTLs, 
including 200 unique SNPs and 223 different genes with a more 
stringent Bonferroni correction).
 We used stringent procedures for trans-eQTL detection 
(Supplementary Note) and various benchmarks to ensure 
reliability: for 26 trans-eQTL genes, the eQTL SNP affected 
multiple probes within these genes (Supplementary Table 5), 
always with consistent allelic directions, suggesting that our 
probe-filtering procedure was effective in preventing false-positive 
trans-eQTLs. Trans-eQTLs showed similar effect sizes across the 
various cohorts (Supplementary Figure 5).
 We did not find evidence that trans-eQTLs were driven by 
differences in age or blood cell counts between individuals 
(Supplementary Figure 6, Supplementary Table 6 and 
Supplementary Note). However, we cannot exclude this possibility 
entirely because FACS analyses on individual cell types had not 
been conducted. We also detected previously reported blood 
trans-eQTLs5 in this study (Supplementary Figure 7, Supplementary 
Table 7 and Supplementary Note).
Table 1. Results of cis- and trans-eQTL mapping analyses
Number of significant 664,097 395,543 1,513 643 
unique SNP-Probe pairs
Number of significant 397,310 266,036 346 200 
unique eQTL SNPs
Number of significant 8,228 5,738 494 240 
unique eQTL probes
Number of significant 6,418 4,690 430 223 
unique eQTL genes
Number of significant 636 326 35 13 
unique eQTL probes not mapping to genes
 Cis-eQTL analysis  Trans-eQTL analysis 
 FDR < 0.05 Bonferroni FDR < 0.05 Bonferroni 
 significance significance significance significance
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 To ensure reproducibility of the detected trans-eQTLs, 
we replicated trans-eQTLs from our discovery meta-analysis in 2 
independent studies of peripheral blood gene expression: 52% in 
KORA F4 (n = 740 samples)22 and 79% in BSGS (n = 862 samples)23 
(FDR < 0.05; Supplementary Figure 8). Irrespective of significance, 
91% and 93% of all 1,513 significant trans-eQTL SNP-probe 
combinations showed consistent allelic direction in these 
replication cohorts compared with in the discovery analysis. 
A meta-analysis of the two replication studies improved replication 
rates: 89% of the 1,513 trans-eQTLs were significantly replicated 
(FDR <0.05), with 99.7% showing a consistent allelic direction. 
Irrespective of significance, 97% of the trans-eQTLs showed a 
consistent allelic direction in this replication meta-analysis 
(Supplementary Figure 8). We found that some trans-eQTLs could 
be detected in three cell type–specific data sets (283 monocyte 
samples9, 282 B cell samples9 and 608 HapMap lymphoblastoid cell 
line (LCL) samples24; Supplementary Figures 9 and 10). Despite the 
different tissues analyzed in these three studies, we were able to 
significantly replicate 7%, 4% and 2% of the trans-eQTLs 
(FDR <0.05), respectively. As 95% of the trans-eQTL SNPs 
explained less than 3% of the total expression variance 
(Supplementary Figure 11 and Supplementary Table 6), we lack 
statistical power to replicate most trans-eQTLs in these smaller 
replication cohorts.
 We subsequently confined further analyses to 2,082 different 
SNPs that have been found to be associated with complex traits at 
genome-wide significance (trait-associated SNPs; reported 
P < 5 × 10−8; out of 4,542 unique SNPs that we tested). 
These 2,082 SNPs showed a significantly higher number of trans-
eQTL effects compared with the 2,460 tested SNPs with reported 
disease associations at lower significance levels (P = 8 × 10−22; 
Supplementary Figure 12 and Supplementary Note): 254 of these 
2,082 SNPs showed a trans-eQTL effect in the discovery analysis 
(reflecting 1,340 SNP-probe combinations; 1,201 of these were 
significantly replicated in blood, reflecting 233 different SNPs and 
103 independent loci). For 671 of these 1,340 trans-eQTLs (50%), 
the trait-associated SNP (or a SNP in strong linkage disequilibrium, 
LD) was the strongest trans-eQTL SNP within the locus or was 
unlinked to the strongest trans-eQTL SNP (Supplementary Table 8 
and Supplementary Note). The 2,082 trait-associated SNPs were 6 
times more likely to cause trans-eQTL effects than were randomly 
selected SNPs (matched for distance to the gene and allele 
frequency; P = 5.6 × 10−49; Supplementary Figure 13 and 
Supplementary Note). SNPs associated with (auto)immune or 
hematological traits were twice as likely to underlie trans-eQTLs 
compared with other trait-associated SNPs (P = 5 × 10−25; 
Supplementary Note). Trait-associated SNPs that also caused 
trans-eQTLs affected the expression levels of nearby transcription 
factors in cis more frequently than trait-associated SNPs that did 
not affect genes in trans (Fisher’s exact P = 0.032; Supplementary 
Note), suggesting that some trans-eQTLs arise owing to altered cis 
gene expression levels of nearby transcription factors.
 We examined the genomic properties of the trans-eQTL SNPs 
(and their perfect proxies identified using data from the 1000 
Genomes Project25,26): these SNPs were significantly enriched for 
mapping within microRNA (miRNA) binding sites (Fisher’s exact 
 22
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P < 0.05; Figure 1A). They mapped to regions in K562 (myeloid) 
and GM12878 (lymphoid) cell lines showing enrichment of histone 
enhancer signals (fold change > 2.5; Figure 1B) compared to the 
signals observed in six non-blood cell lines. Enhancer enrichment in 
myeloid and lymphoid cells supports the validity of our blood-
derived trans-eQTLs. These results suggest that trans-eQTL effects 
are tissue specific, a notion that is supported by our inability to 
replicate a trans-eQTL that was previously identified in adipose 
tissue13 for SNP rs4731702, associated with both type 2 diabetes 
(T2D) and lipid levels.
 These trans-eQTLs can provide insight into the pathogenesis of 
disease. Although RNA microarray studies have identified 
dysregulated pathways for many complex diseases, it is often 
unclear whether associated SNPs first cause defects in the 
pathways whose dysregulation ultimately leads to disease or 
vice-versa. One example of this type of complex disease is SLE, 
which is an autoimmune disease causing inflammation and tissue 
damage. Individuals with SLE have increased type I interferon 
Table 2. Complex traits where multiple unlinked SNPs affect the same 
downstream genes
Immune related traits Type 1 diabetes  GBP4, STAT1
 Type 1 diabetes autoantibodies  GBP4, STAT1
 Celiac disease  CXCR6, FYCO1
 Multiple sclerosis  CD5
Blood pressure traits Diastolic blood pressure LOC338758
 Systolic blood pressure LOC338758
Hematological traits Hemoglobin ALAS2
 Hematological Parameters  FBXO7
 F-cell distribution  ESPN,  PHOSPHO1, GNAS, TSPAN13, VWCE
 Hematocrit  ALAS2
 Serum markers of iron status  ALAS2
 Red blood cell traits  ALAS2
 Serum iron levels ALAS2
 Glycated hemoglobin levels ALAS2
 Hematology traits  ALAS2
 Serum hepcidin  ALAS2
 Beta-thalassemia  PHOSPHO1, VWCE, TSPAN13, ESPN
 Hematological and biochemical traits  AL109955.37-3, RBM38, TRIM58
 Mean corpuscular hemoglobin  ALAS2, C18orf10, DNAJB2, ESPN, HBM, KEL, PDZK1IP1, PIM1,   
  PRDX5, RAP1GAP, UBXN6, VWCE, XK
 Mean corpuscular volume ALAS2, B4GALT3, C18orf10, C1orf128, C22orf13, C5orf4,   
  CCBP2, CSDA, DNAJB2, EIF2AK1, ESPN, FBXO7, HAGH, HBM,   
  HPS1, KEL, KLC3, KRT1, LGALS3, MARCH8, MCOLN1, OSBP2,   
  PDZK1IP1, PHOSPHO1, PIM1, PLEK2, PPP2R5B, PRDX5, PTMS,
  RAP1GAP, RIOK3, TGM2, TSTA3, UBXN6, VWCE, XK
 Mean platelet volume  ABCC3, AL353716.18, AQP10, C19orf33, C6orf152, CABP5,   
  CTDSPL, CTTN, CXCL5, ESAM, F13A1, GNB5, GNG11, GP9,   
  GUCY1A3, ITGA2B, ITGB5, LIMS1, LY6G6F, MMRN1,
  MPL, NRGN, PARVB, PRDX6, PTCRA, RAB27B, RBPMS2,   
  SAMD14, SH3BGRL2, TSPAN9, VCL
Trait Type Complex trait At least two unlinked trait SNPs both affect  
  gene(s):
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(IFN-α) levels, increased expression of IFN-α response genes4,27,28 
and decreased expression of the C1Q complement genes. 
We observed that four common SLE-associated variants affected 
IFN-α response genes in cis (IRF5, IRF7, TAP2 and PSMB9; 
Supplementary Table 3). As most SLE-associated SNPs do not map 
near complement or IFN-α response genes, we assessed whether 
SLE-associated SNPs affect these genes in trans. This was the case 
for rs4917014, for which the SLE risk allele (rs4917014[T]; showing 
genome-wide significance in Asian populations and nominal 
significance in European populations1,29) not only increased 
expression of five different IFN-α response genes (HERC5, IFI6, 
IFIT1, MX1 and TNFRSF21; Figure 2) but also decreased expression 
of three different probes in CLEC10A. We also observed a 
nominally significant association of rs4917014[T] with decreased 
expression of C1QB (P = 5.2 × 10−6; FDR = 0.28), encoding a 
subunit of the C1q complement complex, which has a protective 
role in lupus: complete deletion of the genes encoding the C1q 
subunits practically ensures the development of SLE30,31. CLEC10A 
and CLEC4C belong to the C-type lectin family, which includes 
mannose-binding lectins (MBLs).
 Although, to our knowledge, CLEC10A and CLEC4C have not 
been studied in the context of SLE, the role of MBLs is similar to 
that of the C1q complex, and MBLs are a risk factor for the 
development of autoimmunity in humans and mice3. The rs4917014 
trans-eQTLs replicated well in the peripheral blood and monocyte 
replication data sets and reinforce the role of altered expression of 
the IFN-α pathway, C-type lectin and C1Q genes in SLE. Individuals 
without SLE but who carry the rs497014[T] risk allele show these 
pathway alterations, indicating that these affected pathways are not 
solely a consequence of SLE but could precede SLE onset.
 We investigated the underlying mechanisms of the effects 
exerted by rs4917014. IKZF1 is the only gene overlapping the 
rs4917014 locus. As this gene encodes a transcription factor 
(Ikaros-family zinc finger 1), cis-regulatory effects of rs4917014 on 
IKZF1 and consequent altered IKZF1 protein levels could 
constitute a mechanism for the detected trans-eQTL effects. 
However, because our meta-analysis did not initially detect a 
cis-eQTL on the Illumina probe for IKZF1 located near the 5’-UTR 
of the gene, we investigated the 3’-UTR using Deep Serial Analysis 
of Gene Expression (DeepSAGE) next-generation RNA sequencing 
data from 94 peripheral blood samples32. The variant rs4917014[T] 
allele increased expression levels of the 3’-UTR of IKZF1 
(Spearman’s correlation = 0.45; P = 6.29 × 10−6). 
Using Encyclopedia of DNA Elements (ENCODE) Project33 
chromatin immunoprecipitation and sequencing (ChIP-seq) data, 
we observed significantly increased IKZF1 protein binding within 
genomic locations corresponding with trans-eQTL–upregulated 
genes compared with all other genic DNA (Wilcoxon  
P value = 0.046) and with SLE cis-eQTL–upregulated genes outside 
of the IKZF1 locus (Wilcoxon P value = 4.3 × 10−4), 
thereby confirming the importance of IKZF1 in SLE. IKZF1 is also 
important for other phenotypes: rs12718597, an unlinked intronic 
variant within IKZF1, is associated with mean corpuscular volume 
(MCV)34 and affects the expression of Illumina probe 4390086 near 
the 5’-end of IKZF1 in cis. Ikzf1 knockout mice show abnormal 
erythropoiesis35, suggesting a causal role for human IKZF1 in MCV 
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Two unlinked T1D risk alleles are associated with increased STAT1 and GBP4 
expression. rs3184504[T], a risk allele for T1D (chromosome 12), affects the 
expression of SH2B3 in cis but also affects the expression of 14 unique genes in 
trans, including 2 interferon-γ response genes, GBP4 and STAT1. 
Another, unlinked T1D risk allele (rs4788084[C] on chromosome 16) also 
increases expression of these two interferon-γ genes, suggesting that an 
elevated interferon-γ response is important in T1D.
Type 1 diabetes risk allele rs3184504 (T)
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Type 1 diabetes risk allele rs4788084 (C) 
affects GBP4 and STAT1 in trans 
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as well. However, although rs12718597[A] was associated in trans 
with the upregulation of 31 genes and with the downregulation of 
19 genes, none of the SLE trans-regulated genes overlapped with 
the MCV trans-regulated genes. The latter were mainly involved in 
hemoglobin metabolism and did not show increased IKZF1 binding 
(Wilcoxon P value = 0.35). In summary, these results indicate that 
IKZF1 has multiple functions and that different SNPs near IKZF1 
elicit function-specific effects.
 We identified other trans-eQTLs showing similar phenomena. 
For example, rs174546 (located in the 3’-UTR of FADS1 and 
associated with metabolic syndrome36 and with low-density 
lipoprotein (LDL) and total cholesterol levels37,38) affected the 
expression of TMEM258, FADS1 and FADS2 in cis and the 
expression of LDLR in trans (Supplementary Figure 14). 
LDLR encodes the LDL receptor and contains common variants 
that are also associated with lipid levels38. LDLR gene expression 
levels correlated negatively (P < 3.0 × 10−4) with total, high-density 
lipoprotein (HDL) and LDL cholesterol levels in the tested cohorts 
(Rotterdam Study and EGCUT; Supplementary Table 9), indicating 
that peripheral blood is a useful tissue for gaining insight into the 
downstream effects of lipid-regulating SNPs.
 For 21 different complex traits, at least 2 unlinked variants that 
have been associated with these diseases affected exactly the same 
gene in trans (compared with 1 complex trait similarly affected by 
variants from equally sized but permuted lists of trans-eQTLs; 
Table 2, Supplementary Figure 15 and Supplementary Table 10). 
Although most of these traits are hematological (for example, 
mean platelet volume or serum iron levels), we also observed this 
convergence for blood pressure, celiac disease, multiple sclerosis 
and type 1 diabetes (T1D).
 rs3184504 (located in an exon of SH2B3) and its proxy rs653178 
(located in an intronic region of ATXN2 on chromosome 12) have 
been associated with several autoimmune diseases, including 
T1D39,40 and the production of autoantibodies therein39,40, celiac 
disease8,41, hyperthyroidism42, vitiligo43 and rheumatoid arthritis41, 
as well as with other complex traits such as blood pressure44,45, 
chronic kidney disease46 and eosinophil counts47. We observed a 
cis-eQTL effect for this SNP on SH2B3 (FDR < 0.05) and trans-
eQTL effects on 14 genes (FDR < 0.05; Figure 3), all of which are 
highly expressed in neutrophils. Because the trans-eQTLs effects 
could be explained by known effect of rs3184504 on differences in 
cell count proportions47, we correlated the expression levels of 
trans-regulated genes with cell counts in two cohorts (Rotterdam 
Study and EGCUT) but did not observe significant correlations 
(Supplementary Table 9). The identified trans-eQTLs describe 
different biological functions: the T1D risk allele rs3184504[T] was 
associated with decreased expression of nine genes, most of which 
are involved in Toll-like receptor signaling48 (C12orf75, FOS, IDS, IL8, 
LOC338758, NALP12, PPP1R15A, S100A10 and TAGAP) and with 
increased expression of five genes involved in the interferon-γ 
response (GBP2, GBP4, STAT1, UBE2L6 and UPP1). We observed that 
another T1D risk allele, rs4788084[C]39,40 on chromosome 16, was 
also associated with increased expression of GBP4 and STAT1, 
showing how different T1D risk alleles converge, with both alleles 
causing an increase in the expression of interferon-γ response genes.
 36
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 In summary, our eQTL meta-analysis identified and replicated 
downstream effects for 233 trait-associated SNPs. Our analyses 
show that trans-eQTL mapping in blood for lipid-regulatory and 
immune-mediated disease variants yields insights into downstream 
pathways that are biologically meaningful. Future, larger-scale 




 We performed a whole-genome eQTL meta-analysis of 5,311 
samples from peripheral blood divided over a total of 9 data sets 
from 7 cohorts, including EGCUT14 (n = 891), InCHIANTI15 
(n = 611), Rotterdam Study16 (n = 762), Fehrmann5 (n = 1,240 
on the Illumina HT12v3 platform and 229 on the Illumina H8v2 
platform), HVH17–19 (n = 43 on the Illumina HT12v3 platform and 63 
on the Illumina HT12v4 platform), SHIP-TREND20 (n = 963) and 
DILGOM21 (n = 509). Gene expression data for each data set were 
obtained by isolating RNA using either PAXGene 
(Becton Dickinson) or Tempus (Life Technologies) tubes and then 
hybridizing RNA to Illumina whole-genome Expression BeadChips 
(HT12v3, HT12v4 or H8v2 arrays). Gene expression platforms 
were harmonized by matching probe sequences across the 
different platforms. Mappings for these sequences were obtained 
by mapping the sequences against Build 36 of the human genome 
(Ensembl Build 54, hg18) using the BLAT, BWA and SOAPv2 
sequence alignment programs. Highly stringent alignment criteria 
were used to ensure that probes mapped unequivocally to a single 
genomic position. Genotype data were acquired using different 
genotyping platforms and were harmonized by imputation, using 
the HapMap 2 CEU population as a reference49. Each data set was 
individually checked for sample mix-ups using MixupMapper50. 
For a full description of the individual data sets, the results of the 
sample mix-up analysis, specifics on the gene expression platforms 
used and probe mapping and filtering procedures, see the 
Supplementary Note.
Gene expression normalization
 Gene expression data were quantile normalized to the median 
distribution and were subsequently log2 transformed. Probe and 
sample means were centered to zero. Gene expression data were 
then corrected for possible population structure through the 
removal of four multidimensional scaling components using linear 
regression. We reasoned earlier that normalized gene expression 
data still contain large amounts of non-genetic variation5. 
Therefore, after correction for population stratification, 
we performed principal-component analysis (PCA) on the sample 
correlation matrix. We performed a separate QTL analysis for 
each principal component to ascertain whether genetic variants 
could be detected that affected each principal component. 
If we found an effect on the principal component, we did not 
correct the expression data for this component to ensure that we 
would not unintentionally remove genetic effects from the 
expression data. We established the significance of these 
associations by controlling the FDR, testing each association 



















































The International HapMap Project. Nature 426, 
789–796 (2003).
 50
Westra, H.-J. et al. MixupMapper: correcting 
sample mix-ups in genome-wide datasets 
increases power to detect small genetic effects. 
Bioinformatics 27, 2104–2111 (2011).
132
times (permuting the sample labels for each iteration51). 
Principal components that did not show significance at the FDR 
threshold of 0.0 were removed from the gene expression data by 
linear regression. In all but 2 very small data sets, the first 40 
principal components were removed (excluding those components 
for each cohort that showed a QTL effect). We observed that the 
removal of these 40 components resulted in the identification of 
the highest number of eQTLs in each data set. Although principal-
component correction might remove some eQTL effects, 
we observed that the majority of trans-eQTL effects (95% when 
removing 35 principal components and 90% when removing 45 
principal components) were independent of the number of 
principal components removed (Supplementary Figure 16).
eQTL mapping
 After normalization of the data, we performed both cis- and 
trans-eQTL mapping. eQTLs were deemed cis-eQTLs when the 
distance between the SNP chromosomal position and the probe 
midpoint was less than 250 kb, whereas eQTLs with a distance 
greater than 5 Mb were defined as trans-eQTLs. Only SNPs with a 
minor allele frequency (MAF) of > 0.05 and a Hardy-Weinberg 
equilibrium P value of > 0.001 were included in the analyses. 
Because most cohorts had generated gene expression data using 
the HT12v3 platform, we chose to only include probes that were 
present on this platform. We only tested SNP-probe pairs when 
the SNP passed quality control in at least three cohorts. 
Furthermore, to address issues with respect to computational time 
and multiple testing, we confined our trans-eQTL analysis to those 
SNPs present in the Catalog of Published GWAS (see URLs; 
accessed 16 July 2011). We reasoned that, for genes with strong 
cis-eQTL effects, a cis-eQTL effect might obscure the detectability 
of trans-eQTLs. Therefore, we used linear regression to remove 
cis-eQTL effects before trans-eQTL mapping and observed a 12% 
increase in the number of detected trans-eQTLs (Supplementary 
Figure 17). For each cohort, eQTLs were mapped using a Spearman’s 
rank correlation on imputed genotype dosages. We used a weighted 
z-score method for subsequent meta-analysis52. To generate a 
realistic null distribution, we permuted the sample identifiers of 
the expression data and repeated this analysis ten times 
(Supplementary Figure 18). In each permutation, the sample labels 
were permuted. We then corrected for multiple testing by setting 
the FDR at 0.05, testing each P value in the real data against a null 
distribution created from the permuted data sets51 (Supplementary 
Note). It has been suggested that false-positive eQTL effects can 
arise owing to polymorphisms in the probe sequences53,54. 
Therefore, we tested whether a significant cis-eQTL SNP was in 
LD (r2 > 0.2) with any SNP in the cis probe sequence, using the 
Western European subpopulations of the 1000 Genomes Project25 
(2011-05-21 release; 286 individuals, excluding Finnish individuals) 
as a reference. If we observed this to be the case, the respective 
cis-eQTLs were removed. Furthermore,for each trans-eQTL, we 
investigated whether portions of the probe sequence could be 
mapped to the vicinity of the trans-eQTL SNP (which would imply 
a cis-eQTL rather than a trans-eQTL effect). For this analysis, we 
tried to map the trans-eQTL probe sequences, using very permissive 
settings, within a 5-Mb window centered on the trans-eQTL SNP. 
SNP-probe combinations where at least 15 bp of the probe 
mapped within this 5-Mb window were deemed false positives and 
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were removed from further analysis. After this filtering, we 
recalculated the FDR for both the cis- and trans-eQTL results. 
Trans-eQTL replication
 Replication of the trans-eQTL results was carried out in 5 
independent data sets from 4 cohorts, including data obtained 
from LCLs (HapMap 3, n = 608)24, B cells and monocytes 
(Oxford, n = 282 and 283, respectively)9 and whole peripheral 
blood (KORA F4, n = 740 and BSGS, n = 862)22,23. All cohorts 
applied the same methodology as used in the discovery phase to 
normalize gene expression data, check for sample mix-ups and 
perform trans-eQTL mapping, including ten permutations to 
establish the FDR threshold at 0.05. Finally, we performed a sample 
size–weighted z-score meta-analysis on the two peripheral blood 
replication cohorts (KORA F4 and BSGS). Further details on these 
data sets can be found in the Supplementary Note.
Enhancer enrichment and functional annotation
 To determine whether the significant trans-eQTL SNPs were 
enriched for functional regions on the genome, we annotated the 
trans-eQTL SNPs using SNPInfo55, SNPNexus56,57 and HaploReg58, 
which integrate multiple data sources (such as the ENCODE 
Project33, Ensembl59 and several miRNA databases). We limited 
these analyses to those trans-eQTL SNPs that were previously 
shown to be associated with complex traits at genome-wide 
significance (trait-associated SNPs; reported P < 5 × 10−8). 
These SNPs were subsequently pruned (using the --clump 
command in PLINK with r2 < 0.2). We used permuted trans-eQTL 
data to generate realistic null distributions for each of these tools: 
we selected equally sized sets of unlinked SNPs (r2 < 0.2 in the 
Western European subpopulations of the 1000 Genomes Project25, 
2011-05-21 release; 286 individuals, excluding Finnish individuals) 
that showed the highest significance in the permuted data, ensuring 
that only trait-associated SNPs were included in the null 
distribution, as it is known that trait-associated SNPs in general 
already have different functional properties than randomly selected 
SNPs60 (for example, trait-associated SNPs typically map in closer 
proximity to genes than randomly selected SNPs). We also 
ensured that none of the SNPs in the null distribution were 
affecting genes in trans or were linked to those SNPs (r2 < 0.2 in 
1000 Genomes Project data). We then identified perfect proxies 
(r2 = 1.0 in 1000 Genomes Project data). For SNPInfo and 
SNPNexus, we calculated the enrichment for each functional 
category using a Fisher’s exact test. We examined enhancer 
enrichment in nine different cell types using HaploReg, averaging 
enhancer enrichment over the ten permutations.
Convergence analysis
 We determined which unlinked trait-associated SNPs showed 
eQTL effects on exactly the same gene: for each trait, we analyzed 
the SNPs that are known to be associated with the trait and 
assessed whether any unlinked SNP pair (r2 < 0.2; distance 
between SNPs of >5 Mb) showed a cis- and/or trans-eQTL effect on 
exactly the same gene, as previously described5. To determine 
whether the number of traits for which we observed this 
phenomenon was higher than expected by chance, we repeated 
this analysis 20 times, each time using a different set of permuted 
trans-eQTLs, equal in size to the non-permuted set of trans-eQTLs.
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SLE IKZF1 ENCODE ChIP-seq analysis
 We used IKZF1 ChIP-seq signal data obtained from the 
ENCODE Project33 (IKZF1 ChIP-seq data acquired and processed 
by UCSC, ENCODE; March 2012 Freeze). For every human gene, 
we determined the average signal (corrected for gene size and bias 
in GC content) and performed a Wilcoxon Mann-Whitney test to 
determine whether the upregulated genes (MX1, TNFRSF21, 
IFIT1-LIPA, HERC5, CLEC4C and IFI6) showed a higher ChIP-seq 
signal than the average signal for all other human genes.
URLs
Catalog of Published GWAS (16 July 2011), 
http://www. genome.gov/gwastudies/.
Accession codes
We have made a browser available for all significant trans-eQTLs 
and cis-eQTLs at http://www.genenetwork.nl/bloodeqtlbrowser. 
This browser also provides all trans-eQTLs that we detected at a 
somewhat less stringent FDR of 0.5 to enable more in-depth post 
hoc analyses. Gene expression data are available for download at 
the Gene Expression Omnibus (GEO) (GSE36382, GSE20142, 
GSE20332, GSE33828, GSE33321, GSE47729; GSE48348 and 
GSE48152) and ArrayExpress (E-TABM-1036, E-MTAB-945 and 
E-MTAB-1708).
Note: Any Supplementary Information and Source Data files are 
available in the online version of the paper.
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Part 1 – A broader perspective on the work 
described in this thesis
 Genome-wide association studies (GWAS) have identified 
thousands of genetic variants associated with complex traits and 
diseases1. However, the genome-wide significant variants identified 
per trait so far explain only a limited fraction of the heritability. 
One explanation has been that the common variants identified 
might tag low frequency variants with a large effect size. However, 
this has only been shown for a few loci. This suggests that most of 
the associated variants are tagging common, low risk, causal 
variants2.
 The observation that the great majority of these variants are 
not causing changes to the protein structure (i.e. are non-coding) 
suggests the majority are regulatory variants. To identify such 
regulatory effects, it is very valuable to study how these genetic 
variants affect molecular phenotypes, by conducting quantitative 
trait locus (QTL) mapping. In the various steps from DNA to 
eventual disease phenotype, transcription is the first (intermediate) 
molecular phenotype. Since gene expression levels can now be 
easily measured using microarray-based technologies or through 
RNA-sequencing, expression QTL (eQTL) mapping is now often 
used to better interpret the effects of disease-associated genetic 
variants. Such eQTLs studies are usually conducted in cis (see Box 
1), where only single nucleotide polymorphisms (SNPs) and genes 
are tested that map in close proximity to the same chromosome. 
Cis-eQTLs are very useful for pinpointing potential causal genes 
within disease loci and have been found in large quantities by 
several studies3–24. Distant effects, involving SNPs and genes that 
map at long distances from each other (i.e. trans-eQTLs; see Box 1) 
have been reported by only a few studies9–12,18,25–28. However, 
they are especially interesting because the discovery that a SNP is 
affecting a gene on a different chromosomes implies a biological 
relationship. Trans-eQTL mapping thus enables the detection of 
previously unknown downstream effects of disease-associated and 
other SNPs. Such knowledge can provide important insight into 
pathways that are causally involved in disease pathogenesis. 
However, detecting these trans-eQTLs has been difficult in the 
past, because they can be strongly cell-type-specific9. 
Because these trans-eQTLs have typically been studied in whole 
tissues (i.e. mixtures of different cell types), the observed effect 
sizes are typically small, and because many statistical tests need to 
be conducted, it has been difficult to identify them.
 The work described in this thesis had two main aims: 1) to 
describe computational methods that can be used to improve the 
statistical power to detect cis- and trans-eQTLs, and 2) to identify 
previously unknown cis- and trans-eQTLs, in order to identify the 
downstream effects for many disease-associated genetic variants.
 We have described several computational methods that 
improve power to detect eQTLs by: 1) correcting the eQTL 
datasets for the presence of accidental sample mix-ups, 
2) correcting the gene expression for non-genetic effects, 
3) increasing the sample size through meta-analysis, and 
4) by applying an interaction model to identify cell-type-specific 
effects. 
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To demonstrate the validity of these methods, we combined them 
and conducted several eQTL mapping studies in order to detect 
cis- and trans-eQTLs for: 1) SNPs influencing non-coding RNA gene 
expression levels, 2) SNPs influencing alternative poly-adenylation 
using RNA-seq, and 3) SNPs influencing downstream gene 
expression levels (trans-eQTLs).
 In the first part of this thesis we provided a number of tools 
that can aid in increasing statistical power: in Chapter 2, 
we described the MixupMapper algorithm, which can identify the 
presence of sample mix-ups in eQTL datasets and can also correct 
these errors. We applied this method to several publicly available 
eQTL datasets and found that approximately 3% of all samples have 
been accidentally mixed-up. By correcting these sample mix-ups, 
we observed a 15% increase in the number of detectable eQTLs in 
these public datasets, and we could explain up to 1.24-fold more of 
the heritability for simulated complex traits. Since then, it has been 
shown that it is also possible to predict genotypes from gene 
expression or other high-throughput datasets (e.g. proteomic or 
metabolomics datasets)29. Consequently, this implies that by using 
many different types of quantitative data that have been deposited 
in public databases, it may be possible to identify individuals to a 
considerable extent, which may result in privacy issues30. 
These issues are even more relevant for RNA-seq based 
expression studies, since genotypes can be derived directly from 
raw RNA-sequence reads31. Researchers who aim to deposit raw 
RNA-sequence reads of human samples in public repositories, 
such as the European Nucleotide Archive, need to ensure they 
have the correct clearance and particularly that they have fully 
informed consent from their patients.
 Traditionally, a cis-regulatory element has been assumed to indicate that a certain region on a 
DNA molecule is regulating the expression of a gene that is located on that same DNA molecule. 
A trans-regulatory element can regulate the expression of a gene that is located on a different DNA 
molecule.
 eQTL studies also use the distinction between cis and trans, although with a completely different 
meaning: since eQTL studies have previously been conducted using microarray-based gene expression 
measurements, it was not possible to determine whether a certain allele (located on a certain DNA 
molecule) was affecting the expression of a gene that is located on that same DNA molecule 
(i.e. haplotype).
 The distinction between cis and trans-eQTLs is solely based on the distance between the genetic 
variant and the gene: if the genetic variant maps within 1 megabase of the gene, it is typically 
considered to be a cis-eQTL effect. In this thesis, we have shown that 95% of the cis-eQTL effects can 
be found within 50 kb of the genotype (Chapter 7). Trans-eQTL effects are considered to reflect 
eQTLs that involve a genetic variant and gene that map to different chromosomes or that map at a 
distance of at least five megabases, to exclude any possibility of long-range linkage disequilibrium.
 A cis-eQTL is thus, strictly speaking, not necessarily a cis-regulatory effect (although a cis-
regulatory effect is a cis-eQTL). Luckily, new technologies can resolve this confusion: RNA-sequencing 
permits the detection of allele-specific expression effects, and phasing algorithms now exist that can 
reconstruct large haplotypes (with only a few switching errors). Combined, this now makes it possible 
to determine whether a certain allele has a truly cis-regulatory effect on the gene that resides on the 
same DNA molecule.
Box 1. The confusing cis and trans terminology
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 In Chapter 3, we presented methods to remove non-genetic 
variation in gene expression, by applying principal component 
analysis (PCA). We showed that removing principal components 
(PCs) can yield a more than two-fold increase in the number of 
detectable eQTLs. However, correcting for principal components 
can also remove genetic variation, which is especially relevant for 
trans-eQTL SNPs that affect multiple genes. Our method therefore 
tests each PC for genetic association and does not remove those 
components that show a genome-wide significant genetic 
association. However, the PCs that are used as covariates might 
still capture small genetic effects that are not genome-wide 
significant. Recently, other normalization strategies have therefore 
been suggested, including supervised normalization and correction 
for measured covariates (such as age, gender, cell counts)32. 
A comparison between such normalization methods showed that 
covariate correction outperforms the other normalization 
strategies tested, although PC correction appeared to be an 
alternative that performed well if such covariates were unavailable 
or unknown33. A recently published method, called HCP 
(hidden covariates with prior) combines both methods by using 
Bayesian statistics to define the hidden covariates, which can then 
be corrected through latent factor analysis34.
 Another method to improve the power to detect genetic 
effects is to increase the sample size. In Chapter 3, we described 
methodology to effectively meta-analyze eQTL datasets and 
showed that a cis- and trans-eQTL meta-analysis provides more 
statistical power with biologically meaningful results. We therefore 
used this meta-analysis method, the PC correction method and the 
sample mix-up detection method in the other work described in 
this thesis.
 In Chapter 4 we presented a method that is able to predict the 
cell-type-specificity of eQTLs from gene expression data that was 
obtained from tissues composed of mixtures of cell types 
(in our case, whole blood). As samples are more easily collected 
from whole tissues than isolated cell types, our method enables 
the collection of the large number of samples that is required to 
detect small effects (such as cell-type-specific trans-eQTL effects). 
The interaction effect between genotype, cell count estimate and 
gene expression that was captured by our method was generally 
smaller than the main eQTL effects, requiring us to combine 
multiple datasets through meta-analysis. We were able to validate 
our predictions in eQTL datasets of purified blood cell types, 
thereby indicating the usefulness of our method. Our method is 
especially helpful since eQTL datasets on individual cell types are 
not yet available for many different cell types. Although we have 
provided a proof-of-principle in whole blood, our method is also 
applicable to other compound tissues: if, for the individual cell 
types that comprise this tissue, we know genes that are markers 
for these cell types, it possible to estimate the abundances for each 
cell type. With more public cell-type- and tissue-specific eQTL 
datasets now becoming available (through projects such as GTeX 
and IMMVAR), it will become possible to apply our method to 
many more tissues in the near future.
 In part 2 of this thesis, we have shown that the computational 
methods from part 1 can be effectively used to identify eQTLs 
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reliably. In Chapter 5, we focused on eQTLs derived from long 
intergenic non-coding transcripts (lincRNAs). We showed that the 
genetic regulation of some of these lincRNAs is tissue-specific, 
that different variants regulate non-coding and protein-coding 
transcripts, and that some trait-associated SNPs also regulate 
non-coding transcripts. However, we performed this study using 
microarrays that were designed before many non-coding 
transcripts were known. As such, we could study only a limited 
number of lincRNAs. Studies that apply RNA-seq to measure gene 
expression do not have this limitation and these will likely be able 
to detect many more lincRNA eQTLs in the near future.
 RNA-seq is not limited to the measurement of whole transcript 
abundance: there are special protocols to measure the gene 
expression at certain ends of the transcripts: for example, 
GRO-seq can be used to measure nascent transcription near the 5’ 
end of genes, while DeepSAGE has been developed to specifically 
measure gene expression near the 3’ end, which is often the 
binding site for non-coding regulatory RNAs. We applied the 
DeepSAGE method in Chapter 6 and observed that RNA-seq data 
is more powerful for detecting eQTLs than microarray data due to 
its higher signal-to-noise ratios. Additionally, DeepSAGE can be 
used to assess the length of the poly-A tail of transcripts. 
We found 12 instances where a genetic variant influenced the 
length of a particular transcript, indicating that SNPs can regulate 
gene expression in various ways. However, the sample size of this 
study was rather small, which means that many small-effect eQTLs 
(and especially trans-eQTLs) have likely been missed. To overcome 
this we performed a meta-analysis of eQTL datasets generated 
using different RNA-seq protocols. By integrating different types of 
eQTL datasets, we obtained a comprehensive overview of the full 
spectrum of transcription regulation, including the differences in 















  association 
  study
- 100,000 
   samples
- 20,000 samples






















Future eQTL mapping studies will likely focus on: 1) increasing the sample size through 
meta-analysis, in order to find more small-effect size eQTLs, 2) increasing the number of available 
tissues and cell types, in order to find cell-type-specific effects that are larger, and 3) single cell 
sequencing in order to identify context-specific eQTLs that have even larger effect sizes.
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transcription-start efficiency, and exon usage.
 Finally, we performed two large-scale eQTL meta-analyses 
(Chapters 3 and 7), in which we performed a cis- and trans-eQTL 
meta-analysis (initially on 1,469 individuals from two datasets, 
and subsequently on 5,311 individuals from nine datasets). 
We showed that, in whole blood, trans-eQTLs can be reliably 
detected and also replicated in independent datasets. We showed 
that certain SNPs affect the expression levels of many genes that 
operate within the same pathway. We demonstrated, to our 
knowledge for the first time, that independent SNPs that cause the 
same disease can affect exactly the same downstream genes in 
trans. For some disease-associated SNPs, the downstream trans-
gene expression effects reflect the known hallmarks of these 
diseases, even though we had conducted these meta-analyses in 
healthy individuals. Additionally, we showed that trait-associated 
SNPs are enriched for both cis- and trans-eQTLs and that reported 
GWAS associations with a high significance are more likely to 
result in eQTL effects than associations that were less significant. 
These results indicate that eQTL mapping can reveal the 
downstream effects of disease SNPs, which may be helpful in the 
development of drugs to target these downstream genes. 
However, our results were derived from whole blood data, 
while many of the trait-associated SNPs in the current GWAS 
catalog are immune-related. As such, the downstream effects of 
these SNPs can be picked up in whole blood. The question remains 
whether this is also the case for complex brain diseases, 
for example. Especially for trans-eQTLs, the tissue specificity 
remains to be investigated: the tissue-specific datasets that are 
currently available often have too few samples to detect trans-
eQTL effects properly. However, RNA-seq data for many tissues 
will soon become available in sufficient sample sizes through 
repositories such as the European Nucleotide Archive: 
since RNA-sequence reads also provide information on SNP 
genotypes, it is possible to derive genotype data, enabling eQTL 
analysis. By re-using such RNA-seq data, originally generated by 
many different labs throughout the world for different research 
purposes, we expect it to be possible to identify trans-eQTLs in 
many different tissues in the near future. 
Part 2 – Future perspectives
 Although eQTL study sample sizes keep on increasing, 
sample sizes are still limited in their capacity to detect many 
trans-eQTLs and cis-eQTL effects for rare variants. 
Additionally, because the range of available eQTL studies on 
different cell types and tissues is limited, the question about the 
eQTL effects of trait-associated SNPs in different tissues remains 
largely unanswered. Future eQTL studies will therefore likely focus 
on three different levels in order to find the downstream effects of 
trait-associated variants (Figure 1): 
1) They will increase the sample size by meta-analysis to identify 
small-effect cis- and trans-eQTLs in bulk tissues (such as blood). 
2) Based on these eQTLs, future studies will then zoom into 
specific cell types where the eQTLs show larger effects. 
3) They will likely improve the results by using single-cell RNA 












in which these eQTLs show particularly strong effects 
(e.g. a specific context could be when a blood cell has been 
activated by a viral or bacterial trigger).
Allele-specific expression
 Except for Chapter 6, all the studies in this paper have been 
performed on gene expression data obtained from microarrays. 
Because microarrays are only able to measure gene expression 
levels as an average over all alleles in diploid organisms, local eQTL 
effects were previously annotated as being cis-eQTL effects, 
while the traditional cis definition (Box 1) implies that gene 
expression originates from the same allele as the variant 
(i.e. allelic imbalance of transcription, or allele-specific expression, 
ASE). Previously, ASE was measured through RT-PCR, 
precluding genome-wide assessment of ASE. This can now be 
assessed genome-wide through RNA-seq: by assessing the number 
of reads in heterozygote individuals, and by inferring haplotypes 
from reference datasets, RNA-seq is able to determine ASE on a 
large scale (Figure 2). There is a relationship between eQTLs and 
ASE: eQTLs and ASE frequently overlap35,36 and the number of 
reads in the ASE signal correlate with the effect size of the eQTL17. 
ASE without an overlapping eQTL signal suggests that the ASE 
variants are rare and ASE can thus be applied to detect cis-eQTL 
effects originating from rare variants13,36. The mechanisms behind 
ASE are still unclear: one study suggested that ASE is mediated by 
cis regulatory elements (CREs; elements such as DNAse-I 
hypersensitive regions, enhancers, etc.)17, while another study 
suggested that ASE is genetic rather than epigenetic and may be 
mediated by transcript structure variation13. ASE can also be 
assessed as a quantitative trait, in order to map aseQTLs: 
641 SNPs with an eQTL also showed an aseQTL, some of which 
were located more than 1 megabase away from the transcription 
start site36.
Larger meta-analyses
 Current eQTL studies, including those that have been 
presented in this thesis, have identified cis-eQTL effects for the 
majority of protein-coding genes. However, it is likely that trans-
eQTL effects are even more numerous, although their effects are 
likely to be very small: of the 430 trans-eQTLs detected in the 
meta-analysis presented in Chapter 7, more than 70% explained 
 When genetic association studies, including eQTL studies, detect a significantly associated variant, 
this does not necessarily mean that the variant identified is also the variant causing the phenotypic 
variation (e.g. the difference in gene expression levels). There are several factors that can obscure the 
true causal variant in association studies. The associated variant may be in linkage disequilibrium (LD) 
with other variants in the locus: LD describes the likelihood of observing two alleles on the same 
haplotype and with increasing LD between variants, it becomes increasingly difficult to distinguish 
causal variants. Additionally, there may not have been enough power to test low frequency variants 
(e.g. population-specific variants), or these variants may not have been included in the test because 
they were not present on the genotyping platform or in the imputation reference set. Meta-analysis 
can help to pinpoint the causal variant: by combining association signals from multiple independent 
datasets, statistical power can be increased to detect significant effects for low frequency variants, 
and to determine what is the most significantly associated variant for variants that are in strong (but 
not perfect) LD, thereby helping to pinpoint the causal variant.
Box 2. Fine-mapping existing eQTL
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less than 1% of the gene expression variation. Despite their small 
sample size, however, detecting more trans-eQTLs is important to 
determine the downstream effects of disease variants, especially 
when these trans-eQTL effects converge on the same genes,
since this may help identify key disease driver genes (Figure 3).
Thus, in order to fi nd more trans-eQTLs with even smaller effect 
sizes, eQTL studies should be scaled up, similar to what was done 
for GWAS. Such meta-analyses will also permit us to fi ne-map 
existing eQTL more accurately, providing a higher-resolution 
overview of the downstream effects of both common and rare 
SNPs (Box 2). However, the cumulative sample size for many 
individual tissues or cell types is not yet large enough to fi nd 
small-effect eQTLs. To overcome this, several methods have now 
been developed that allow meta-analysis over different tissues 
simultaneously37,38. Such large-scale, multi-tissue, eQTL meta-
analyses will likely generate important biological insights into the 
downstream effects of many trait-associated variants.
 An important issue that remains is multiple testing.
When performing trans-eQTL analyses, billions of statistical tests 
need to be conducted. However, with ever increasing knowledge 
on the genes that are involved in specifi c pathways, it will also 
become possible to leverage external biological knowledge on 
these pathways to improve the statistical power: by averaging the 
expression levels of multiple genes that work in a specifi c pathway, 
signal-to-noise ratios can be improved, because noisy 
measurements of individual genes will be combined into a more 
robust and single pathway activity estimate. This will also result in 
fewer statistical tests being needed, because instead of testing 
SNPs against every human gene, only a limited number of pathways 
will need to be tested. Although such pathway-based eQTL 
methods have been proposed39, few studies have used them so far 
in a human setting25.
 Finally, another important issue is to have access to the large 









































No allele specific expression Allele specific expression 
Figure 2.
Allele-specifi c expression can be determined using RNA-seq based gene expression data and 
phased genotypes. The number of reads is measured for individuals that are heterozygous for a 
certain exonic variant. If the number of reads per individual (represented as a dot in the fi gure) is 
more or less equal for both alleles (left), there is no allele-specifi c expression, and when there is a 
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Figure 3.
Unraveling how disease-associated SNPs eventually cause disease will require an approach that 
integrates multiple phenotypes. First, using cell-type-specific eQTL datasets, we can define the 
effects of disease variants on the gene expression of local genes, or cis-eQTLs. These cis-eQTL 
effects (for example on a transcription factor) can also cause trans-eQTL effects, some of which 
may converge on the same gene, possibly across multiple tissues. We can thus consider these 
genes as key genes for the disease. Finally, different phenotypes, such as methylation levels, 
protein levels and the microbiome can be analyzed for genetic effects, interactions between the 
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For instance, human whole blood eQTL data is now available for 
over 20,000 samples. Joint re-analysis of this data will likely yield 
important biological insight into the downstream effects of many 
trait-associated variants. Additionally, it is possible to use such 
whole blood eQTL datasets to make inferences about the specific 
cell-types in which eQTLs manifest themselves (by using the 
abundance of such cell types as an interaction term and by 
performing meta-analysis across different datasets). 
However, while gene expression data is generally available (through 
databases such as the Gene Expression Omnibus, ArrayExpress, 
and more recently the European Nucleotide Archive), 
genotype data is available for only a limited number of eQTL 
datasets. This impedes progress on integrative approaches that can 
fully exploit such eQTL datasets to increase statistical power to 
identify smaller, but potentially very meaningful biological 
downstream eQTL effects. Initiatives such as dbGAP are therefore 
laudable, because they provide ways of sharing raw genotype data 
in a controlled and secure manner30. This might help to convince 
more researchers to make their data available to others 
(although researchers need to ensure they have ethical approval 
and informed consent from their patients that raw genotype data 
can be exchanged). When (legal) hurdles preclude such sharing, 
alternative strategies, such as performing eQTL meta-analyses40 
(where no raw genotype data, but only summary statistics are 
being exchanged), might provide ways to share such data for 
gaining novel biological insight.
Larger tissue- and cell-type-specific datasets
 Although current studies, including the studies presented in 
Chapters 4 and 5 of this thesis, have shown that numerous 
trait-associated variants act in a tissue- or cell-type-specific way, 
it is likely that many cell-type-specific eQTLs have been missed, 
because their relevant tissue or cell type has not been investigated 
so far. As such, the question what is the disrupted tissue or cell 
type remains unanswered in many diseases; it may be important to 
know this in order to better understand the molecular disease 
mechanism (Figure 3). To provide insight into this issue, 
large-scale studies are currently underway that interrogate many 
different tissues or cell types from the same individuals. 
The Genotype-Tissue Expression project (GTEx)41, for example, 
aims to sample a range of tissues from approximately 900 samples. 
Gene expression is quantified using RNA-seq, which will enable the 
GTEx project to answer questions about the tissue specificity of 
cis- and trans-eQTLs, but will also provide insight into transcript 
isoform differences, ASE and differential exon usage between 
tissues. One of the aims of the GTEx project is to sample similar 
tissues to those used in the ENCODE project, which will then add 
information about the tissue-specific epigenetic signals underlying 
the regulation of gene expression caused by genetic variants 
(e.g. DNASe-I hypersensitivity and various histone modifications). 
Although the GTEx project will provide an extremely valuable 
resource for identifying the tissue specificity of eQTLs, each of 
these tissues still consists of many different cell types. Any of these 
cell types might be responsible for the observed eQTL effect in the 
compound tissue5,9,42,43. To detect these cell-type-specific eQTLs in 
blood, the ongoing ImmVar project44 is focusing on a number of 
purified immunological cell types from approximately 600 
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cell types. With the full dataset, the ImmVar project will likely 
provide insight into the downstream effects of many genetic 
variants associated with immune-related diseases. 
Single-cell eQTL analysis
 All of the studies presented in this thesis, and nearly all other 
published eQTL studies, have so far been conducted while 
interrogating multiple cells per sample simultaneously. Since many 
eQTL papers have moved from studying whole tissues to individual 
cell types, the next logical step would be to study individual cells. 
This is particularly interesting, because it will permit identification 
of eQTLs that could well depend on the specific context in which a 
cell operates. Some effects of genetic variants on gene expression 
levels might manifest themselves only in those cells that have just 
been activated by a certain external stimulus (e.g. viral, bacterial, 
or other relevant trigger). If disease-associated SNPs only work in 
such a context, it could well be that such effects are not detectable 
when studying cells in bulk. The first paper to investigate this 
concept used single-cell RNA-seq and concentrated on 1,440 single 
cells from 15 individuals45. Many eQTLs were only detectable when 
studying single cells, and these would have been missed if the 
expression had been averaged over multiple cells. 
Another attractive property of single-cell RNA-seq is that it might 
address a long-standing question in biology: how many different 
cell types are present in a given tissue (e.g. blood)? This can be 
determined by performing single-cell RNA-seq and generating 
expression profiles on thousands of individual cells, with 
subsequent comparison of the expression profiles (e.g. through 
principal component analysis). Although there are still many 
challenges on how to generate and analyze single-cell RNA seq 
data reliably and robustly46,47, this technology will likely mature 
quickly, leading to much lower costs and permitting many research 
groups to initiate single-cell eQTL studies in the near future.
Molecular phenotypes underlying gene expression 
regulation
 Although eQTLs provide insight into the downstream effects of 
genetic variation, they do not explain how gene expression is 
regulated by the genetic variant (Figure 3). Apart from regulation 
by other transcripts, gene expression may also be regulated by 
epigenetic marks: for example, some bases within the DNA, 
especially cytosine, can be methylated, which can modulate gene 
expression. Additionally, DNA is wrapped around complexes of 
histone proteins (histones consist of 4 subunits, H1 – H4), 
maintaining a higher order structure in the form of chromatin. 
Chromatin that is tightly packed with histones (heterochromatin) 
is less accessible to the transcription machinery and is thus 
associated with repression of transcription, while chromatin that is 
loosely packed with histones (euchromatin) is associated with 
active transcription. The density of chromatin packaging can be 
measured by treating the DNA-protein complex with DNAse-I 
(an enzyme that degrades DNA), followed by next generation 
sequencing (DNAse-seq) of the DNA fragments that were not 
digested. Treating the reads as a quantitative trait, a study on 
DNAse-I hypersensitivity QTLs (dsQTL) estimated that up to 55% 
of the eQTL SNPs were most likely also dsQTL SNPs48. 
Furthermore, the different histone proteins themselves can also be 
modified with, for example, methyl or acetyl groups, which can be 
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measured using ChIP-seq. These different modifications are 
associated with different processes, such as promotor activity and 
accessibility of chromatin. ChIP-seq data has been generated for 
many different tissues and cell lines for the ENCODE project and 
show enrichment for trait-associated SNPs within functional 
elements49. A recent study that assessed the overlap between trait-
associated SNPs and such histone modifications reported that 
trait-associated SNPs often overlapped with specific histone 
modifications and that these signals were specific for certain cell 
types50. Finally, using chromatin conformation capture (3C and its 
variations 4C, 5C and Hi-C), interactions between loops of 
chromatin can be detected, which may also affect gene 
expression51, and these loops have recently been linked to trans-
eQTLs52. Although these epigenetic studies have been useful in 
elucidating the regulatory potential of genetic variants, the studies 
were generally performed using small sample sizes. As sample sizes 
increase, future studies will likely provide insight into the 
relationship of these different epigenetic signals and the cis- and 
trans-regulation of gene expression. The different epigenetic signals 
may also interact with each other to affect gene expression. 
Integrative analysis of the different epigenetic layers with gene 
expression will help to elucidate the precise mechanism of genetic 
regulation that determines the final gene expression.
Regulation of gene expression by other transcripts
 Apart from protein-coding genes, a large fraction of the 
transcripts are non-coding and include piRNAs, snoRNAs, miRNAs 
and lncRNAs. piRNAs are transcripts of 26-31 nucleotides; 
they regulate the transcription of genes in germline cells by binding 
to PIWI proteins and may also alter DNA methylation levels of 
these genes53,54. snoRNAs are small ncRNAs of up to 300 
nucleotides that function in the nucleolus, where they regulate 
ribosomal RNA stability53. miRNAs are small transcripts of 19-24 
nucleotides that promote mRNA degradation or inhibit translation 
by binding through the RISC complex53. The specific binding sites 
of these miRNAs are hard to predict but they often appear to be 
located near the 3’ UTR of transcripts55. lncRNAs are a family of 
long ncRNAs (>200 nucleotides), which may regulate gene 
expression through regulation of epigenetic signals or by 
promoting degradation or stabilization of mRNAs53.The targets of 
many of these ncRNAs are still unknown, partly because probes 
for many of these transcripts, especially the small (< 50 bp) 
ncRNAs, are often not present on the microarray platforms. 
Additionally, for these small ncRNAs, special protocols for 
RNA-sequencing should be applied56. As a consequence, the 
expression of these transcripts has not yet been systematically 
assessed in large numbers of samples. However, these transcripts 
may provide additional mechanisms for cis- and trans-eQTLs: 
for example, variants in the 3’ UTR of genes can affect the binding 
sites of miRNAs, leading to deregulation of the transcript 
abundance. Or, variants located in ncRNAs may alter the binding 
affinity with their target transcripts, causing deregulation and 
subsequent trans effects. In Chapter 5 of this thesis we showed 
that lincRNAs are often influenced by genetic variation. 
Future, large-scale, RNA-seq-based studies that investigate these 
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Molecular phenotypes downstream of gene 
expression
 eQTL studies have now provided a functional interpretation for 
many trait-associated SNPs. Future integrative approaches that 
also ascertain the effect of the trait-associated variants on 
different molecular levels (e.g. effects on protein levels, metabolite 
levels, or on the composition of the microbiome; Figure 3), 
and their possible interactions, will likely provide detailed 







 DNA consists of 23 pairs of chromosomes which is present  
in almost every cell in the human body. A DNA molecule consists 
of two long intertwined strands of bases (which together form  
a double helix). The bases are chemical compounds that are 
abbreviated by the letters A, T, C and G and they encode genetic 
information. This genetic information can be transcribed into RNA 
molecules, which can have different functions. RNA molecules can 
regulate the transcription of other parts of the genome 
(transcription) or can be translated into a protein (translation). 
Depending on the origin of the cell (e.g. liver or brain cells), 
different parts of the genetic information can be transcribed,  
and as a consequence, different proteins will be produced,  
causing the cell to display different characteristics and functions  
in different organs or tissues. 
 Changes in the DNA can alter the structure or the amounts  
of RNA molecules that are being produced, which can eventually 
cause disease. Some diseases arise from a single change in the 
DNA (mutations that cause Mendelian diseases), while the majority 
is caused by different combination of many DNA changes (so-called 
complex diseases).
 Through genome-wide association studies (GWAS),  
changes in the DNA sequence have been identified that increase  
or decrease disease risk for complex diseases. These changes are 
in the form of single nucleotide polymorphisms (SNPs) and involve 
a single base-pair. However, the majority of these SNPs are not 
located within genes that encode proteins and the number of genes 
which surround these SNPs is highly variable. Moreover, some of 
these SNPs are located in regions that do not contain any genes  
at all. As a consequence, after a GWAS study has been completed, 
the actual mechanism between the identified SNP and the disease 
is still often unclear.
 Because the first step in the biology between SNP and disease 
is transcription into RNA, this process has been widely studied. 
The level at which DNA is transcribed into RNA can be measured 
using microarray platforms and RNA-sequencing. Subsequently,  
the genotypes of the SNP can be correlated with the transcription 
levels, to identify expression quantitative trait loci (eQTLs).  
Since eQTLs describe the effect of the SNP on transcription levels, 
they provide information about the downstream effects of SNPs 
(particularly disease-associated SNPs), and can thus provide 
information about the mechanism between the SNP and a certain 
disease. eQTLs can be local effects (cis-eQTL), where the SNP is 
located within a couple of hundred thousand bases from the 
affected RNA transcript, or they can be distant effects 
(trans-eQTL), where the SNP can be located on a completely 
different chromosome to the affected transcript. 
 This thesis presents methods to increase the statistical power 
to detect eQTLs with small effect size (part 1) and also presents 
specific eQTL association studies that provide novel biological 














 In Chapter 2, we present MixupMapper, a method that can  
be applied to eQTL datasets to detect accidental sample mix-ups 
that can occur on collection or in the laboratory. We applied the 
method to six publicly available datasets to assess the effects  
of sample mix-ups on the detection of eQTLs. Additionally,  
we performed simulations to determine the effect of sample 
mix-ups on our ability to explain the heritability of GWAS traits. 
We showed that, on average, 3% of the samples in public databases 
have been accidentally mixed-up, and that these mix-ups can have  
a large effect on the researchers’ ability to detect small genetic 
effects. Consequently, just a few sample mix-ups in a database  
can have a large effect on our ability to explain the heritability  
of (disease) phenotypes. 
 In Chapter 3 we provide further methodology to increase  
the statistical power to detect eQTLs, by normalization of gene 
expression data through principal component analysis (PCA).  
Since PCA is able to capture variation in gene expression data  
that is not caused by genetic effects, correction for these 
components increases the statistical power to identify eQTLs.  
To further increase power, we performed a meta-analysis between 
two whole-blood eQTL datasets, enabling us to increase the 
sample size to identify small-effect eQTLs. Using both approaches, 
we were able to detect 340 trans-eQTL effects, and showed that 
independent trait-associated SNPs can show convergent effects  
on the same downstream genes, providing insight into the 
downstream pathways that are affected by these SNPs. 
 We applied a similar meta-analysis approach to seven 
independent, whole-blood eQTL datasets in Chapter 4.  
We used an interaction model that incorporates information on 
the differences in cell-type proportions across samples. In order to 
estimate these proportions, we developed a method that is able to 
predict these measurements from the gene expression data itself. 
We finally showed that the interaction effects identified describe 
cell-type-specific eQTLs, by replicating them in six independent 
but purified cell-type-specific eQTL datasets.
 Not all genes code for proteins: a considerable fraction of  
all genes is transcribed into non-coding transcripts. In chapter 5, 
we describe an investigation into the genetic regulation of these 
transcripts in five different tissues, in which we showed that long 
intergenic non-coding RNAs (lincRNAs) are often genetically 
regulated as well. We also showed that the genetic regulation of 
these lincRNAs is often tissue-specific. 
 Although genes can vary their total expression levels,  
they can also generate different types of transcripts (i.e. isoforms). 
Transcripts can differ at their 3’ end: they typically contain a tail  
of repeated adenosine bases (poly-A tail), but the length of this  
tail can differ, which can influence the translation of the gene into 
protein. RNA-sequencing data is well suited for identifying these 
isoform and poly-A tail differences. In Chapter 6 we describe using 
the RNA-sequencing technique DeepSAGE to investigate the 
genetic regulation of the length and usage of different poly-A  
tails of transcripts and identified 12 poly-adenylation QTLs. 
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In Chapter 7 we report how we applied our methods to a large-
scale eQTL meta-analysis of 5,311 independent, whole-blood 
samples. We identified 1,513 trans-eQTL effects for trait-associated 
SNPs, indicating that eQTL mapping is a powerful tool 
for providing biological insight into the downstream effects  
of trait-associated and other SNPs. We discovered that two 
independent SNPs that show a cis-eQTL effect on the same gene 
(IKZF1) resulted in completely different trans-eQTL effects, 
and that disease-associated SNPs can sometimes have trans-eQTL 
effects on genes that describe the hallmark molecular features  
of these diseases. 
In Chapter 8, we evaluate all our results and provide possible 
future directions for the biological interpretation of disease-
associated genetic variants.
The main conclusions of this thesis are:
-  Trait-associated SNPs are enriched for local (cis-) eQTL and distant 
(trans-) eQTL effects.
-  Cis- and especially trans-eQTLs can provide valuable insight into the 
downstream effects of trait-associated SNPs.
-  Multiple, independent, trait-associated SNPs can affect the same 
downstream (trans-eQTL) genes, which can identify important ‘driver’ 
genes
-  Trans-eQTL effects can describe the hallmark processes of disease, 
even when the eQTL effect has been detected while studying only 
healthy individuals.
-  eQTL effects are not limited to protein-coding genes, but can also be 
detected for non-coding genes. They can also influence the poly-A tail 
of transcripts.
-  eQTL effects can be cell-type-specific. This cell-type specificity can be 
detected in gene expression data obtained from whole tissues, which 
consist of many different cell types.
-  The power to detect eQTLs can be improved by meta-analysis and by 

















 DNA bestaat uit 23 paren chromosomen, die aanwezig zijn  
in vrijwel iedere cel in het lichaam. Een DNA molecuul bestaat  
uit twee vervlochten strengen (die gezamenlijk de vorm hebben 
van een dubbele helix) en zijn opgebouwd uit zogenaamde 
basenparen (chemische verbindingen die afgekort worden met  
de letters A, T, C en G). Deze basen dragen de genetische 
informatie. Deze genetische informatie kan overgeschreven 
worden tot zogenaamde RNA (transcriptie). RNA moleculen 
kunnen de transcriptie van andere RNA moleculen beïnvloeden en 
kunnen vertaald worden naar eiwitten (translatie). Welk deel van 
het DNA wordt overgeschreven tot RNA, verschilt van cel tot cel  
(een levercel heeft bijvoorbeeld een ander transcriptie programma 
dan een brein cel) en hierdoor worden er verschillende eiwitten 
geproduceerd, waardoor verschillende cellen verschillende functies 
en eigenschappen hebben.
 Veranderingen in het DNA kunnen gevolgen hebben voor  
de hoeveelheid transcriptie of de structuur van RNA moleculen.  
Zulke veranderingen kunnen leiden tot ziekte. Sommige ziektes 
ontstaan vanuit een enkele verandering in het DNA (mutaties die 
zogenaamde Mendeliaanse ziekten veroorzaken), terwijl verreweg 
de meeste ziekten (zogenaamde complexe ziekten) veroorzaakt 
worden door combinaties van verschillende veranderingen in  
het DNA.
 
 Door het uitvoeren van genoom-wijde associatie studies 
(GWAS) zijn er de afgelopen jaren veel veranderingen in het  
DNA (in de vorm van enkele basenpaar veranderingen, genaamd 
SNPs) gevonden die het risico voor het ontwikkelen van complexe 
ziektes verhogen. Echter, het merendeel van deze SNPs ligt niet in 
genen die eiwitten beschrijven en liggen soms op plekken in het 
DNA waar helemaal geen genen aanwezig zijn. Als een gevolg 
hiervan is het na het uitvoeren van een GWAS vaak lastig gebleken 
om te bepalen via welk mechanisme de geassocieerde varianten 
uiteindelijk ziekte veroorzaken.
 Om dit inzicht te verkrijgen, is er recentelijk veel aandacht 
besteed aan het onderzoeken van (variatie in) transcriptie, omdat 
dit de eerste moleculair biologische stap is van genetische variant 
naar uiteindelijke ziekte. De mate van transcriptie (expressie) kan 
worden gemeten met technieken als microarrays en RNA-
sequencing. Door de expressie van het transcript te correleren 
met de genotypen van de SNP kunnen zo ‘expression quantitative 
trait loci’ (eQTL) geïdentificeerd worden. Deze eQTL beschrijven 
het effect van de variatie in het DNA op de transcriptie niveaus en 
beschrijven als gevolg daarvan de directe functionele gevolgen van 
de variant en daarmee inzicht in het ziekte proces. eQTL kunnen 
lokale effecten zijn (cis-eQTL), waarbij de afstand tussen de SNP en 
het transcript tot enkele honderdduizenden basenparen beperkt is. 
Deze afstand kan echter ook groot zijn (trans-eQTL), waarbij de 
SNP miljoenen basenparen verwijderd kan zijn van het transcript, 
of op een compleet ander chromosoom kan liggen. 
 Dit proefschrift beschrijft methodes die de statistische power 
vergroten om deze eQTLs te kunnen detecteren (deel 1), 
maar presenteert ook specifieke eQTL studies die het biologisch 
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inzicht in de functionele gevolgen van ziekte geassocieerde SNPs  
hebben vergroot (deel 2).
 In hoofdstuk 2 presenteren we MixupMapper, een methode die 
toegepast kan worden op eQTL datasets om sample verwisselingen 
te detecteren, die kunnen ontstaan bij het verzamelen en verwerken 
van samples in het laboratorium. We passen deze methode toe op 
zes publiekelijk beschikbare eQTL datasets om het effect van sample 
verwisselingen op de eQTL resultaten te laten zien. Verder voeren 
we simulaties uit om te bepalen wat het effect is van sample 
verwisselingen op de mogelijkheid om de erfelijkheid van ziektes  
te bepalen uit GWAS resultaten. We tonen aan dat gemiddeld 3% 
van de samples in de publieke datasets per ongeluk verwisseld zijn, 
en dat een beperkt aantal sample verwisselingen een groot effect 
kan hebben op het vermogen om eQTL effecten te detecteren.
 In hoofdstuk 3 laten we zien dat de statistische power om 
eQTLs te vinden verder kan worden vergroot door het toepassen 
van principale component analyse (PCA) op de gen expressie data. 
De principale componenten kunnen niet-genetische variatie in gen 
expressie beschrijven, waardoor het corrigeren van de gen 
expressie data voor deze componenten de statistische power 
vergroot. Daarnaast beschrijft hoofdstuk 3 dat de statistische 
power verder kan worden vergroot door het uitvoeren van een 
meta-analyse. Door het toepassen van beide methodes op twee 
bloed eQTL datasets, vergroten we het aantal bekende trans-eQTL 
effecten tot 340. Verder laten we zien dat twee onafhankelijk met 
ziekte geassocieerde trans-eQTL SNPs effecten convergerende 
effecten kunnen hebben op dezelfde genen, waardoor regulatoire 
netwerken gevormd worden.
 Eenzelfde meta-analyse strategie is toegepast in hoofdstuk 4  
op zeven onafhankelijke eQTL datasets. In dit hoofdstuk passen  
we een interactiemodel toe, dat gebruik maakt van verschillen  
in celtype proporties in bloed tussen individuen, om de cel type 
specificiteit van eQTLs te detecteren. Om deze celtype proporties 
te schatten, beschrijven we een methode die in staat is de 
proporties te voorspellen aan de hand van gen expressie data.  
De voorspelde celtype specificiteit repliceren we vervolgens in  
zes onafhankelijke celtype specifieke eQTL datasets. 
Hiermee tonen we aan dat onze meta-analyse celtype specifieke 
eQTLs correct kan detecteren in een weefsel dat uit meerdere 
celtypen bestaat (in dit geval bloed).
 Niet alle genen worden in eiwitten omgezet: een grote fractie 
van alle genen worden omgezet in zogenaamde non-coding RNAs 
(ncRNA). In hoofdstuk 5 onderzoeken we de genetische regulatie 
van deze transcripten in vijf verschillende weefsels, en laten zien 
dat bepaalde ncRNAs genetisch gereguleerd zijn en dat deze 
regulatie vaak weefselspecifiek is.
 Genen worden niet alleen gereguleerd op het niveau van  
gen expressie. Zo kunnen er van een gen verschillende transcript 
varianten bestaan (zogenaamde isoformen). Daarnaast kan het 3’ 
uiteinde van genen gewijzigd zijn: transcripten hebben vaak een 
staart die bestaat uit een herhaling van adenosine basen (poly-A 
staart). De lengte van deze staart kan verschillen, hetgeen de 
translatie naar het eiwit kan beïnvloeden. Deze verschillen in de 
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expressie van transcript isoformen en de poly-A staart lengte 
kunnen gedetecteerd worden met RNA-sequencing. In hoofdstuk 6 
passen we de RNA-sequencing techniek DeepSAGE toe om de 
genetische regulatie van de poly-A staart lengte te onderzoeken en 
identificeren we 12 poly-adenlyatie QTLs.
 
 In hoofdstuk 7 passen we de verschillende methodes om de 
statistische power te vergroten toe in een meta-analyse van in 
totaal 5,311 onafhankelijke bloed samples. Met deze meta-analyse 
identificeren we 1,513 trans-eQTL effecten voor met ziekte 
geassocieerde SNPs en tonen we aan dat eQTL associaties 
belangrijk inzicht kunnen leveren in de functionele gevolgen van 
deze varianten. Daarnaast laten we zien dat twee SNPs, die beide 
een cis-eQTL hebben op hetzelfde gen (IKZF1), verschillende 
trans-eQTL effecten kunnen hebben, en dat trans-eQTL effecten 
voor met ziekte geassocieerde varianten de kenmerkende 
eigenschappen van deze ziektes kunnen beschrijven.
 In hoofdstuk 8 plaatsen we de resultaten van dit proefschrift in 
een bredere context en bespreken we nieuwe methoden die op 
termijn de biologische gevolgen van ziekte geassocieerde varianten 
kunnen help opsporen.
De belangrijkste conclusies van dit proefschrift zijn:
-  Met ziekte geassocieerde SNPs zijn verrijkt voor cis- en  
trans-eQTL effecten.
-  Cis- en vooral trans-eQTL effecten kunnen waardevolle inzichten 
bieden in de functionele gevolgen van met ziekte geassocieerde 
varianten.
-  Meerdere, onafhankelijke, met ziekte geassocieerde varianten kunnen 
dezelfde trans-eQTL genen beïnvloeden en daarmee belangrijke, 
mogelijke ‘driver’ genen blootleggen.
-  Trans-eQTL effecten kunnen de kenmerkende eigenschappen van 
ziektes beschrijven, zelfs als de eQTLs gedetecteerd zijn in gezonde 
individuen.
-  eQTL effecten zijn niet beperkt tot genen die coderen voor eiwitten, 
maar kunnen ook gevonden worden voor genen die niet coderen voor 
eiwitten.
-  Genetische variatie kan een effect hebben op de lengte van de poly-A 
staart van transcripten.
-  eQTL effecten kunnen celtype specifiek zijn. Deze celtype specificiteit 
kan gedetecteerd worden in gen expressie data uit weefsels die uit 
meerdere celtypen bestaan. 
-  De statistische power om eQTLs te detecteren kan verhoogd worden 
door meta-analyse en door gen expressie data te corrigeren voor 
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